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“Would you tell me, please, which way I ought to go from here?" 
"That depends a good deal on where you want to get to," said the Cat. 
"I don't much care where –" said Alice. 
"Then it doesn't matter which way you go," said the Cat. 
"– so long as I get somewhere," Alice added as an explanation. 
"Oh, you're sure to do that," said the Cat, "if you only walk long enough." 
"But I don't want to go among mad people," Alice remarked. 
"Oh, you can't help that," said the Cat: "We're all mad here. I'm mad. You're mad." 
"How do you know I'm mad?" said Alice. 
"You must be," said the Cat, "otherwise you wouldn't have come here." 
 
Lewis Carroll's novel, Alice's Adventures in Wonderland 
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Abstract 
Iron deficiency is the most prevalent nutrient deficiency affecting all age groups 
worldwide. Deleterious alterations on cognition, psychological morbidity and physical 
performance have been observed in several reports; however, the main body of literature focuses 
on infants, children, adolescents or women of childbearing age. These groups are considered to 
be at high risk due to physiologic conditions. Nonetheless, several pathological conditions are 
also risk factors for iron deficiency, with many of them highly prevalent in older individuals. In a 
growing older society, considering that older individuals are at greater risk of cognitive decline, 
neuropsychological morbidity, decrements in physical performance and impaired functional 
ability, the study of the factors influencing these outcomes are of utmost importance. Still, 
despite of all the evidence pointing for a role of iron deficiency in cognition, mood and physical 
functional ability, there is a worrying small amount of research in older individuals.  
In this work, by first using a cross-sectional analysis, we investigated the association of 
low iron status with cognitive performance, neuropsychological morbidity and physical functional 
ability in a cohort of older individuals (n=151). Next, using a quasi-experimental study design 
(n=12, intervention; n=10, non-intervention), namely intervention via an iron-fortified fruit–based 
dessert, we addressed if low dosage iron fortification of foods is feasible and effective in altering 
(and/or correcting for) the effects of low iron status.  
In order to reduce the number of multiple comparisons, principal component analysis of 
cognitive, psychological, physical variables and iron biomarkers was performed and the obtained 
dimensions used for analysis. We observed that the storage [body iron, soluble serum transferrin 
receptor (sTFR), ratio of sTFR to the logarithmic value of ferritin (sTFR – Log(FT)) index  and 
ferritin (FT)] and erythropoiesis [red cells blood Count (RBC), hemoglobin and hematocrit] 
dimensions were significant predictors of the memory dimension [selective reminding test (SRT) - 
consistent long term retrieval (CLTR), - long term storage (LTS) and - delayed recall (DR) and the 
Consortium to establish a registry for Alzheimer's disease (CERAD) (total hits and DR)], along 
with the interaction of storage and nutritional status. The geriatric depression scale (GDS) score 
was predicted by the transport [serum iron (Fe) and transferrin saturation (TF sat.)], transport 
saturation [transferrin (TF) and total iron binding capacity (TIBC)] and erythropoiesis dimensions. 
The functional tiredness (mobility-, lower limb- and upperlimb-tiredness) dimension was predicted 
by the storage, transport, red cells composition [mean corpuscular volume (MCV), mean cell 
hemoglobin (MCH), mean cell hemoglobin concentration (MCHC) and red cell distribution width 
(RDW)] and erythropoiesis dimensions.  After 12 weeks (+/- 2 weeks) of intervention, the daily 
consumption of an iron fortified dessert was associated with an improvement of the total and 
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sub-scores of performance-oriented mobility assessment, along with hand grip strength and lower 
limb tiredness.  
Our observations indicate that lower iron status is associated with poorer memory ability, 
depressive mood and functional tiredness from activities of daily living. Furthermore, results 
indicate that the physical negative effects of low iron status seem to be recovered by iron 
supplementation, highlighting the importance of prevention. Identification of molecular bases of 
the associations here reported is paramount and further research is needed.  
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Resumo 
A deficiência de ferro é o deficit nutricional mais prevalente em todo o mundo, afetando 
todas as faixas etárias. Vários estudos têm demonstrado um impacto negativo da deficiência de 
ferro sobre a cognição, a morbidade psicológica e desempenho físico; no entanto, os referidos 
estudos debruçam-se essencialmente em crianças, adolescentes ou mulheres em idade fértil, 
nos quais várias condições fisiológicas concorrem para que estes grupos sejam considerados de 
alto risco. No entanto não devemos descurar, igualmente, que várias condições patológicas são 
fatores de risco para deficiência de ferro, sendo muitas delas altamente prevalentes em idosos. 
Numa sociedade cada vez mais envelhecida, e onde os indivíduos mais velhos apresentam risco 
acrescido de declínio cognitivo, morbidade neuropsicologia, decréscimos no desempenho físico e 
capacidade funcional comprometida, o estudo dos fatores que influenciam estas consequências 
do envelhecimento são de extrema importância. Apesar de todas as evidências apontarem para 
um papel da deficiência de ferro na cognição, humor e capacidade física funcional, a 
investigação em idosos é escassa.   
Neste trabalho, utilizando uma análise transversal, investigámos as associações de 
baixos níveis de ferro com o desempenho cognitivo, a morbidade neuropsicológica e a 
capacidade funcional física em idosos. Através de um estudo quasi-experimental, investigamos, 
ainda, se a fortificação de alimentos com pequenas doses de ferro é viável e eficaz para 
melhorar a capacidade cognitiva, o humor e a condição física.  
Com o objetivo de reduzir o número de comparações múltiplas foi realizada a análise 
dos componentes principais das variáveis cognitivas, psicológicas, físicas e dos biomarcadores 
de ferro e os componentes obtidos utilizados para análise estatística. Observou-se que os 
componentes armazenamento [ferro corporal, receptor solúvel da transferrina (sTFR), indice do 
rácio do sTFR para a transformação logarítmica da ferritina (sTFR – Log(FT)) e ferritina (FT)] e 
eritropoiese [eritrócitos (RBC), hemoglobina e hematócrito], bem como a interação do 
componente armazenamento com estado nutricional, foram preditores significativos do 
componente memória [teste de memoria selectiva (SRT) – evocação da memória a longo prazo 
(CLTR), - armazenamento na memória a longo prazo (LTS) e – evocação tardia (DR); e o 
Consórcio para estabelecer um registro para a doença de Alzheimer (CERAD) (total de respostas 
certas e DR)]. O valor da escala de depressão geriátrica (GDS) foi previsto pelos componentes 
transporte [ferro sérico (Fe) e saturação da transferrina (TF sat.)], saturação do transporte 
[transferrina (TF) e capacidade total de ligação do ferro (TIBC)] e da eritropoiese. Os 
componentes armazenamento, transporte, composição células vermelhas [volume corpuscular 
médio (MCV), hemoglobina corpuscular média (MCH), concentração de hemoglobina 
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corpuscular média (MCHC) e a anisocitose (RDW)] e eritropoiese foram preditores significativos 
do componente obtido para o cansaço associado às atividades funcionais diárias. Observámos, 
ainda, que após 12 semanas (+ / - 2 semanas), o consumo diário de uma sobremesa fortificada 
em ferro se associa a uma melhoria no total e subtotais de avaliação da mobilidade orientada 
para o desempenho, juntamente com força de preensão manual e menor cansaço dos membros 
inferiores.  
Estes resultados indicam que os níveis de ferro estão associados a menor memória, a 
humor depressivo e a cansaço funcional nas atividades da vida diária. Além disso, os resultados 
sugerem que os efeitos negativos de baixo nível de ferro a nível físico melhoram com a 
suplementação de ferro, destacando a importância da prevenção do declínio nos níveis de ferro. 
Importa no futuro a confirmação destes resultados em estudos de base populacional, assim 
como a identificação das bases moleculares que lhes estão subjacentes.  
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Iron is essential for several biochemical/biological processes. Namely, it is a component 
and cofactor of various enzymes, participating in oxygen transport and storage, mitochondrial 
electron transport, catecholamine metabolism and neurotransmitters and DNA synthesis, among 
others (J. L. Beard, Connor, & Jones, 1993; Hill, 1985; IOM, 2001; M. B. Youdim & Green, 
1978). In normal conditions, healthy adults have approximately 35 to 45 mg of iron per kilogram 
of body weight (premenopausal females have lower iron stores due to recurrent menstrual blood 
losses), being more than two thirds incorporated in hemoglobin (Nancy C. Andrews, 1999). 
Imbalance in iron homeostasis, both excess and deficiency, are deleterious to human health and 
are associated with conditions such as hemochromatosis, neurodegenerative disorders (i.e. 
Parkinson and Alzheimer diseases), type II diabetes and anemia (Iron Deficiency Anemia – IDA) 
(Hentze, Muckenthaler, & Andrews, 2004; Jiang et al., 2004; Zecca, Youdim, Riederer, Connor, 
& Crichton, 2004; Zhao et al., 2012).  
Paradoxically, although iron is one of the most abundant elements on the planet, iron 
deficiency is the most common nutritional deficiency (Boccio & Iyengar, 2003). While several 
causes can be present in the etiology of the disorder, it can, in general, be explained as an 
imbalance between iron intake, absorption and losses (Cook, 2005; Zimmermann & Hurrell, 
2007). The inability to maintain, for a long period of time, adequate plasma iron levels and/or 
body iron stores, leads to iron deficiency (ID) anemia (IDA) (De Domenico, McVey Ward, & 
Kaplan, 2008), the most common hematological disorder (McLean, Cogswell, Egli, Wojdyla, & de 
Benoist, 2009; Mukhopadhyay & Mohanaruban, 2002). In fact, the World Health Organization 
(WHO) estimates that, worldwide, more individuals have IDA than any other health problem 
(Mathers, Fat, Boerma, & Organization, 2008; McLean et al., 2009). Although all age groups are 
vulnerable to ID, infants, adolescents, women of childbearing age or pregnant, and middle-
aged/older individuals (defined as age ≥ 60 years) are particularly susceptible (De Benoist, 
Cogswell, Egli, & McLean, 2008; McLean et al., 2009; WHO, 2001). In adults, ID and IDA can 
result or be associated with a wide range of adverse effects, including: fatigue, reduced work 
performance, diminished exercise capacity, impaired thermoregulation, immune dysfunction, 
gastrointestinal disturbances, and neurocognitive impairment (Susan F. Clark, 2008; Haas & 
Brownlie, 2001; Zimmermann & Hurrell, 2007). 
Of particular concern, the raise of life expectancy in the last century has led to an 
increase of the aged population worldwide (Christensen, Doblhammer, Rau, & Vaupel, 2009). 
Specifically, in the last 160 years women’s life expectancy has increased 3 months per year in an 
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almost linear trend, with the same trend observed for men, albeit at a slower pace (Oeppen & 
Vaupel, 2002). ‘Normal’ healthy aging is associated with a degree of cognitive decline, termed 
“age-related cognitive decline/aging” (defined as no dementia, mild cognitive impairment or 
other specific cognitive decline-associated syndromes/diseases), as well as with physical 
challenges and decrements (Beddington et al., 2008; Deary et al., 2009; Guralnik, Fried, & 
Salive, 1996; Janssen, Heymsfield, & Ross, 2002). Despite being indisputable that life 
expectancy increase should be celebrated, this current demographic and societal phenomenon 
will result in an increasing number of older individuals with various age-associated health 
concerns/problems and pathologies (including, for example, cancer, fractured hips, strokes, 
dementia), which may occur concurrently (that is, co- or multi-morbidities) (Rechel et al., 2013; 
The, 2012). Furthermore, aged individuals are also the largest consumers of prescribed drugs or 
medication (Qato et al., 2008), with age-associated disease burden and medication consumption 
accounting for significant health care needs, which is reflected by an increase in the expenditure 
of the health and welfare systems of nations (Rechel et al., 2013). Of relevant note, several 
morbidities and therapeutic drugs that are highly prevalent in older individuals are also possible 
causes of ID (see 1.2.1 – From basics to clinics) (Susan F. Clark, 2008).  
Taken together, aging and ID can be deleterious for health and wellbeing, particularly in 
cognition and physical ability. Notably, however, extremely little focused research has been 
conducted in this population strata. A systematic review and meta-analysis found an increased 
risk of incident dementia in anemic individuals; however, the type of anemia was not addressed 
(Peters et al., 2008). Although anemia is used as an indicator of ID and the terms anemia, ID 
and IDA are used interchangeably, it should be noticed that anemia can also be caused by 
vitamin B12 deficiency, which is a well-known cause of dementia (Reynolds, 2006; WHO, 2001). 
Furthermore, physical functional ability in the elder has been associated with anemia (Chaves, 
2008; Denny, Kuchibhatla, & Cohen, 2006; Penninx et al., 2003; Penninx et al., 2004; Mya 
Thein et al., 2009). Still, to the best of our knowledge no study has addressed associations with 
ID.  
The growing older population and the potential reversibility, amelioration or prevention of 
the delirious effects of ID in cognition and physical functionality dictate the need of studies that 
multi-disciplinarily address and explore the association between iron status, cognitive ability and 
physical functional performance in middle-aged/older individuals.  
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1.1. Iron homeostasis  
The physiology of iron metabolism has been known for more than a half a century, 
mostly by means of human and animal studies using iron isotopes. More recently, the 
discoveries of key molecules that are involved in intestinal iron absorption allowed a better 
understanding of this process at the molecular level (Frazer & Anderson, 2005; T. Ganz, 2008). 
Iron is a nutrient classified as an essential trace element with the ability to easily gain and loose 
electrons (inter-conversion between ferric [Fe3+] and ferrous [Fe2+] forms) (De Domenico et al., 
2008; T. Ganz, 2008; Hentze et al., 2004). This chemical property of iron makes it an useful 
component of oxygen binding molecules, cytochromes and non-heme enzymes, largely explaining 
its biological importance, but also underlying the reasons for its deleterious and toxic effects 
when in excess (Hentze et al., 2004). Iron can catalyze a “fenton-type” redox reaction where the 
ferrous form interacts with hydrogen peroxide or lipid peroxidases originating free radicals (i.e. 
superoxide anions and the hydroxyl radical) that ‘attack’ and damage cellular membranes, 
nucleic acids and proteins (Nancy C. Andrews, 1999; Hentze et al., 2004). In humans, there is 
no known physiological regulated form to actively excrete iron, and since both iron overload and 
deficiency lead to several disorders, iron homeostasis must be tightly regulated via absorption 
and storage mechanisms (Nancy C. Andrews, 1999; De Domenico et al., 2008; Zimmermann & 
Hurrell, 2007). Daily, 1 to 2 mg of iron is absorbed from dietary sources, with similar amounts 
lost by epithelial cell shedding (skin, gastrointestinal and urinary tract cells) and fluids loses 
(menstruation, minor bleeding, tears and sweat) (T. Ganz, 2008; Miret, Simpson, & McKie, 
2003). Despite of the small amounts that renew (and/or ‘recycle’) the iron pool, the erythron (all 
the erythrocyte, their precursors and organs involved in their production) has daily requirements 
of 20 to 30 mg (Nancy C. Andrews, 1999; Miret et al., 2003). 
 
1.1.1. Iron absorption and metabolism 
As mentioned, although 1 to 2 mg of iron are absorbed by enterocytes each day to 
compensate the losses, these amounts only represent a small portion of the body iron daily 
needs. The mean dietary intake of iron for an adult ranges from 12 to 18 mg/day, which is 
sufficient to meet the dietary reference allowance (8 mg/day for men and post-menopausal 
women and 18mg/day for pre-menopausal women) (IOM, 2001). Dietary iron can be divided in 
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two components: (i) heme iron (protoporfirin IX – from hemeproteins) and (ii) nonheme iron 
(dietary ferritin and iron salts and chelates). These have distinct bioavailabilities. Heme iron is 
found mainly in meat food sources and corresponds to up to 15% of the dietary iron, the 
remaining is nonheme iron which is found mainly in vegetable sources (Hallberg, 2001). Heme 
and nonheme iron are absorbed in the small intestine, where a gradient for absorption occurs, 
with higher rate at the duodenum and decreasing in the jejunum and in the ileum (De Domenico 
et al., 2008; Gibson, 2005; Miret et al., 2003). The enterocytes (polarized intestinal epithelial 
cells) are responsible for all iron absorption (Nancy C. Andrews, 1999). These cells, which derive 
from stem cells in the intestinal crypts (crypts of Lieberkuhn) and migrate up the villus, are 
characterized by an apical side (presenting the brush-border) and a basolateral side that are in 
contact with the intestinal lumen and the blood stream, respectively (Fuqua, Vulpe, & Anderson, 
2012). Even though not all the processes involved in the intestinal iron absorption are clearly 
understood, it is know that absorption occurs through the transport across the apical membrane, 
translocation across the cytosol and release to the circulation through the basolateral membrane 
(De Domenico et al., 2008; Han, 2011). Heme and nonheme iron are absorbed by different 
mechanisms in an independent and not mutually exclusive manner (Nancy C. Andrews, 1999; 
Han, 2011; West & Oates, 2008), with much of what is known about iron absorption being 
limited to nonheme iron, despite of heme iron being far more efficiently absorbed and having 
outmost importance from the nutritional point of view (Miret et al., 2003; Wienk, Marx, & Beynen, 
1999).  
Evidence sustains two hypotheses for heme iron absorption: (i) iron binds to a receptor in 
the brush-border membrane of duodenal enterocytes and is translocated by endocitosys across 
the apical membrane, and (ii) iron is transported from the intestinal lumen to the cytoplasm of 
the enterocyte through the heme carrier protein 1/proton coupled folate transporter 
(HCP1/PCFT), whose physiological relevance is unclear (Figure 1) (Shayeghi et al., 2005; West & 
Oates, 2008; Zimmermann & Hurrell, 2007).  Evidence also indicates that heme iron can, as 
well, be absorbed by receptor-mediated endocytosis, but a high-affinity receptor for heme iron 
has yet to be identified (Fuqua et al., 2012; West & Oates, 2008). Morphological studies using 
electron microscopy report the appearance of secondary lysosomes containing heme, in rats and 
dogs, upon administration of heme or hemoglobin close to the duodenal loops (West & Oates, 
2008). 
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Absorption of dietary ferritin, a protein that binds inorganic iron, has begun to be recently 
more studied than all other nutritional forms of iron (E. C. Theil, 2004; Elizabeth C Theil, 2011). 
However, although there is some evidence that it is taken into the enterocyte by a phytate-
resistent clathrin (receptor)-dependent endocytosis, mediated by a not yet identified high affinity 
receptor, the precise mechanism is unknown (Fuqua et al., 2012; Elizabeth C Theil, 2011). With 
exception for the dietary ferritin, nonheme iron is transported across the brush-border membrane 
via the divalent metal transporter 1 (DMT1) (Nancy C. Andrews, 1999; De Domenico et al., 
2008; Miret et al., 2003; Zhang & Enns, 2009a, 2009b). The DMT1 co-transports hydrogen and 
iron and, as the name indicates, iron must be in its ferrous state (Fe2+) (De Domenico et al., 
2008; Mackenzie & Garrick, 2005; Zhang & Enns, 2009b). Most of the dietary iron is present in 
the intestinal lumen in the ferric form (Fe3+), so it must be reduced prior to transportion by a 
brush-border ferric reductase. The duodenal cytochrome b (DCYTB) is a major reducing agent, 
but other reductases, such as the six transmembrane epithelial antigen of the prostate 2 
(STEAP2), and ascorbic acid, also contribute (Nancy C. Andrews & Schmidt, 2007; Fuqua et al., 
2012; T. Ganz, 2008; Han, 2011; Hentze et al., 2004; Zimmermann & Hurrell, 2007). Ascorbic 
acid can exert the effect of a reducing agent in itself or hypothetically act as a cofactor of the 
DCYTB (Mackenzie & Garrick, 2005; McKie et al., 2001).     
Intestinal nonheme iron absorption can be affected by several factors that range from the 
physiologic status of the individual (discussed further ahead) to dietary factors. In fact, although it 
is now possible to shed light and/or explore several of the luminal aspects that affect iron 
absorption, the establishment of a quantitative model for it remains complex (Hallberg, 2001; 
Miret et al., 2003). Once iron is released from food components, ferric iron will remain soluble as 
long as the environment favors an acidic pH, which is not a problem in the stomach but can be 
at the intestinal lumen. The acidic microenvironment of the duodenal surface, along with the cell 
surface reductase activity from the DCYTB will maintain significant levels of soluble and ferrous 
iron (Miret et al., 2003). Furthermore, several luminal reactions can occur with food components 
or secreted molecules that will enhance or inhibit nonheme iron absorption. From the dietary 
components that affect iron absorption citric acid, ascorbic acid and some amino acids (e.g.: 
cysteine) will favor iron absorption either by maintaining iron soluble (citric acid) or by reducing 
ferric iron to ferrous iron (ascorbic acid and cysteine). On the contrary, the presence of phytate, 
polyphenols and tannic acid will result in the formation of complexes with iron (booth ferric and 
ferrous iron) and inhibit its absorption (Han, 2011). Calcium, copper and lead, due to absorptive 
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competition, are also involved in the inhibition of nonheme iron (Nancy C. Andrews, 1999; 
Pasricha et al., 2010). Furthermore, gastroferrin, a stomach glycoprotein, is probably an 
important iron absorption regulator by the formation of iron complexes; although, the direction of 
the regulation is still debatable (Miret et al., 2003).  On the other hand, heme iron is far more 
bioavailable than nonheme iron and therefore its absorption is less affected by the external 
factors here addressed for nonheme iron (Han, 2011).  
 
 
Figure 1 - Summary diagram of the established and putative iron absorption pathways in the 
intestinal enterocyte.  
 
After entering the enterocyte, iron has two possible fates: (i) stored in ferritin (FT), or (ii) 
exported and reach circulation (Nancy C. Andrews, 1999). Again, there is some lack of 
knowledge regarding heme iron metabolism. It is known that it is absorbed, appearing in 
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membrane bound vesicles where it is degraded by heme oxigenase (HO), splitting it into bilirubin 
and ferrous iron. These will then enter the labile iron pool in the enterocyte, although the 
mechanism by which iron leaves the vesicle is unknown (Shayeghi et al., 2005; West & Oates, 
2008). In support, it has been shown that 90% of the iron from radio-labeled hemoglobin 
administered via enteral route is recovered after 3 hours from the portal circulation as nonheme 
iron (West & Oates, 2008). This mechanism is plausible for the heme iron that enters the 
enterocyte by endocytosis. The heme iron that is thought to enter via the heme transporter 
HCP1/PCFT is still hypothetically considered to be exported via the feline leukemia virus 
subgroup C receptor (FLVCR), a cell surface protein capable of actively exporting heme. 
Nonetheless, no studies have yet determined the FLVCR function and localization in the 
enterocyte (Latunde-Dada, Simpson, & McKie, 2006; West & Oates, 2008).   
With regard to nonheme iron more is known. After the uptake by the enterocyte it will 
either constitute, with the iron released from heme, the (i) intracellular labile iron pool (having a 
molecular nature that is not known but probably consists of low molecular weight chelates or 
chaperone proteins that bind to and transport iron) (Dunn, Suryo Rahmanto, & Richardson, 
2007), or (ii) it can be stored in FT, a cytosolic iron-storage protein (De Domenico et al., 2008). 
Iron stored as FT will be lost with the senescent enterocytes and the iron from the enterocyte 
labile iron pool will be, if needed and possible, exported to the plasma through the basolateral 
membrane transporter ferropotin (FPN) where it will bind to plasma transferrin (TF) (De 
Domenico et al., 2008; R. E. Fleming & Ponka, 2012; Fuqua et al., 2012; Munoz, Garcia-Erce, & 
Remacha, 2011). 
Ferropotin is the only iron exporter in the duodenal mucosa, macrophages and 
hepatocytes (De Domenico et al., 2008; Dunn et al., 2007; Zhang & Enns, 2009a). It is likely 
that FPN exports iron in the ferrous form; however, TF only binds ferric iron (Fuqua et al., 2012; 
Munoz et al., 2011). In the basolateral membrane, iron export through the FPN is dependent of 
hephaestin (HP), a ferroxidase that converts ferrous iron to ferric iron and allows it to bind to TF 
(Zhang & Enns, 2009a). While other cells rely on the circulating ferroxidase ceruloplasmin (CP) 
for iron oxidation, enterocyte FPN relies on the membrane-bounded paralog HP. Independently of 
the cell, the feroxidase activity is indispensable for the FPN, since without feroxidase activity FPN 
is internalized and degraded, preventing iron from being exported and leading to its accumulation 
in the cell, stored by the FT (De Domenico et al., 2008; Fuqua et al., 2012; Miret et al., 2003).   
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As previously mentioned, nearly all of the iron exported from the enterocyte is bound to 
TF, which can bind two molecules of ferric iron. This mechanism of iron chelation dampens the 
toxicity of the free iron and maintains iron in a soluble form. Under normal circumstances 20 to 
30% of the circulating TF binds iron, which is ensured by the high binding affinity of TF to iron 
and the high concentration of apo-transferrin (apo-TF, iron free form of TF). TF is also responsible 
for delivering iron to the cells that express TF receptors (Nancy C. Andrews & Schmidt, 2007; De 
Domenico et al., 2008).   
Several mechanisms have been identified to be involved in the cellular TF-dependent iron 
uptake. The ubiquitously expressed transferrin receptor 1 (TFR1) is the major vehicle for cellular 
iron uptake and is also the most well studied mechanism of internalization of the diferric-TF 
complex. Other cellular iron importers have been identified, including the transferrin receptor 2 
(TFR2 – expressed in hepathocytes, erythroid cells and duodenal crypt cells) and cubilin 
(expressed in epithelial cells of the kidney)(Hentze et al., 2004; Hentze, Muckenthaler, Galy, & 
Camaschella, 2010; Sheftel, Mason, & Ponka, 2012). TFR1 is presented in the cell surface to the 
plasma as a dimer and binds two diferric-TF molecules. The complex formed by the differic-TF 
and TFR1 localizes in clathrin-coated pits that are endocytosed. A proton-pump acidifies the early 
endosome containing the diferric-TF/TFR1 complex, promoting conformational changes in both 
and releasing iron. Thereafter, the ferric iron released from the complex is reduced to ferrous iron 
by the ferriredutase STEAP3 and transported to the cytosol by DMT1 (Gkouvatsos, Papanikolaou, 
& Pantopoulos, 2012; Hentze et al., 2004; Sheftel et al., 2012; Zhang & Enns, 2009a). After the 
release of the ferric iron, the complex apo-TF/TFR1 returns to the cell surface, the apo-TF is 
released, and the cycle restarts (N. C. Andrews, 2008; Gkouvatsos et al., 2012; Mayle, Le, & 
Kamei, 2012).  
Once iron enters the cell, the amount of iron that is not needed for immediate use is 
sequestered from the iron labile iron pool by FT (Hentze et al., 2004; Sheftel et al., 2012). The 
labile iron pool represents approximately 3 to 5 % of the cellular iron stores and is composed of 
iron associated to low molecular weight chelates (Gkouvatsos et al., 2012). FT is an 
heteropolymer of 24 subunits H (heavy or heart) and L (light or liver) types that can encapsulate 
up to 4500 iron atoms, solubilizing and maintaining them in a less reactive form. Iron stored in 
FT is readily available for cellular utilization. Thus, in addition to the storage function, FT also has 
enzymatic properties (oxidization of ferrous iron to ferric iron) (N. C. Andrews, 2008; Nancy C. 
Andrews & Schmidt, 2007; De Domenico et al., 2008; Hentze et al., 2004).  
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Intracellular iron can be directed to several sites (for example, to the nucleus, FT or the 
labile iron pool), but much of it is directed to the mitochondria where the synthesis of heme and 
iron-sulfur (Fe-S) clusters takes place. Despite of the great biological significance of this process, 
the mechanism responsible for the traffic of iron to the mitochondria remains unclear (Hentze et 
al., 2004; Napier, Ponka, & Richardson, 2005). Nonetheless, it is accepted that mitochondrial 
iron export requires Fe-S cluster biosynthesis. Fe-S clusters and heme are exported from the 
mitochondria by specific transporters; for Fe-S clusters these are postulated to be the ATP-
binding cassette, subfamily B, member 7 (ABCB7) (Dunn et al., 2007; Napier et al., 2005). After 
being exported from the mitochondria, heme will be used for insertion in several proteins such as 
hemoglobin and cytochromes, although the mechanism for heme release from the mitochondria 
remains unclear (Dunn et al., 2007; Hentze et al., 2010; Munoz et al., 2011). 
As previously mentioned, in normal conditions, 1 to 2 mg of iron are absorbed by 
enterocytes each day to compensate the losses, but these amounts only represent a small 
portion of the body iron daily needs. A total of 3000 to 5000 mg of iron can be present in a 
healthy adult. The erythron incorporates more than two thirds of the total body iron as 
hemoglobin; approximately 1800 mg of iron are incorporated in circulating erythrocytes and near 
300 mg are present in the bone marrow and in erythroid precursors. Hemoglobin synthesis is 
responsible for nearly 80% of the iron demands in humans (20 to 25 mg/day) (Hentze et al., 
2004; Zhang & Enns, 2009b). The amount of iron that is present in the erythron normally 
exceeds the iron that is present in iron-stores, which are mainly the hepatocytes (approximately 
1000 mg) and the reticuloendothelial macrophages (estimated in nearly 600 mg). A small 
amount is also present in other cells and tissues, such as muscle cells (300 mg incorporated into 
myoglobin) and circulating bounded to TF (3 mg) (Nancy C. Andrews, 1999; T. Ganz, 2008; 
Hentze et al., 2004). The daily demands of iron are supported mainly by the macrophages in the 
liver and spleen, which phagocytize the senescent erythrocytes and recycle the iron. The iron in 
the hemoglobin is released, as previously mentioned, by the HO, and exported into circulation 
through FPN (relying on CP as a ferroxidase) or directly by the FLVCR  (Donovan & Andrews, 
2004; Munoz et al., 2011; Zhang & Enns, 2009a, 2009b). The circulating heme can be 
transported to the hepatocytes by the hemopexin and, subsequently, degraded for iron release 
(Zhang & Enns, 2009a). 
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Figure 2 – Adult iron distribution and daily whole body iron metabolism. 
 
Since there is no known mechanism of iron excretion, a highly regulated mechanism of 
absorption and release from the stores is needed to maintain iron homeostasis at the cellular and 
systemic levels (Nancy C. Andrews, 1999; T. Ganz, 2008; Hentze et al., 2004). Still, the 
molecular basis of the complex homeostatic network has only recently been uncovered (T. Ganz, 
2008; Simpson & McKie, 2009).  
At a cellular level, iron homeostasis is maintained through transcriptional, translational 
and post-translational mechanisms. The messenger ribonucleic acid (RNA) of several iron related 
proteins has untranslated regions denoted as iron-responsive elements (IRE). The IREs are found 
in the 5’ untranslated region of the messenger RNA that encodes for FPN, TF chains, 
mitochondrial aconitase and erythroid 5-aminolevulinic acid synthase (enzyme of heme 
biosynthesis); whereas, the messenger RNA that encodes for TFR1 and DMT1 have IRE at the 3’ 
untranslated region. The cytosolic proteins iron-regulatory proteins (IRP) recognize and bind to 
IRE, exerting regulatory effects. The binding of IRP to the IRE in the 5’ untranslated regions 
precludes translation; while the formation of the IRP/IRE complex in 3’ untranslated regions 
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stabilizes the messenger RNA and prevents its degradation (De Domenico et al., 2008; Hentze et 
al., 2004). Two IRPs have been identified, IRP1 and IRP2, with share sequence homology but 
have different properties (N. C. Andrews, 2008). In iron-depleted cells the IRP binds to IRE, a 
process that does not happen in iron-replete cells (T. A. Rouault, 2006). This is possible due to 
the iron sensing properties of the IRPs. In the presence of high cellular iron levels, a Fe-S cluster 
will assemble in the IRP1 converting it to an aconitase, inhibiting the binding of IRP1 to IRE. On 
the contrary, in iron depleted cells the absence of the Fe-S cluster allows IRP1 to be in its RNA-
binding form. The IRP2 does not contain the Fe-S cluster and seems to have lost the aconitase 
activity along the evolutionary process. While in iron-depleted cells the IRP2 accumulates, in iron-
replete cells it is targeted for degradation (N. C. Andrews, 2008; De Domenico et al., 2008; 
Hentze et al., 2004; T. A. Rouault, 2006). Iron cytosolic concentration is rapidly adjusted by the 
IRP/IRE regulatory system and the function of several iron-dependent components and processes 
is therefore optimized (T. A. Rouault, 2006). 
At a systemic level several signals such as iron absorption (“mucosal block”), oxygen 
tension (hypoxia regulator), iron levels (stores regulator) and systemic iron needs (erythroid 
regulator) regulate iron absorption, storage and transfer (R. E. Fleming & Ponka, 2012; Hentze et 
al., 2004; Simpson & McKie, 2009). Circulating iron status is maintained at balanced levels by 
two main mechanisms: (i) absorption regulation, and (ii) regulation of release by the 
macrophages and hepatocytes (T. Ganz, 2008). In 1960, the hypothesis that a humoral 
substance was responsible for match iron absorption to the iron demands was put forward by 
Beutler et al. (Beutler & Buttenwieser, 1960). However, only in 2001 Nicolas et al. (Nicolas et al., 
2001) demonstrated that hepcidin, the peptide sequenced in 1998 by Ganz and collaborators 
(Park, Valore, Waring, & Ganz, 2001), had an iron regulator function that made it a leading 
candidate for the long-sought iron-regulatory hormone (Robert E. Fleming & Sly, 2001). The small 
size of its gene, the lack of shared sequence motifs with other iron related genes and the rarity of 
mutations prevented the discovery of hepcidin by genetic methods, but several serendipitous 
events helped to bring hepcidin and its function to the knowledge of the scientific community 
(Tomas Ganz, 2011). Hepcidin, a 25 amino acid peptide hormone is the principal systemic 
regulator of intestinal iron absorption and iron efflux from macrophages. This hormone is 
primarily produced by the hepatocytes in the liver and in smaller amounts by other cell types 
upon cleavage of a pro-peptide hormone with 84 amino acids by the convertase furin. The 
biological action of hepcidin is exerted by its binding to FPN, which leads to FPN phosphorylation, 
 14 
 
internalization and ubiquitin-mediated lysossomal degradation. Since FPN is the only exporter of 
iron from enterocytes, macrophages and hepatocytes, its degradation results in a decrease of the 
delivery of iron from the enterocytes and the reticulo-endothelial system to the plasma (N. C. 
Andrews, 2008; Fuqua et al., 2012; T. Ganz & Nemeth, 2006; Gkouvatsos et al., 2012). A 
similar mechanism has been recently proposed to occur at the barriers of the brain, in this case 
regulating iron delivery into the central nervous system (Marques et al., 2009). 
Hepcidin is negatively regulated by iron (circulating and stores), erythropoietic needs, 
inflammation and hypoxia. (Tomas Ganz, 2011; Gkouvatsos et al., 2012).  Specific conditions, 
such as inflammation, are potent suppressors of iron absorption by enterocytes and release by 
macrophages. There is evidence that this effect is mediated by hepcidin since inflammatory 
cytokines, with special emphasis on IL-6, activate hepcidin expression. This mechanism is the 
major contributor to the anemia of chronic disease (ACD – also called anemia of chronic 
inflammation) (T. Ganz & Nemeth, 2006; Hentze et al., 2010). Iron absorption is regulated in 
several different manners, being the iron from diet the first regulator. After the ingestion of a 
significant amount of dietary iron, the enterocyte becomes refractory to iron absorption. This 
phenomena, so-termed “mucosal block”, probably results from an accumulation of intracellular 
iron that will change the levels of DMT1 and DCYTB, which will prevent further iron uptake 
(Nancy C. Andrews, 1999; De Domenico et al., 2008). Iron absorption is also regulated in cases 
of normoxia and hypoxia by the hypoxia inducible factor (HIF), a nuclear transcription factor first 
described as the major oxygen regulated transcription factor through the control of erythropoietin 
expression and, therefore, of oxygen supply to red cell production (Simpson & McKie, 2009). HIF 
is also described to regulate Hepcidin expression. Recently, compelling data has indicated that 
DCYTB, DMT1 and possibly FPN genes, which are highly up regulated in hypoxia and iron 
deficiency, are also HIF-2α dependent for expression (Mastrogiannaki et al., 2009; Shah, 
Matsubara, Ito, Yim, & Gonzalez, 2009).  (Nancy C. Andrews, 1999; Han, 2011).  
In summary, iron homeostasis is a very highly regulated process for which several 
pathways and molecular players participate. 
 
 
 
 15 
 
1.1.2. Assessment of iron status  
Bone marrow  
Bone marrow grading is the gold standard for iron deficiency assessment and provides 
the definitive diagnosis. The major limitations of this method are the high invasiveness, cost 
(expensive) and pain incurred by the assessment procedure. Therefore, bone marrow aspiration 
is rarely performed and alternative sensitive and less invasive tests are used (Fairweather-Tait, 
Wawer, Gillings, Jennings, & Myint, 2013; Gale, Torrance, & Bothwell, 1963; G. H. Guyatt et al., 
1992; Raiten et al., 2011; Rimon, Levy, Sapir, & et al., 2002).  
 
Hemoglobin 
The assessment of the prevalence of ID in developed countries is commonly obtained 
from representative samples with specific indicators of iron status, such as serum FT, TF 
saturation and free erythrocyte protoporphyrin; whereas, estimates from developing countries are 
commonly based in hemoglobin measurements (Zimmermann & Hurrell, 2007). Iron 
homeostasis is a continuum that ranges from iron overload to iron depletion being ID and IDA 
intermediate states (Figure 3), (WHO, 2001).  
 
 
Figure 3 - Conceptual diagram of the relationship between iron deficiency and/or anemia in a 
hypothetical population. Adapted from WHO (2001). 
 
Despite of the low sensitivity and specificity of hemoglobin as an indicator of ID, its levels 
are commonly used in surveys of anemia (of all causes) (Lynch, 2010). Nevertheless, anemia (of 
all causes) surveys for assessment of ID are inadequate since they do not properly correlate with 
each other, which may justify the limited success of public health programs based on 
hemoglobin levels (Cook, Flowers, & Skikne, 2003; Mei et al., 2005). Underlying this may be that 
anemia has multiple precipitating factors in addition to iron deficiency, such as genetic disorders, 
 16 
 
infectious diseases and other nutritional deficiencies (McLean et al., 2009; Pang & Schrier, 
2012; Patel, 2008), which may differ between places. Therefore, anemia, IDA and ID are 
commonly, although not correctly, used as synonymous. Despite this, the overall prevalence of ID 
is estimated to be equal to the prevalence of anemia (of all causes), since it is assumed that IDA 
represents 50% of all anemias and the prevalence of ID alone is considered equal to that of IDA 
(Susan F Clark, 2009; De Benoist et al., 2008; Lynch, 2010; McLean et al., 2009). As previously 
mentioned, the assessment of iron status in developing countries is mainly preformed using 
hemoglobin measurements and anemia as a proxy; accordingly, it is thus stated that iron 
deficiency is the main cause of anemia in underprivileged environments (WHO, 2001).   
Inadequate supply of iron to the erythroid marrow over time will lead to an inadequate 
support for optimal erythropoiesis in the developing red cell mass, which will reduce hemoglobin 
concentrations to below-optimal levels and, consequently, cause anemia (Bainton & Finch, 
1964). Specifically, the WHO classifies hemoglobin values under 12 and 13 g/dL for adult non-
pregnant women and adult males, respectively, as defining anemia. These values were defined 
as under two standard deviations (-2SD) of the distribution mean for hemoglobin in a normal 
population of the same gender and age living at the sea level. As such, anemia definition is 
largely a statistical definition rather than a physiological definition (WHO, 2001). It also important 
to note that a hemoglobin value overlap can occur between persons with iron deficiency and 
normal non-anemic individuals. Taking into account all the limitations of hemoglobin levels (or 
anemia cutoff points) for ID assessment it is clear that hemoglobin should not be used as a 
stand-alone indicator (Gibson, 2005).  
 
Hematocrit and red cell indices  
Hematocrit (or packaged cell volume) and red cells indices are often used for differential 
diagnosis of anemia, which include also iron deficiency anemia. Hematocrit, along with 
hemoglobin, is used for anemia diagnosis. In cases of early ID a nearly normal hematocrit value 
can be observed; whereas, in cases of mild to severe ID, both hemoglobin and hematocrit are 
below the threshold of normality. Several limitations are described for hematocrit use in ID 
determination. Briefly, hematocrit falling only occurs in a later stage of ID, thus resulting in poor 
sensitivity. Furthermore, the same factors that affect hemoglobin also affect hematocrit, so lower 
values of hematocrit can be observed due to causes other than ID, resulting in a poor specificity, 
and several internal and external factors can affect its value resulting in poor precision. Cutoff 
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points for hematocrit values are also defined; however, and similarly to hemoglobin, they do not 
specifically identify iron deficient individuals (Gibson, 2005). 
Red cell indices are calculated with the values measured for hemoglobin, hematocrit and 
red cells blood Count (RBC) and include mean corpuscular volume (MCV), mean cell hemoglobin 
(MCH), mean cell hemoglobin concentration (MCHC) and red cell distribution width (RDW). MCV 
can be manually calculated as the hematocrit (volume fraction) divided by the RBC (1012/L) and 
therefore is a measure of the average size of red blood cells (expressed in femtoliters – fL). In 
iron deficiency, red cells can be small (microcytosis). However, other nutritional disorders can 
also affect MCV such as vitamin B12 and folic acid deficiencies (both causing abnormal large cells 
- macrocytosis) and vitamin B6 (also causing small red blood cells). The ratio of hemoglobin (g/L) 
to RBC defines the MCH and is expressed in picograms (pg). Changes in MCH occur in the same 
direction as MCV either in iron deficiency or in vitamin B12 and folic acid deficiencies. MCHC can 
be obtained dividing the hemoglobin by hematocrit and is a measure of the mean hemoglobin 
amount in each red blood cell. This is the red cell index less affected by age; nonetheless, it is 
also the least useful for iron deficiency identification because it is the last value to fall. RDW is a 
measure of the variation of size in red cells and is usually increased in iron deficiency. Again, 
alterations in RDW can occur in several pathologies and nutritional deficiencies, so RDW is also 
not a specific indicator of iron deficiency (Gibson, 2005).  
 
Serum iron, total iron binding capacity and transferrin saturation 
In the fasting state serum iron levels reflect the migration of iron to bone marrow from 
the reticulo-endothelial system indicating the iron supply adequacy for erythropoiesis 
(Fairweather-Tait et al., 2013; Gibson, 2005). Reliability of serum iron is questionable since it is 
affected by diurnal rhythms, ingestion of iron and inflammatory states (Fairweather-Tait et al., 
2013). A useful indicator used for iron deficiency diagnosis is the total iron binding capacity 
(TIBC), which reflects the amount of serum iron binding sites that are not occupied. TIBC is 
increased early in iron deficiency (even before iron-deficient supply for erythropoiesis) as a result 
of the increase in TF production needed for higher iron transport and uptake. TF saturation is 
calculated from serum iron and TIBC [as follows: serum iron (µg/dL) / TIBC (µg/dL)] and, 
similarly to serum iron, is a measure of iron supply to erythropoietic tissues (Fairweather-Tait et 
al., 2013; Gibson, 2005).  
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Serum ferritin 
Tissue ferritin is an intracellular protein involved in iron storage. Serum ferritin is slightly 
different than tissue ferritin and contains little or no iron (Worwood, 1990). Serum FT function in 
the serum is unknown, however it seems to be released from the reticulo-endothelial system 
(Gibson, 2005). Serum FT is the only iron status indicator that can be used to identify normal, 
deficient and excessive iron status because its concentration is closely related to body iron 
storage (1 µg/L of serum FT correspond to 8-10 mg of iron stored). Despite of this close 
correlation, when iron stores are depleted serum FT remain low but no longer directly reflects the 
severity of tissue iron deficiency (Gibson, 2005; Raiten et al., 2011; Zhu, Kaneshiro, & Kaunitz, 
2010). This is also considered to be the single best laboratory test for the diagnosis of iron 
deficiency since its predictive value is of 0.95 (G. H. Guyatt et al., 1992; Zhu et al., 2010). Due to 
its high predictive value, simple cutoff points have been established for iron deficiency diagnosis: 
values lower than 15 µg/L define iron deficiency, while values higher than 100 µg/L rule out iron 
deficiency and the intermediate values need further investigation (G. H. Guyatt et al., 1992). 
However, serum FT is influenced by age and is also an acute phase protein and, thus, in case of 
inflammation serum FT should not be used as an iron status marker (Fairweather-Tait et al., 
2013; Raiten et al., 2011; Zhu et al., 2010). For older individuals values lower than 45 µg/L 
should be used for iron deficiency diagnosis (Gordon H Guyatt et al., 1990). A cutoff point of 30 
µg/L for the general population is usually used in the majority of the diagnostic studies of iron 
deficiency (Johnson-Wimbley & Graham, 2011).   
 
Soluble serum transferrin receptors  
As previously described, when an insufficiency of intracellular iron occurs, the expression 
of TFR-1 on the cell surface is up-regulated and allows for a higher iron uptake. In human serum 
the concentration of the soluble serum TFR (sTFR), a soluble form of the transmembrane TFR, is 
proportional to the expression of TFR (Gibson, 2005), rendering it possible to use sTFR as marker 
of iron deficiency and erythropoietic activity (Fairweather-Tait et al., 2013). Bone marrow 
erythroid precursors are the main source (75 to 80%) of sTFR and, unlike serum ferritin, sTFR 
levels are not affected by age or inflammatory conditions (Susan F Clark, 2009; R. Stewart & 
Hirani, 2012; Zhu et al., 2010). Despite of the usefulness and reliability of sTFR, the assay is not 
standardized, is expensive and not widely available, which prevents its clinical application (Choi et 
al., 2005; Zhu et al., 2010). Furthermore, folate and/or vitamin B12 affect erythropoiesis and 
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consequently sTFR concentrations, confounding the interpretation of the assay for iron status 
assessment (Gibson, 2005).  
 
Ratios and algorithms  
The ratio of sTFR to the logarithmic value of ferritin (sTFR – Log(FT) ratio) is also 
considered a good indicator for the diagnosis of iron deficiency, especially in cases where iron 
deficiency occurs in combination with other morbidities that elicit an acute phase reaction (for 
example, elevation of C-reactive protein) (Susan F Clark, 2009; Punnonen, Irjala, & Rajamaki, 
1997).  
The Cook algorithm (Cook et al., 2003) for body iron calculation (body iron (mg/kg) = -
[log(sTFR*1000/serum FT) – 2.8229/0.1207]) is an index for iron status alterations. It is 
relatively new and can be used as an epidemiological measure for monitoring populations where 
inflammation has been excluded or is rare, and it can also be used as a measure of effectiveness 
in intervention studies (Fairweather-Tait et al., 2013). 
 
Use of multiple indicators of iron status  
Indicators of iron deficiency have limitations and the use of a single measurement can 
lead to an erroneous classification of the iron status due to the overlap of normal and abnormal 
values of the measurement depending on the confounding factors (e.g.: age, inflammatory states 
or nutritional deficiencies). Thus, the use of multiple indices can be a more reliable alternative to 
identify abnormalities of iron metabolism. Usually, a combination of three indicators is used and 
abnormal values for at least two rules in iron deficiency (Gibson, 2005). However, due to the high 
predictive value, low values of ferritin have been used as a single indicator for iron deficiency in 
the absence of inflammation (G. H. Guyatt et al., 1992; Raiten et al., 2011; Rimon et al., 2005). 
Furthermore, serum ferritin concentration is the most powerful test for iron deficiency (Goddard, 
McIntyre, & Scott, 2000). Table 1 provides a summary of the principal indices used for iron 
assessment, the normal values and the cutoff points for iron deficiency. 
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Table 1 - Cut off points for ID diagnosis. Adapted from Susan F Clark, 2009; Gibson, 2005; G. 
H. Guyatt et al., 1992; Gordon H Guyatt et al., 1990; Herbert, 1987; Johnson-Wimbley & 
Graham, 2011; Punnonen et al., 1997; Rimon et al., 2002; Zhu et al., 2010; Zimmermann & 
Hurrell, 2007 
Measurements  Normal I. D. 
MCV(fL) 80-100 <80 
MCHC (g/L) 320-360 <320 
RDW (%) ≤14 >14 
Serum iron (µg/dL) 115±50 <71 
Serum ferritin (µg/L) 100±60 <30/<45 a 
Transferrin saturation (%) 35±15 <20 
TIBC (µg/dL) 330±30 ≥360 
sTFR (mg/L) ≤1.76 >1.76 
sTFR – Log(FT) ratio ≤1.5 >1.5 
a Aged individuals    
 
1.2. Iron deficiency 
1.2.1. From basics to clinics  
In 1937, McCance and Widdowson observed that there is no mechanism for iron 
excretion, implying that homeostasis is maintained by the regulation of absorption (Hallberg, 
2001; Miret et al., 2003). It is estimated that daily 1 to 2 mg of dietary iron is absorbed, which is 
enough to compensate the continuum losses that results from cell shedding and fluids loses. As 
previously mentioned, iron homeostasis is narrowly regulated at the absorptive level; although, 
even in iron overload, 0.5 mg of iron are absorbed and in iron deficiency, despite of the increase 
in absorption, only 2 to 4 mg are absorbed (Miret et al., 2003). Inadequate iron intake and 
absorption are the main causes of ID, particularly when they are insufficient to overcome 
physiologic needs and/or pathologic conditions (i.e.: blood losses) (see Table 2 for details). Each 
1 ml of blood contains approximately 0.5 mg of iron, therefore the occurrence of significant blood 
losses (due to hemorrhagic events or excessive menorrhea) markedly increases the risk of iron 
deficiency (Zimmermann & Hurrell, 2007) and the small amounts of iron absorbed make it time 
consuming to revert.  
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Table 2 - Physiologic and pathologic conditions that can cause ID or IDA. Adapted from Nancy 
C. Andrews, 1999; Susan F. Clark, 2008; Susan F Clark, 2009; Munoz, Garcia-Erce, & Remacha, 
2011b 
Physiologic conditions Pathological conditions 
 Increased iron/dietary demands  Chronic inflammatory states 
  Pregnancy   Chronic renal disease 
  Lactation   Congestive heart failure 
  Infants   Obesity 
  Children and adolescents  Medications  
  Menstrual losses   Proton-pump inhibitors  
     H2 antagonists 
     Antacids 
     Aspirin 
     NSAIDs 
    Gastrointestinal conditions  
     Ulcer (gastric/duodenal/peptic) 
     Gastritis (Erosive/H. pylori) 
     Chronic atrophic gastritis  
     Esophagititis  
     Celiac/Chrohn’s disease 
     Malabsorptive states  
     Gastrectomy 
     Colonic adenoma  
     Carcinoma 
    Blood losses  
     Excessive menstrual losses  
     Blood donation  
     Excessive surgical blood losses  
     Inflammatory bowel disease 
    Other 
     Hepatic disease  
     Restless leg syndrome 
     Athletic induced ID 
     Intestinal helminthes 
     Erythropoiesis-stimulating agents 
     Malaria 
     Human Immunodeficiency Virus 
 
Previous studies on ID mainly focused on infants, children and women of childbearing 
age. Only a handful of studies on the elderly have been conducted (Hsu et al., 2013). In aging, 
although unlikely that physiologic conditions will be responsible for the development of ID late in 
life, several of the iron-related/caused pathological conditions are highly prevalent in older 
individuals (Susan F. Clark, 2008). Hypochlorhydria can be a substantial cause of iron deficiency 
given the low production of acid in the stomach (needed to keep iron soluble); it is highly 
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prevalent in older individuals due to several causes, such as atrophic gastritis, medication (e.g.: 
proton-pump inhibitors, antacids and H2 antagonists) and Helicobacter pylori (Annibale et al., 
1999; Susan F. Clark, 2008; Zimmermann & Hurrell, 2007). The mismatch between iron 
absorption and iron demands is also observed in gastrointestinal conditions, including ulcers, 
inflammatory bowel diseases, both by bleeding or absorption impairment (Annibale et al., 1999; 
Gasche, Lomer, Cavill, & Weiss, 2004).  
In hepatic conditions, iron deficiency has also been observed since the liver is the main 
storage place of iron as FT and the site of TF synthesis. Ultimately, in liver diseases iron may 
become trapped and therefore not released for transportation to other tissues (Susan F. Clark, 
2008; Intragumtornchai, Rojnukkarin, Swasdikul, & Israsena, 1998). Also, in cirrhotic patients 
the absorption of some micronutrients is compromised, contributing for nutritional deficiencies 
among which iron deficiency is common (Susan F. Clark, 2008; Peng et al., 2007).  
The inadequate delivery of iron for incorporation in the erythroid precursors despite of an 
adequate storage of iron in the bone marrow is termed functional iron deficiency. This type of 
“iron deficiency” is present in some cases such as malignancy, anemia of chronic disease (ACD 
– also called anemia of chronic inflammation) or chronic kidney disease (Thomas et al., 2013). 
ACD is observed both in infectious and noninfectious diseases. The linkage between ACD and 
iron deficiency is mediated by hepcidin and inflammatory cytokines (such as interleukin-6). In 
infection and inflammation the production of hepcidin is upregulated resulting in hypoferremia 
(Nancy C. Andrews, 1999; N. C. Andrews, 2008; Brugnara, 2003; T. Ganz & Nemeth, 2006). 
The risk to develop chronic kidney disease is higher in older individuals, and subjects with 
chronic kidney disease are at a higher risk of developing iron deficiency, especially if under 
hemodialysis (due to increased iron loses) or treatment with erythropoiesis stimulating agent (due 
to the increased iron demands) (Susan F. Clark, 2008; Wittwer, 2013). Recently, it was also 
demonstrated that patients with heart failure may be more susceptible to iron deficiency due to 
depletion of iron stores, defective iron absorption and/or reduced availability of iron recycled in 
the reticuloendothelial system (Nanas et al., 2006; Opasich et al., 2005). 
Among others, all of the above-mentioned factors may be highly prevalent in older 
individuals and, individually or by their interaction can alter iron homeostasis and mediate the 
development of iron deficiency. 
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1.2.2. Epidemiology of iron deficiency  
Iron deficiency is the major cause of anemia. The WHO Department of Nutrition for 
Health and Development, based on the Vitamin and Mineral Nutrition Information System 
(VMNIS), has estimated anemia prevalence at global, regional and national levels (De Benoist et 
al., 2008; Mathers et al., 2008). The most recent data available regarding IDA prevalence was 
published in the WHO report The Global Burden of Disease: 2004 Update (2008) (Mathers et al., 
2008)), in which it is estimated that IDA corresponds to 60% of all anemias in non-malaria areas 
and 50% in areas were malaria is prevalent (given the high hemolysis present) (Mathers et al., 
2008). In fact, IDA, at any moment, is the most prevalent health condition. A prevalence equal or 
higher than 5% is considered a public health problem (WHO, 2001). In 2004, it was estimated 
that 1 159 millions (in a population of 6 437 millions) of individuals across the world have IDA, 
which accounts for a prevalence rate of 18% (Table 3). Despite of Africa and South East Asia 
contributing to more than a half (56.6%) of the cases, IDA is highly prevalent in every WHO 
region. Europe presents the second lowest prevalence of IDA. These estimates are made based 
on nonspecific markers, such as hemoglobin and predictive equations (McLean et al., 2009) and, 
therefore, data should be interpreted with caution. 
 
Table 3 - Prevalence of IDA in WHO regions, 2004 
 Cases of IDA (millions) Population (millions) Prevalence (%) 
World 1 159.3 6 437 18.0 
Africa 193.8 738 26.3 
South East Asia 462.4 1 672 27.7 
The Americas 66.4 874 7.6 
Eastern Mediterranean 88.5 520 17.0 
Europe 77.7 883 8.8 
Western Pacific 269.0 1 738 15.5 
 
The main body of literature regarding irons status in European countries dates back to 
the 80s and early 90s, with authors basing their estimates in hemoglobin determination and only 
a few reporting data from southern European countries. Also, no data are available for older 
individuals probably due to the high number of confounding factors present in this population 
group (Hercberg, Preziosi, & Galan, 2001). In the United States of America, the Centers for 
Diseases Control and Prevention, using specific markers of iron status (serum FT, TF saturation 
and free erythrocyte protoporphyrin), in the population sample examined in the National Health 
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and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2000, reported a prevalence 
of iron deficiency in older individuals that ranged from 3% to 9% and a significant increase in iron 
deficiency prevalence in females between the ages of 50 to 70 years (Control & Prevention, 
2002).   
Epidemiological data regarding death and disability adjusted life years (DALY) was 
recently updated in the Global Health Estimates for the years 2000–2012 ("WHO | Estimates for 
2000–2012," 2014). In Europe, IDA as a cause of death only overcomes the barrier of 
thousands in aged individuals strata (60 or years or older), with a higher expression in females, 
which is expected since there are more females in that age group (Table 4). Interestingly, despite 
of being in older individuals that ID is more life threatening, this is the population group in which 
the effects of ID are less studied. 
 
Table 4 - Deaths (population in thousands) due to IDA by age and sex, in WHO regions. Global 
health estimates 2012 ("WHO | Estimates for 2000–2012," 2014). 
 Males Females 
Total 
 0-14 15-59 60+ 0-14 15-59 60+ 
World 
8.711 
(963.536) 
14.686 
(2.230.904) 
16.692 
(371.994) 
9.062 
(899.757) 
17.030 
(2.167.894) 
23.980 
(441.372) 
90.160 
(7.075.457) 
Africa 
6.863 
(191.908) 
10.576 
(233.995) 
5.092 
(20.234) 
7.192 
(187.547) 
12.137 
(234.858) 
7.070 
(23.986) 
48.930 
(892.528) 
South East Asia 
330 
(276.787) 
564 
(588.968) 
847 
(71.593) 
391 
(253.799) 
1.045 
(561.881) 
2.034 
(80.333) 
5.212 
(1.833.361) 
The Americas 
890 
(119.163) 
1.512 
(293.118) 
4.799 
(58.664) 
769 
(114.236) 
1.420 
(299.602) 
6.157 
(71.996) 
15.546 
(956.779) 
Eastern 
Mediterranean 
275 
(104.502) 
397 
(191.473) 
316 
(19.011) 
305 
(98.971) 
468 
(178.161) 
415 
(20.252) 
2.175 
(612.370) 
Europe 
54 
(81.140) 
152 
(279.788) 
1.773 
(76.324) 
37 
(77.066) 
158 
(283.617) 
3.504 
(106.549) 
5.678 
(904.484) 
Western Pacific 
298 
(186.954) 
1.448 
(633.244) 
3.781 
(123.978) 
366 
(165.275) 
1.778 
(599.502) 
4.704 
(135.797) 
12.374 
(1.844.750) 
 
Since iron deficiency is more prevalent in Africa and South East Asia the burden of iron 
deficiency (Table 5) is higher in these regions. Cost effectiveness of public health strategies and 
the burden of iron deficiency are measured in cost per DALY saved (Horton, 2006; Longfield, 
Smith, Gray, Ngamkitpaiboon, & Vielot, 2013), therefore low income countries will be the ones in 
which fortification will result in higher economic gains. Interventions to improve iron status have 
also been proposed to improve human capital since work capacity is reduced in iron deficiency 
(Haas & Brownlie, 2001).  
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Table 5 - Burden of disease in DALYs (population in thousands) due to IDA by age and sex, in 
WHO regions. Global health estimates 2012 ("WHO | Estimates for 2000–2012," 2014). 
 Males Females 
Total 
 0-14 15-59 60+ 0-14 15-59 60+ 
World 
14.596.920 
(963.536) 
5.215.420 
(2.230.904) 
1.163.788 
(371.994) 
12.790.183 
(899.757) 
12.033.058 
(2.167.894) 
1.827.788 
(441.372) 
47.627.157 
(7.075.457) 
Africa 
4.286.630 
(191.908) 
1.752.296 
(233.995) 
238.619 
(20.234) 
3.758.726 
(187.547) 
2.640.851 
(234.858) 
301.709 
(23.986) 
12.978.831 
(892.528) 
South East Asia 
5.358.228 
(276.787) 
2.104.376 
(588.968) 
451.869 
(71.593) 
4.821.630 
(253.799) 
5.781.635 
(561.881) 
751.513 
(80.333) 
19.269.251 
(1.833.361) 
The Americas 
1.168.139 
(119.163) 
418.009 
(293.118) 
169.581 
(58.664) 
743.312 
(114.236) 
518.521 
(299.602) 
143.455 
(71.996) 
3.161.017 
(956.779) 
Eastern 
Mediterranean 
1.753.883 
(104.502) 
542.680 
(191.473) 
99.294 
(19.011) 
1.478.751 
(98.971) 
1.205.345 
(178.161) 
123.502 
(20.252) 
5.203.455 
(612.370) 
Europe 
612.534 
(81.140) 
212.935 
(279.788) 
108.048 
(76.324) 
493.197 
(77.066) 
698.247 
(283.617) 
203.093 
(106.549) 
2.328.054 
(904.484) 
Western Pacific 
1.391.653 
(186.954) 
177.884 
(633.244) 
93.408 
(123.978) 
1.466.129 
(165.275) 
1.153.815 
(599.502) 
296.026 
(135.797) 
1.662.945 
(944.176) 
 
1.2.3. General health  
Iron deficiency will lead to iron deficient erythropoiesis, which ultimately will result in iron 
deficiency anemia. Therefore, the health outcomes of iron deficiency include the ones associated 
with anemia. Traditionally, iron deficiency has been considered to have clinical consequences 
only in the presence of anemia (Anker et al., 2009). However, several examples demonstrate 
beneficial effects of iron treatment even in non-anemic patients; such is the case of iron 
treatment in non-anemic subjects with restless leg syndrome who presented greatly reduced 
symptomatology (Satija & Ondo, 2008).  
In older individuals, several deleterious health consequences are associated with anemia 
including physical performance decline, frailty, higher risk of falling, diminished quality of life, 
cardiovascular disease, cognitive impairment, morbidity, hospitalization and mortality (Beghe, 
Wilson, & Ershler, 2004; Chaves, 2008; Fairweather-Tait et al., 2013; Hsu et al., 2013; Pang & 
Schrier, 2012; Patel, 2008; Peters et al., 2008; Price, Mehra, Holmes, & Schrier, 2011; Roy, 
2011; M. Thein et al., 2009; Van Puyvelde, Cytryn, Mets, & Beyer, 2009). Evidence clearly and 
consistently demonstrates the existence of an anemia association with poor health outcomes. 
However, the inference about causality is restricted due to the inherent limitations of 
observational studies, which compose the main body of literature on this topic (Chaves, 2008). 
For example, Hsu et al. (Hsu et al., 2013) found that iron deficiency, measured by serum iron, 
was associated with cardiovascular disease and all causes of mortality; although, several 
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limitations make the interpretation and causality of this study difficult. Using a more specific, but 
limited, set of iron biomarkers in a larger cohort, Morkedal et al. (Mørkedal, Laugsand, 
Romundstad, & Vatten, 2011) reported an association of low iron status with an higher risk of 
death by ischemic heart disease, particularly if low iron status was observed in earlier stages of 
the follow-up. The authors suggested that low iron status may be a late sign of ischemic heart 
disease or that unknown prevalent disease at baseline could influence the associations between 
low iron status and death. In a prospective study in Finland (Marniemi et al., 2005), the relative 
risk of acute myocardial infarction was diminished in individuals in the highest tertile of baseline 
serum iron and the ones in the middle tertile had a reduced risk of stroke. The ones in the 
highest tertile of serum TF presented an increased risk of stroke. Of note, other reports have 
failed in demonstrating these associations (Jia, Aucott, & McNeill, 2007). 
For the observed associations, several factors/indicators/mechanisms can plausibly 
explain the association of iron deficiency and cardiovascular disease and mortality. Iron 
deficiency may reflect undiagnosed conditions since iron deficiency is associated with renal 
failure, cancer and inflammation that per se are associated with higher mortality rates. 
Malnutrition is associated with increased mortality and an iron deficient state could be a 
surrogate marker for it (Fairweather-Tait et al., 2013; Hsu et al., 2013). 
Iron deficiency has also been implied in regulation of body temperature related to 
secretion and utilization of thyroid hormones (Boccio & Iyengar, 2003). It is also known that iron 
deficiency impacts on immune function and in resistance to infections; however, the results on 
this topic are somehow conflicting. Some studies suggest beneficial effects of mild iron deficiency 
on resistance to infection while others report that, independently from the severity, iron deficiency 
is always deleterious for immune function (Oppenheimer, 2001; Walter, Olivares, Pizarro, & 
Muñoz, 1997).  
 
1.2.4. Physical performance and functional ability 
The association of anemia and physical functional ability has been highlighted in several 
reports in the last years (Denny et al., 2006; Lucca et al., 2008; Onem et al., 2010; Penninx et 
al., 2003; Penninx et al., 2004; M. Thein et al., 2009). Although hemoglobin is used as a marker 
for iron status, no conclusions can be drawn from these studies on the impact of iron deficiency 
in physical functional ability. Still, theoretically, iron deficiency can impair physical functioning of 
older adults. Also of interest, subjects with iron deficiency present a 50% decrease in muscle 
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myoglobin content, electron transport capacity and cytochorme oxidase activity  and the delivery 
of oxygen to muscle is limited in anemia (J. L. Beard, 2001; P. Dallman, 1982; P. R. Dallman, 
1986; Davies, Maguire, & Brooks, 1982).  
The effects of iron deficiency per se in the physical performance and functional ability of 
older individuals have yet to be elucidated. A critical review (Haas & Brownlie, 2001) of the 
effects of iron deficiency on work capacity hypothesized that severe and moderate iron deficiency 
anemia has a causal effect on reduced work capacity. Endurance capacity was also 
compromised in severe and moderate iron deficiency anemias and energetic efficiency was 
affected in all levels of iron deficiency (severe and moderate iron deficiency anemia and iron 
deficiency without anemia).  
 
1.2.5. Brain and cognition 
The central nervous system, along with retina and the testis, is independent of the liver 
regulatory axis of iron homeostasis (Tracey A. Rouault & Cooperman, 2006). The movement of 
iron from plasma to cerebrospinal fluid seems to be regulated by the blood-brain and the choroid 
plexus-cerebrospinal fluid barriers (Marques et al., 2009). Similar to the intestinal absorption, 
iron uptake to the brain is decreased when the iron status is high and increased when it is low, in 
a process that is highly selective (J. Beard, 2003; Ke & Qian, 2007).  Also, the distribution of iron 
in the brain is not equal in all regions with some (namely: basal ganglia, substantia nigra and 
deep cerebellar nuclei) particularly rich in iron, some even richer than the liver (J. Beard, 2003; 
M. H. Youdim, 2008). Iron homeostasis is paramount for normal brain function and brain iron 
deficiency will disrupt several important processes, possibly altering neurochemistry and 
conducting to a pathological state. Still, studies on the effects of iron deficiency on brain function 
only in recent years have received attention from the scientific community (Hare, Ayton, Bush, & 
Lei, 2013; M. H. Youdim, 2008), with the majority of these with focus in infants and in animal 
models (J. Beard, 2003; Ke & Qian, 2007; Mesquita et al., 2012). 
Within the brain, iron has an important role in metabolism, including in processes such 
as synthesis, packaging, uptake and degradation of neurotransmitters. Furthermore, it can 
indirectly affect brain function through peroxide reduction, amino acid metabolism and 
membrane functioning alteration by fat desaturation (J. L. Beard, 2001). Although the molecular 
bases are not completely understood (Fretham, Carlson, & Georgieff, 2011; Muñoz & Humeres, 
2012), it is known that iron deficiency has time-, duration- and severity-dependent deleterious 
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effects on gene profiling, myelination, neurotransmission, learning and memory. The major body 
of human studies on this topic focuses in the developmental periods, but the effects of iron 
deficiency in later ages were not carefully examined (J. Beard, 2003). Still, in some cases, the 
effects of iron deficiency during developmental periods can be observed even in adults and are 
supported by the irreversible effects observed in animal models of development (J. Beard, 2003; 
Lozoff, 2007; Lozoff et al., 2006). Furthermore, although development seems to be a critical 
period, there is evidence that the deleterious effects of iron deficiency on neuronal function, 
behavior and cognitive function are not restricted to early ages (J. Beard, 2003; Bruner, Joffe, 
Duggan, Casella, & Brandt, 1996; Muñoz & Humeres, 2012). In older children and in adults, 
observational evidence suggests a strong link between iron deficiency and cognitive deficit, and 
the alterations can be reverted by the correction of iron deficiency, suggesting that time of iron 
deficiency matters (J. Beard, 2003; J. L. Beard et al., 2005; Bruner et al., 1996; Falkingham et 
al., 2010).  
Iron deficiency and its associations with cognition in older individuals remain largely 
unexplored. In fact, only one report on this age strata was found in the literature. In a cross 
sectional study, Yavuz et. al. (Yavuz et al., 2012) found an association between ID and mini-
mental state examination (MMSE); however, the statistical analysis was not controlled for 
confounding factors such as age and education. Falkingham et al. (Falkingham et al., 2010), in a 
systematic review and meta-analysis of randomized controlled trials of iron supplementation on 
cognition, found some evidence that iron supplementation improved attention, concentration and 
intelligence quotient, but no studies included men, post-menopausal women or the elderly.  
 
1.2.6. Mood 
It is widely accepted that certain micronutrient deficiencies can be associated with 
depression and/or depressive mood, and that psychological morbidity can affect appetite and 
nutritional ingestion (Sarris, Schoendorfer, & Kavanagh, 2009). In older individuals, anemia per 
se, even in the absence of iron deficiency, has been associated with depressive symptomatology 
(Hamer & Molloy, 2009; Onder et al., 2005). Iron deficiency has also been associated with 
depressive symptoms in premenopausal women (Laura E. Murray-Kolb, 2011). Yet, there is 
remarkably little research regarding neuropsychological morbidity and iron status especially in 
older subjects. To our knowledge, the only study measuring this association was conducted by 
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Stewart and Hirani (R. Stewart & Hirani, 2012), who reported a significantly higher depressive 
mood in individuals with anemia, low ferritin and high sTFR after controlling for age, sex, social 
class, multivitamin intake, smoking status and body mass index (BMI).  
 
1.3. T(h)reat(en) the iron deficiency  
Iron deficiency is treatable and preventable (Miller, 2013). While treating iron deficiency 
the focus should be targeting the underlying cause of it, which is often difficult to determine, and 
the main goal should be the repletion of iron stores (Goddard et al., 2000; Mahan, Escott-Stump, 
Raymond, & Krause, 2012). In order to replenish iron stores of adults, oral administration of iron 
is the first line of treatment and, depending on the severity of the case, 50 to 200 mg of 
inorganic iron, in the ferrous form, are daily prescribed and should be maintained 3 months after 
hemoglobin normalization (Mahan et al., 2012). Regarding efficiency and adverse effects, 
intermittent dosage and low dosage therapies have been also studied with promising results, with 
the latter being recommended by the WHO for developing countries (Pasricha et al., 2010; 
Stoltzfus, Dreyfuss, & Organization, 1998).  
The prevalence of adverse gastrointestinal symptoms due to oral iron therapy ranges 
from 10 to 20% and is more frequent when iron is taken in an empty stomach to maximize its 
absorption (Mahan et al., 2012; Rimon et al., 2005). Several forms of iron are available in the 
market (Table 6), although the most common preparations include iron sulphate, iron gluconate 
or iron fumarate (Alleyne, Horne, & Miller, 2008; Macdougall, 1999). Despite of the different 
molecular weights of the formulations, when given at equivalent dosages of elemental iron these 
have similar tolerability and efficacy (Pasricha et al., 2010). Adverse side effects of oral iron 
therapy are mainly gastrointestinal and include nausea, epigastric distention and discomfort, 
heartburn, diarrhea or constipation. In patients suffering from these side effects, dose reduction, 
interval alteration and changes in iron preparations are proposed (Alleyne et al., 2008; Susan F. 
Clark, 2008; Mahan et al., 2012).  
Parenteral iron administration can be used in patients who do not tolerate oral iron 
therapy, and/or do not comply with the prescribed treatment, have higher requirements due to 
bleeding or hemodialysis, or do not absorb iron secondarily to gastrointestinal disease or gastric 
resection (Susan F. Clark, 2008; Macdougall, 1999; Mahan et al., 2012). Parenteral iron therapy 
is a second line of treatment since the rise in hemoglobin levels is not faster than the one 
observed in oral therapies. Also, it is painful, expensive and can cause anaphylactic reactions and 
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adverse drugs reactions (Susan F. Clark, 2008; Goddard et al., 2000). Similar to oral iron 
administration, there are several formulations for parenteral iron administration which can be 
administered intravenously or intramuscularly (Table 6) (Alleyne et al., 2008; Susan F. Clark, 
2008; Macdougall, 1999; Pasricha et al., 2010). 
At a population level, several strategies can be used, alone or in combination, to prevent 
and correct iron deficiency. The main strategies used include (i) nutritional education with dietary 
modification or diversification, (ii) iron supplementation, and (iii) iron fortification of foods (Gera, 
Sachdev, & Boy, 2012; Zimmermann & Hurrell, 2007). Despite of all these strategies being 
effective, with some having an added beneficial indirect effect on problems such as malaria and 
helminth control or delayed clamping of the umbilical cord (Miller, 2013; Stoltzfus et al., 1998), 
here we will focus on food fortification.  
 
Table 6 – Common iron compounds used in iron deficiency treatment and prevention. Adapted 
from Dary & Hurrell, 2006; Macdougall, 1999  
Oral preparation Parenteral preparations  Food fortificants  
Ferrous sulfate Iron dextran Ferrous sulfate Ferrous fumarate 
Ferrous fumarate Iron dextrin Ferrous gluconate  Ferrous succinate 
Ferrous gluconate Iron hydroxisacharate Ferrous lactate  Ferric saccharate 
Ferrous succinate Iron sodium gluconate Ferrous bisglycinate Ferric orthophosphate  
Iron polymaltose  Iron polymaltose Ferric ammonium citrate  Ferric pyrophosphate  
Polysaccharide-iron complex  Iron sorbitol citrate Sodium iron EDTA Elemental iron 
 
Iron fortification is the central component of the efforts to control and prevent iron 
deficiency (Miller, 2013). It is also the most practical sustainable and cost-effective long term 
solution at the population level (Zimmermann & Hurrell, 2007). The average annual costs/person 
of food fortification can range from $0.06 (€0.04) in Southeast Asian sub-region to $0.15 (€0.11) 
in the European sub-region according to the WHO classification, indicating that the cost are not 
high when observed the beneficial effects obtained (Horton, 2006; Laxminarayan et al., 2006). 
Despite of the cost-effectiveness of iron fortification, iron is the most challenging nutrient to be 
used as a supplement. The iron compounds with the higher bioavailability are also the ones that 
strongly interact with food constituents and produce undesirable organoleptic alterations. 
However, there are several options (Table 6), with different properties that can be suitable 
depending on the food vehicle (Dary & Hurrell, 2006). Thus, success of iron fortification of foods 
is dependent of the food vehicle, the duration of storage, the fortificant and the composition of 
the food [for example: highly soluble (low molecular weight), high-affinity complexes such as Na-
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Fe-EDTA are suitable for food vehicles rich in phityc acid and for long shelf-life foods] (Dary & 
Hurrell, 2006; Mackenzie & Garrick, 2005). 
The effects of iron food fortification are unequivocal and beneficial for nutritional status 
and hemoglobin concentration, suggesting that iron fortification of foods is effective and can be a 
viable public health option to combat iron deficiency (Gera et al., 2012). Still, once again, the 
main body of literature assessing the effect of iron fortification is focused on children and we 
found no literature regarding the health impacts of iron fortification in older adults. Regarding 
children, there is no evidence that iron fortification improves growth (Sachdev, Gera, & Nestel, 
2006) or resistance to infections (Gera & Sachdev, 2002), albeit a significant moderated positive 
effect of iron fortification was observed in mental development (Sachdev, Gera, & Nestel, 2005).  
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2. Research objectives  
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Here we investigate whether a low iron status is associated with decrements in cognitive 
and/or physical performance in senior individuals. This derived from lines of evidence in other 
population groups (strata) showing that in children, women of child bearing age and pregnant 
women, and/or in cancer patients, there is an association between the iron status and  the 
cognitive and physical performances. Furthermore, the biochemical knowledge about the 
importance of iron to muscle proteins and to the oxygen transport system, particularly to the 
brain, which has high iron requirements, provides the molecular/biological basis for the research 
goals.  
 
Specifically, in a cohort of older individuals, using a cross-sectional analysis followed by a 
quasi-experimental (intervention) study, the objectives were to: 
1. Correlate cognition, mood, functional ability and physical performance with iron 
status (cross-sectional analysis); 
2. Assess the effectiveness and usefulness of low dosage of iron, through fortified foods 
(usually recommended for the prevention of nutritional deficiencies), to normalize 
iron status of aged individuals (intervention branch);  
3. Investigate whether cognition, mood, functional ability and physical performance 
could be ameliorated or normalized by the treatment of ID. 
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3. Material and methods 
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3.1. Subjects and procedures  
The n=162 participants enrolled in the study were recruited from health primary care 
centers (Braga and Guimarães/Vizela), internal medicine outpatient care (Hospital de Braga) and 
emergency department visits (Hospital de Braga). Participants were older community-dwelling 
individuals aged 55 years or more, males and females, with a general good health status, 
integrated in the community and with independency to perform the activities of the daily living. 
Exclusion criteria at enrollment included incapacity and/or inability to attend the assessment 
sessions, cognitive impairment, dementia diagnosis and/or inability to understand informed 
consent, disorders of the central nervous system and/or overt thyroid pathology. The cohort was 
established in accordance with the principles expressed in the Declaration of Helsinki and the 
work approved by the national ethical committee (Comissão Nacional de Protecção de Dados) 
and by local ethics review boards. All the participants gave voluntary informed signed consent. 
Blood samples were collected by venipuncture and a baseline characterization was 
conducted which comprised a clinical interview, nutritional status and body composition 
assessment and evaluation of physical functional ability (Moment A1, Figure 4). From the 
participants that were initially characterized, a subset (with and without ID) was selected for 
enrollment in the intervention study (n=41). Selection of participants was based on the results of 
the blood analysis [ID was defined as low serum FT level or two biomarkers (MCV, MCHC, RDW, 
Fe, TF sat., TIBC, sTFR sTFr-LogFT index)] indicating ID as described elsewhere (L. E. Murray-
Kolb & Beard, 2007; Rimon et al., 2005; Yavuz et al., 2012); the cutoff points used were: 
MCV<80 fL, MCHC<32 g/dL, RDW>14%, Fe<71 µg/dL, FT<45 ng/mL, TF sat.<20%, TIBC≥360 
µg/dL, sTFR>1.76 mg/dL and sTFr-LogFT index>1.5. Exclusion criteria at enrollment for the 
intervention branch included: severe anemia (hemoglobin<9 mg/dL), chronic renal disease 
(previously diagnosed or creatinine >2.5 mg/dL); celiac or Crohn disease; ongoing treatment for 
ID; TF saturation above 55%; and/or premenopausal women. Individuals that met the inclusion 
criteria for the iron fortification branch were invited to consume an iron fortified desert at 
breakfast (daily) or assigned to a non-iron fortification intervention branch and submitted to all 
the procedures that were performed in the iron fortification branch, with the exception of the daily 
intake of the iron fortified desert. A similar amount of individuals with iron deficiency (with or 
without anemia) was allocated to each branch (with or without iron-fortified food). For this subset 
of individuals [intervention with fortification (cases, n=12) and non-fortification (non 
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supplemented, n=10)] an additional assessment was performed in order to obtain a more 
detailed characterization regarding neurocognitive/psychological dimensions, functional ability 
and physical performance (Moment A2, Figure 4). 
The intervention had a duration of 14 weeks (+/- 2 weeks), after which a final endpoint 
assessment was performed (Moment B, Figure 4), with monitoring midpoints distributed 
throughout the study to guarantee and motivate the continued desert intake and/or participation 
in the study. The endpoint assessment consisted in a blood sample collection, nutritional status 
and body composition assessment, evaluation of physical performance and functional abilities, 
and neurocognitive/psychological assessment. 
Overall assessments were conducted at the local health care centers or in the Clinical 
Academic Center – Braga (CCA-B). 
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Figure 4 – Flow Diagram of the study. 
3.2. Iron food fortification 
Participants in the quasi-experimental intervention study that were assigned to the 
iron fortification branch consumed an iron and ascorbic acid fortified fruit based desert. 
Theoretical development of the deserts was performed by our team and accounted for the daily 
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requirements (recommended dietary allowance and upper limit for individuals with 50 years of 
age or older) of iron and ascorbic acid according to the data available from the Food and 
Nutrition Board of Institute of Medicine (IOM, 2000, 2001). Iron and ascorbic acid supplements 
were chosen in accordance with the “Guidelines on food fortification with micronutrients” (Dary & 
Hurrell, 2006) of the WHO and the FAO and based on bioavailability and physical characteristics 
of the food vehicle. Briefly, it was defined that each daily dose should contain 15 mg of elemental 
iron in the form of ethylenediaminetetraacetic acid ferric sodium salt [120 mg of Na(Fe3+)EDTA 
with 12.5% mass of iron] and 90 mg of vitamin C (ascorbic acid – E300) corresponding to a 2:6 
mass ratio (iron:ascorbic acid) described to increase iron absorption from foods 2- to 3-fold (Dary 
& Hurrell, 2006; Hurrell, 2002). Technical development was handled by Frutech (Frulact SGPS; 
Maia; Portugal) and sensory analysis was performed by Frutech technicians and our team. Two 
deserts of different flavors were chosen (apple and peach) and produced by Frulact Nutrição 
(Frulact Nutrição, Lda; Maia, Portugal). Apple and peach puree (50% of mass) were used as a 
major ingredient. After shelf life tests, bromatological analysis were performed by an independent 
laboratory (Silliker Portugal, S.A.; V. N. Gaia, Portugal), yielding 14.8 mg of iron and 158 mg of 
ascorbic acid per 120 g (daily dose) of apple desert and 13.26 mg of iron and 168 mg of 
ascorbic acid per 120 g (daily dose) of peach-based desert. Since ascorbic acid is easily lost 
during processing and storage, the higher amounts of ascorbic acid than the foreseen ensured 
that after storage losses and in the end of the shelf life a sufficient amount was still present. 
3.3. Laboratory analyses  
Blood samples were collected by venipuncture before the assessments and immediately 
sent to the Pathology Laboratory at the Hospital de Braga for analyses. Blood cells count and 
hemogram were performed using certified standardized methods and comprised RBC (1012/L), 
hemoglobin (mg/dL), hematocrit (%), MCV (fL), MCH (pg), MCHC (g/dL) and RDW (%). Serum 
iron (Fe; µg/dL) and TIBC (µg/dL) were determined by a colorimetric method using Dimension 
Vista System Flex reagent cartridge (Siemens, Frimley, Camberly, UK). High sensitive C-reactive 
protein (hsCRP; mg/dL), TF (mg/dL), FT (ng/mL) and serum concentration of sTFR (mg/dL) 
were measured by chemiluminescent immunoassays. Dimension Vista System Flex reagent 
cartridge (Siemens, Frimley, Camberly, UK) was used to measure TF, FT and sTFr; the BN* II 
and BN ProSpec System (Siemens, Frimley, Camberly, UK) was used to measure hsCRP. All 
determinations were performed following the manufacturers’ instructions. Detection limits for 
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hsCRP, Fe, TIBC, TF, FT and sTFR are 0.175 mg/dL, 5 µg/dL, 8 µg/dL, 8.75 mg/dL, 0.5 
ng/mL and 0.017 mg/L respectably. Serum TF saturation (%) was calculated as a percentage of 
serum total iron divided by TIBC. sTFR-LogFT index was calculated by sTFR divided by the 
logarithm of FT. Body iron was calculated using the Cook algorithm (Cook et al., 2003) as 
follows: body iron (mg/kg) = -[log(sTFR*1000/FT) – 2.8229/0.1207].  
3.4. Neurocognitive/psychological assessment  
Tests were selected to provide mood and cognitive (general cognitive status and 
executive and memory functions) profiles, as previously reported (Santos et al., 2013). The 
neurocognitive/psychological characterization was performed by a team of trained psychologists 
following the instructions provided in the Standard Operating Procedures (SOP) manual, which is 
a written  manual were all the procedures for test application are described and is used as 
guideline, ensuring the standardization of the test application and results comparability. 
3.4.1. Baseline characterization 
The following cognitive measures were used: global cognitive status was assessed with 
the MMSE (Folstein, Folstein, & McHugh, 1975) and the Montreal cognitive assessment (MOCA) 
(Nasreddine et al., 2005); short-term verbal memory with the digit span forward test (DS forward; 
subtest of the Wechsler adult intelligence test WAIS III), verbal working memory with the digit 
span backward test (DS backward; subtest of the Wechsler adult intelligence test WAIS III) and 
digit span total score (DS total; calculated by the summation of DS forward and DS backward) 
(Strauss, 2006); multiple trial verbal learning and memory with the selective reminding test [SRT 
– List A; parameters: consistent long term retrieval (CLTR), long term storage (LTS), delayed 
recall (DR) and intrusions] (Buschke, Sliwinski, Kuslansky, & Lipton, 1995), and the consortium 
to establish a registry for Alzheimer's disease-word list test [CERAD, parameters: Total hits and 
DR hits] (Morris et al., 1989); response inhibition/cognitive flexibility with the Stroop color and 
word test [Stroop, parameters: Words (W), Colors (C) and Words/colors (W&C)] (Strauss, 2006). 
The geriatric depression scale (GDS, long-version) (Yesavage et al., 1983) was used for 
depressive mood evaluation. 
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3.4.2. Additional assessment 
Additionally to the neurocognitive/psychological characterization preformed in moment 
A1, the Boston naming test 15-item version (BNT-15) test (Lansing, Ivnik, Cullum, & Randolph, 
1999; Mack, Freed, Williams, & Henderson, 1992) and the controlled oral word association test 
F-A-S (COWAT-FAS, FAS – Admissible) (Lezak, 2004) were performed in moment A2 for the 
subjects enrolled in the intervention study for additional neurocognitive characterization,. Also, 
further measures were added to the psychological assessment, namely: Beck anxiety inventory 
(BAI) (Beck & Steer, 1990), Beck depression inventory (BDI) (Beck, Ward, & Mendelson, 1961) 
and the perceived stress scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983).  
3.4.3. Endpoint characterization  
At the endpoint assessment, since several neurocognitive tests do not possess test-retest 
validity, the Addenbrooke's cognitive examination-revised (ACER) (Mioshi, Dawson, Mitchell, 
Arnold, & Hodges, 2006) was used to assess general cognitive status and dimension specific 
scores. The SRT [SRT – List B; parameters: CLTR, LTS, DR and intrusions] and a different subset 
of images of the BNT-15 were also used; despite of differences in the lists and the subset of 
images, the results of SRT and BNT-15 from baseline characterization and endpoint 
characterization were directly comparable which avoids learning interference. Neuropsychological 
assessment was performed using depression, anxiety and stress scales – 21 items (DASS-21) 
(Lovibond & Lovibond, 1995).   
3.5. Assessment of functional ability and physical performance  
The questionnaire of functional ability (QoFA) was the only instrument used to assess 
functional ability at the baseline characterization (Moment A1). All the remaining tests, as nest 
described, were used in the additional characterization (Moment A2) and in the endpoint 
assessment (Moment B). Instructions provided in the SOP manual were followed. 
3.5.1. Questionnaire of functional ability  
The QoFA is a scale that measures the ability of older individuals to perform physical 
activities of daily living (Avlund, Kreiner, & Schultz-Larsen, 1996). The instrument is composed of 
16 questions, for each question two more are made regarding tiredness and help needed to 
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perform the task. The instrument is composed of 3 subscales in relation to tiredness, (i) mobility 
tiredness, (ii) lower limb tiredness and (iii) upper limb tiredness, and 2 subscales in relation to 
dependency, (iv) mobility help and (v) physical activities of daily living help. Higher values in each 
subscale represent higher functionality. The instrument was applied after a brief explanation of its 
structure and aims.  
3.5.2. Hand grip strength 
The Jamar hand dynamometer (Lafayette Instrument Company, USA) was used. This 
instrument is the most widely cited in the literature and accepted as the gold standard by which 
other dynamometers are evaluated. The dial reads force in kg with markings at intervals of 2 kg, 
allowing assessment to the nearest kg. Here we used an adaptation of the protocol of the 
American Society of Hand Therapists that was recently proposed (Roberts et al., 2011). The 
same procedure was used for left hand and three measurements for each hand, alternating 
sides, were taken. The recorded result was always the highest results in each trial. Hand 
dominance was recorded (right, left or ambidextrous – people who can genuinely write with both 
hands). The best of the six grip strength measurements was used for statistical analyses. 
3.5.3. 6-m timed walk 
The 6-m timed walk (6MTW) is an adaptation of the 10 m timed walk which is well 
established for use in assessment of patients with stroke. The validity and reliability of the 6MTW 
to assess walking ability has been demonstrated (Lam, Lau, Chan, & Sykes, 2010). Gait speed 
(m/min) and cadence (steps/min) was calculated from the data collected. 
3.5.4. Tinetti evaluation  
The performance oriented mobility assessment (POMA) is a simple and easy to 
administer test used to evaluate gait and balance (Tinetti, 1986). The test was originally 
proposed to assess the risk of falling in older individuals. It is composed by 2 scales, one with 9 
parameters for the assessment of static balance and a second with 10 parameters which assess 
gait balance.  
 46 
 
3.6. Nutritional status and body composition assessment 
All the procedures described in this section were performed at the baseline 
characterization (Moment A1) and at the endpoint assessment (Moment B).  
3.6.1. Mini nutritional assessment  
The mini nutritional assessment (MNA) is a screening tool that helps to identify aged 
malnourished people or at risk of malnutrition before the development of alterations in weight or 
in serum proteins (Kondrup, Allison, Elia, Vellas, & Plauth, 2003).  The full MNA is composed of 
2 parts: (i) ‘Screening’ to identify malnourished people or at risk of malnutrition, and (ii) 
‘Assessment’ to allow for the determination of potential causes of malnutrition. All the questions 
of the MNA were applied in a face-to-face interview; data on body mass index (BMI), mid arm 
circumference and calf circumference were obtained during the anthropometric characterization. 
The malnutrition indicator score was calculated by the summation of the score obtained in the 
screening and assessment, which result in a classification in 3 categories: malnutrition, at risk of 
malnutrition and normal nutritional status.  
3.6.2. Weight and bioelectrical impedance analysis  
Weight and relative body fat mass (%BF) were measured with the participants wearing 
light wear using a Tanita® BF 350 Body Composition Analyzer (Tanita Corporation, Tokyo, 
Japan), which uses the foot-to-foot bioelectrical impedance analysis (BIA)(Yanovski, Hubbard, 
Heymsfield, & Lukaski, 1996) to estimate %BF. Participants were invited to stand on the scale 
without support and with the weight equal distributed in both legs. The output variables were 
calculated according to the manufacture’s embedded software. 
3.6.3. Anthropometric characterization  
Anthropometric characterization consisted in the measurements of height, waist 
circumference, hip circumference, mid arm circumference, calf circumference; and the thickness 
of: triceps skinfold, biceps skinfold, subscapular skinfold and suprailiac skinfold. All 
measurements were taken in accordance with the international standards for anthropometric 
assessment (A. Stewart, Marfell-Jones, Olds, & Ridder, 2011) from the International Society for 
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the Advancement of Kinanthropometry, in triplicate and the mean value used to calculate the 
derivate indexes. 
Briefly, height was measured without shoes using a stand-alone stadiometer Seca® 217 
(Seca GmBH & Co Kg, Hamburg, Germany). Circumferences were measured using an ergonomic 
and smooth measuring tape Seca® 201 (Seca GmBH & Co Kg, Hamburg, Germany) and only 
the minimal amount of pressure was made warranting that the tape was not excessively indented 
to the skin. Waist circumference was measured at the mid-point between the lower costal (10th 
rib) border and the iliac crest in the end of a normal expiration (end tidal). Hip circumference was 
taken in a horizontal plane at the level of the greatest posterior protuberance of the buttocks, 
which usually corresponds anteriorly to the level of the symphysis. Mid arm circumference was 
measured at the mid-point between acromial surface of the scapula and the olecranon process 
perpendicular to the longest axis of the arm. Calf circumference was measured with the subjects 
seated and the knee bent at 90º angle, the tape was slipped in order to measure the maximum 
girth of the calf perpendicular to the longest axis of the leg. BMI was calculated according to the 
weight (kg)/height (m)2 ratio. 
Skinfolds thickness was measured using the Lipotool (Liposoft 2008 & Adipsmeter V0) 
(Amaral et al., 2011). All participants were in the anatomical position and relaxed, the 
measurements were taken in the right side of the body. Triceps skinfold thickness was measured 
in the arm at the mid-point between acromial surface of the scapula and the olecranon process 
in the most posterior site of the triceps when viewed from the side. Biceps skinfold thickness was 
measured at the same level of the triceps skinfold in the most anterior site of the biceps when 
viewed from the side. Triceps and biceps skinfolds were measured parallel to the longest axis of 
the arm.  Subscapular skinfold thickness was measured at the point 2 cm from the subscapular 
point in a line 45° laterally downward determined by the natural fold of the skin. Suprailiac 
skinfold was taken when the right arm of the participant was abducted to the horizontal. This 
skinfold was measured at the line that defines the anterior-posterior division and immediately 
superior to the iliac crest. The direction of the fold runs slightly downwards anteriorly as 
determined by the natural fold of the skin. The mean value of the skinfold thickness was used to 
estimate body density taking into account that for individuals with age comprised between 50 and 
59 it was calculated using the Durnin and Womersley (Durnin & Womersley, 1974) sex-specific 
equations and for older individuals the Visser et al.(Visser, Heuvel, & Deurenberg, 1994) sex-
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specific equations. %BF was calculated from body density using the Brozek et al. (Brožek, 
Grande, Anderson, & Keys, 1963) (%BF-Brozek) equation.  
3.7. Statistical analysis 
Characteristics of participants are presented in mean and standard deviation (mean; SD) 
for normal distributed variables and in median and interquartile range for variables with a non-
normal distribution. To evaluate normal distribution of the variables, skewness and kurtosis 
values were calculated and the approximate normal distribution was defined for variables with 
absolute values of skewness below 3 and of kurtosis below 8 (Kline, 2011). Log transformations 
were performed to normalize the distribution of skewly distributed variables (hsCRP, FT; sTFR 
and sTFR-LogFT index). Independent samples t-test (for variables with normal distribution) and 
Mann-Whitney U test (for variables with non-normal distribution) were performed to analyze the 
differences in socio-demographic variables, anthropometric, psychological, neurocognitive and 
physical functional ability between men and women; individuals with or without ID in the cross-
sectional study and in the same variables at baseline between non supplemented and 
supplemented in the longitudinal study. To quantify the strength of the differences, Cohen´s d 
was calculated as a measure of effect size (.2 is considered a small effect size, .5 a medium 
effect size and .8 a large effect size) (Kotrlik & Williams, 2003); in Mann-Whitney U test r was 
calculated and reported as the measure of effect size. Differences in categorical variables were 
assessed using Chi squared test and effect size reported as Phi () or Cramer’s V (c). When 
assumptions for Chi-square tests on contingency tables were violated the two tailed significance 
level of Fisher exact test was used (P(Fisher exact test; 2 tailed)). 
All variables were converted into z-scores to express all variables in the same scale. 
Principal component analysis (PCA) was conducted to reduce the number of variables with a 
minimum loss of information and, therefore, reducing the number of comparisons. New 
component scores were obtained (using the regression method) and were used in subsequent 
analyses. The reliability of each component was analyzed using Cronbach’s alpha. Components 
were considered reliable when Cronbach’s alpha was higher than .6 (DeVellis, 2011). Variables 
not included in PCA were analyzed independently.  
Binary logistic regression analysis was used to test if nutritional status (MNA) and body 
composition (BMI, %BF-Tanita and %BF-Brozek) were significant predictors of ID when controlled 
for potential confounding factors (age, gender and hsCRP) using the enter method.  
 49 
 
Analyses of covariance (ANCOVA) were used to test differences in dependent variables 
(psychological, neurocognitive and physical functional ability) between individuals with or without 
ID, controlling for the principal confounding factors (age, education, gender and hsCRP for 
psychological variables; the previous plus GDS score for neurocognitive variables and 
dimensions; and age, BMI and hsCRP for physical functional ability dimensions). Education 
(school years; <4=0; ≥4=1) was converted to a dummy variable due to the high concentration of 
individual in the 4 years.  
Hierarchical regression analysis was performed to compare different hematological 
dimensions (that resulted from PCA) as predictors of previously mentioned dependent variables 
controlling for the principal, above mentioned, confounding factors (using enter method). 
Interaction (mediator effect) between nutritional status and hematological dimensions was tested 
using a mean centered methodology and hierarchical regression analysis as previously described.  
Analysis of repeated measures (general linear model – repeated measures ANOVA) was 
used for comparison of variables across different time-points (when repeated measures were 
available) during the intervention study. For non-normal distributed variables (skewly distributed) 
(FT, sTFR and sTFR-LogFT index) logarithmic transformation was applied allowing the use of 
repeated measures ANOVA, therefore data are presented as geometric mean and back-
transformed 95% confidence intervals. Two independent sample t-tests (pre- and post-
intervention) were used to compare data from different variables measuring the same construct 
before and after intervention (no repeated measures available).  
Statistical analysis was conducted using the SPSS package v22 (IBM SPSS Statistics) 
and statistical significance was defined at p < .05 level. In the tables the most relevant significant 
results are highlighted in gray color. 
3.8. Team 
This thesis project is based on a larger study addressing predictors of healthy cognitive 
aging. As such, a multidisciplinary team participates and conducts the various aspects of the 
study. With respect to the data presented in this thesis: 
The design and supervision of the study was accomplished by Professor Joana Palha, 
Professor Nuno Sousa and Dr. Nadine Correia Santos. 
Measurement of blood parameters was done at the Pathology Laboratory at the Hospital 
de Braga.  
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Neurocognitive and neuropsychological assessments were performed by Teresa Costa 
Castanho, Liliana Amorim and Pedro Silva Moreira. 
Functional ability, physical performance, nutritional status evaluations and body 
composition assessments were performed by me. I was also responsible by data analysis, with 
the valuable support and insights of Professor Patricio Costa, Dr. Nadine Correia Santos and 
Pedro Silva Moreira, and writing of this report. 
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4. Results 
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4.1 Cross-sectional analysis: iron status correlates of cognition and physical 
status and performance 
4.1.1 Participants characterization  
The initial sample was composed by 162 individuals, from which 11 participants were 
excluded due to malnutrition (n=2), chronic kidney disease (n =1; creatinine >2.5 mg/dL), high 
inflammatory status (n=7; hsCRP> 10 mg/L) and iron overload (n=1; TF saturation>55%). After 
exclusion the study sample comprised 151 individuals [females, n=82 (54.3%); males, n=69 
(45.7%)]. Characteristics of the participants, for the all sample and by gender are shown in Table 
7. No significant differences were observed between females and males for age although, as 
expected and previously reported for similar samples (Santos et al., 2014), males had more 
years of formal education than females. No significant differences were observed in gender 
distribution by BMI classes or class of nutritional status. 
 
Table 7 - Socio-demographic, anthropometric and nutritional characteristics of participants.  
Variables (mean; SD) All  Females  Males   
Socio-demographic  
   
t(df); p; Cohen’s d 
 
Age (yrs) 66.30; 7.87 67.16; 7.66 65.29; 8.04 1.459(149); .147; .240 
 
Education (school yrs)  5.19; 3.83 4.40; 3.45 6.12; 4.08 -2.757(133.799); .007; .460 
Anthropometric 
   
t(df); p; Cohen’s d 
 
Weight (kg) a 72.88; 11.69 68.77; 10.65 77.48; 11.14 -4.762(140); <.001; .806 
 
Height (m) a 1.59; 0.09 1.53; 0.05 1.65; 0.07 -12.568(140); <.001; 2.128 
 
BMI (kg/m2) a 28.97; 3.86 29.48; 4.00 28.4; 3.64 1.664(140); .098; .282 
 
Waist circ. (cm) a 95.69; 10.58 93.65; 11.18 97.97; 9.43 -2.468(140); .015; .418 
 
Hip circ. (cm) a 101.46; 7.73 102.98; 8.15 99.75; 6.90 2.534(140); .012; .429 
 
%BF-BIA (%) b 32.70; 7.85 37.27; 5.49 27.41; 6.80 9.427(136); <.001; 1.621 
 
%BF-Brozek (%) a 34.54; 6.99 40.09; 2.99 28.33; 4.51 18.49(140); <.001; 3.130 
BMI class (n; %) 
   
2(df); p; c 
 
Normal 23; 16.20 12; 8.45 11; 7.75 2.744(2); .250; .139 
 
Overweight 67; 47.18 31; 21.83 36; 25.35  
 
Obesity 52; 36.62 32; 22.54 20; 14.08  
Nutritional status (n; %) 
   
2(df); p;  
 
Risk of malnutrition 20; 14.08 14; 9.86 6; 4.23 2.758(1); .146; .139 
 
Normal  122; 85.92 61; 42.96 61; 42.96  
a n=142 [females=75 (52.82%). males=67 (47.18%)]; b n=138 [females=74 (53.62%). males=64 (46.38%)]. Data 
presented for all sample and by gender. Statistical test performed between gender.  
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Descriptive statistics for neuropsychological and cognitive variables are presented in 
Table 8. Females scored significantly higher in neuropsychological variables indicative of higher 
depressive mood and perceived stress, and significantly lower in all neurocognitive variables 
Stroop W, Stroop W&C, MMSE and MOCA.  
From the PCA, two cognitive dimensions were obtained based on the neurocognitive 
variables (with less than 10% of missing values), termed: (i) executive dimension, and (ii) memory 
dimension (Figure 5). The executive dimension (executive functioning, Cronbach’s alpha: 0.880) 
was composed of the Stroop (W, C and W&C) and DS (backward and total) parameters. The 
variables DS forward and MMSE total score had low communalities in the solution and were 
excluded from the final model. The memory dimension (memory function, Cronbach’s alpha: 
0.933) was composed of the SRT (CLTR, LTS and DR) and the CERAD (total hits and DR) 
parameters. Intrusions in SRT were excluded due to low communalities. Significant differences 
were observed in the executive dimension with females scoring lower, and no differences were 
observed in the memory dimension (Table 8, Figure 6).  
 
 
Figure 5 – Diagram of neurocognitive dimensions formation by PCA. 
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Table 8 - Neuropsychological and neurocognitive variables in all sample and by gender. 
 Variables (mean; SD) All  Females  Males   
Psychological    t(df); p; Cohen’s d 
 GDS 11.25; 6.36 13.23; 6.10 8.88; 5.88 4.437(149); <.001; .730 
 PSS a 20.37; 7.52 22.73; 7.67 17.77; 6.46 4.093(137); <.001; .700 
Neurocognitive    t(df); p; Cohen’s d 
 DS – Forward  7.39; 2.24 6.84; 1.99 8.04; 2.35 .825(149); .411; .136 
 DS – Backward  4.16; 2.32 3.60; 1.91 4.81; 2.58 .825(149); .410; .136 
 DS – Total 11.55; 4.15 10.44; 3.43 12.86; 4.55 .733(149); .465; .120 
 Stroop – W b 65.29; 21.70 58.04; 21.23 73.73; 19.17 -4.640(143); <.001; .778 
 Stroop – C c 48.34; 14.79 46.99; 14.57 49.90; 15.00 -1.196(146); .234; .198 
 Stroop – W&C c 29.72; 12.99 27.44; 11.61 32.33; 14.04 -2.289(132.34); .024; .385 
 SRT – LTS  25.34; 13.77 23.43; 13.22 27.62; 14.15 -1.881(149); .062; .309 
 SRT – CLTR  15.58; 12.81 14.8; 12.46 16.51; 13.25 -.813(149); .418; .134 
 SRT – DR d 5.65; 2.85 5.55; 2.78 5.78; 2.94 -.497(140); .620; .084 
 CERAD – Total hits e 17.59; 4.93 17.24; 5.15 17.99; 4.68 -.898(140); .371; .152 
 CERAD – DR  e 5.77; 2.40 5.48; 2.42 6.09; 2.37 -1.515(140); .132; .256 
 MMSE 26.52; 3.27 25.67; 3.58 27.52; 2.54 -3.708(145.03); <.001; .593 
 MOCA f 18.06; 5.13 16.98; 5.17 19.45; 4.78 -2.644(115); .009; .497 
Cognitive dimensions     t(df); p; Cohen’s d 
 Executive g  0; 1.00 -.26; .91 .30; 1.02 -3.505(141); .001; .592 
 Memory h  0; 1.00 -.10; 1.00 .11; 1.00 -1.259(131); .210; .220 
a n=139 [females=73 (52.52%). males=66 (47.48%)]; b n=145 [females=78 (53.79%). males=67 (46.21%)]; c n=148 
[females=79 (53.38%). males=69 (46.62%)]; d n=142 [females=77 (54.23%). males=65 (45.77%)]; e n=142 
[females=75 (52.82%). males=67 (47.18%)]; f n=117 [females=66 (56.41%). males=51 (43.59%)]; g n=143 
[females=76 (53.15%). males=67 (46.85%)]; h n=133 [females=70 (52.63%). males=63 (47.37%)]. Data presented 
for all sample and by gender. Statistical test performed between gender.  
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Figure 6 – Mean value of neurocognitive and neurpsychological variables/dimensions by 
gender. 
 
Two dimensions were obtained from the subscales of the QoFA: (i) functional-T 
dimension (functional tiredness, Cronbach’s alpha: .763), composed by mobility tiredness, lower 
limb tiredness and upper limb tiredness subscales; and (ii) functional-H dimension (functional 
help, Cronbach’s alpha: .690), composed by mobility help and PADL help (Figure 7). Similar to 
the variables of origin, higher scores represent higher functionality, so higher scores on 
functional-T represent less tiredness and higher scores on functional-H represent less need of 
help. In all physical functional variables sub-scales and dimensions (Table 9, Figure 8) females 
scored significantly lower than males. 
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Figure 7 – Representation of functional dimension obtained by PCA. 
 
Table 9 - Physical functional ability sub-scales and functional dimensions. 
Variables (mean; SD) All  Females  Males   
Functional ability – QoFA a    t(df); p; Cohen’s d 
 Mobility tiredness 4.45; 1.94 3.77; 2.00 5.26; 1.52 -5.191(146.19); <.001; .838 
 Lower limb tiredness 4.24; 1.13 3.90; 1.29 4.64; .75 -4.351(131.4); <.001; .689 
 Upper limb tiredness 3.76; .77 3.57; 1.00 3.99; .12 -3.73(82.72); <.001; .569 
 Mobility help 11.05; 2.06 10.59; 2.48 11.59; 1.22 -3.211(120.32); .002; .504 
 PADL help 18.59; 2.87 17.98; 3.41 19.3; 1.84 -3.025(126.62); .003; .477 
Functional components a    t(df); p; Cohen’s d 
 Functional tiredness 0; 1.00 -.37; 1.14 .43; .57 -5.529(122.2); <.001; .869 
 Functional help 0; 1.00 -.25; 1.18 .29; .62 -3.600(124.31); <.001; .567 
a n=150 [females=81 (54%); males=69 (46%)]. Data presented for all sample and by gender. Statistical test 
performed between gender.  
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Figure 8 – Distribution of functional dimensions by gender. 
 
Hematologic variables are shown in Table 10. The hsCRP was measured to assess the 
inflammatory status of participants and no significant differences were observed between males 
and females. With exception for MCV and RDW, all the red cells indices and iron biomarkers 
variables were significantly different, with the direction of difference indicating a lower iron status 
of females (iron biomarkers: lower Fe, FT, TF Sat.; sTFR, sTFr-LogFT index and Body iron; higher 
TF and TIBC).  
Similar to previously described (L. E. Murray-Kolb & Beard, 2007), dimensions of 
hematologic variables were obtained (here using PCA). For these analyses, log-transformation of 
non-normal distributed variables was used and posteriorly transformed into z-scores (FT, sTFR 
and sTFr-LogFT index). In some cases z-scores of variables were inverted (multiplied by -1) in 
order to make higher values represent higher iron status (RDW, TF, TIBC, sTFR and sTFr-LogFT 
index). Five components were obtained using the hematologic factors: four of them using the 
same factors described by Murray-Kolb et al.(L. E. Murray-Kolb & Beard, 2007), (i) storage, (ii) 
transport, (iii) red cells characteristics (red cells C) and (iv) erythropoiesis; and a new one 
obtained from the remaining biomarkers, (iv) transport saturation (transport S) (Figure 9).  
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Figure 9 - Representation of hematological dimensions obtained by PCA. 
 
Table 10 - Hematologic variables and dimensions for iron status assessment. 
Variables (mean; SD) All  Females  Males  
 
Inflammatory indices 
   
Z(U); p; r 
 hsCRP (mg/dL)  a ¥ £ 1.90; 2.62 2.35; 2.80 1.60; 2.50 -1.430(2378); .152; .117 £ 
Red cells indices b    t(df); p; Cohen’s d 
 RBC (1012/L) 4.56; 0.43 4.37; 0.41 4.79; 0.35 -6.615(144); <.001; 1.108 
 Hemoglobin (mg/dL) 13.80; 1.60 13.01; 1.35 14.77; 1.34 -7.850(144); <.001; 1.314 
 Hematocrit (%) 40.37; 4.12 38.40; 3.66 42.76; 3.31 -7.478(144); <.001; 1.252 
 MCV (fL)  88.55; 4.33 87.92; 4.27 89.30; 4.31 -1.931(144); .056; .323 
 MCH (pg) 30.24; 1.84 29.78; 1.72 30.81; 1.83 -3.512(144); .001; .588 
 MCHC (g/dL) 34.15; 0.99 33.86; 0.94 34.50; 0.93 -4.123(144); <.001; .690 
 RDW (%) 13.37; 0.88 13.47; 0.91 13.25; 0.84 1.509(144); .134; .253 
Iron biomarkers c    t(df); p; Cohen’s d 
 Fe (µg/dL) 
c
 93.13; 29.46 86.58; 25.05 100.65; 32.41 -2.903(125.38); .004; .493 
 TF (mg/dL)  c 248.34; 42.63 255.74; 42.52 239.85; 41.45 2.279(144); .024; .381 
 FT (ng/mL) c ¥ £ 132.00; 204.25 84.50; 129.00 221.50; 235.75 -4.840(1418.5); <.001; .401 £ 
 TF sat. (%) c 27.93; 10.02 25.27; 8.45 30.97; 10.85 -3.501(125.89); .001; .595 
 TIBC (µg/dL) c 345.00; 55.32 354.10; 56.98 334.56; 51.82 2.156(144); .033; .360 
 sTFr (mg/L) d ¥ £ 1.11; .49 1.20; .60 1.01; .38 -3.420(1831); .001; .281 £ 
 sTFr-LogFT index c ¥ £ .55; .31 .63; .34 .45; .20 -4.880(1408); <.001; .404 £ 
 Body iron (mg/kg) c 14.91; 4.68 13.37; 4.33 16.67; 4.46 -4.524(144); <.001; .756 
Iron dimensions    t(df); p; Cohen’s d 
 Storage  c 0; 1.00 -.28; .93 .32; .98 -3.754(144); <.001; .627 
 Transport  c 0; 1.00 -.25; .84 .29; 1.09 -3.276(124.79); .001; .557 
 Transport S. c 0; 1.00 -.17; 1.01 .20; .96 -2.241(144); .027; .374 
 Red cells C.  b 0; 1.00 -.25; .97 .30; .96 -3.429(144); .001; .574 
 Erythropoiesis b 0; 1.00 -.49; .88 .59; .80 -7.639(144); <.001; 1.279 
a n=149 [(females=81 (54.36%). males=68 (45.64%)]; b n=146 [(females=80 (54.79%). males=66 (45.21%)]; c 
n=146 [(females=78 (53.42%). males=68 (46.58%)]; d n=148 [(females=80 (54.05%). males=68 (45.95%)]; ¥ 
Variables not normally distributed. data presented in median and interquartile range (median. IQR); £ Mann–Whitney 
U test. results presented in Z(U); p; r. Data presented for all sample and by gender. Statistical test performed between 
gender.  
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Figure 10 – Distribution of hematological dimensions by gender. 
 
Storage dimension (storage of iron; Cronbach’s alpha: .925) was composed by FT 
(inverted), body iron, sTFR (log-transformed and inverted) and sTFr-LogFT index (log-transformed 
and inverted). Transport dimension (iron transport in blood stream; Cronbach’s alpha: .856) 
included Fe and TF sat.. Transport S. dimension (saturation of iron carrying capacity in the blood 
stream; Cronbach’s alpha: .979) was obtained by the reduction of TF and TIBC (both inverted). 
Red cells C. dimension (composition, dimension and variability of red cells; Cronbach’s alpha: 
.822) constructed with MCV, MCH, MCHC and RDW (inverted). Erythropoiesis dimension 
(number and relative volume of red cells and hemoglobin sufficiency; Cronbach’s alpha: .967) 
composed by RBC, hemoglobin and hematocrit (Figure 9). Higher values in these dimensions 
represent higher iron status and, therefore, similar to the origin variables. Female presented a 
significantly lower iron status in all iron dimensions.  
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4.1.2 Relevance of iron deficiency for cognition, mood and physical 
performance 
ID was defined as low serum FT level or as the presence of two biomarkers indicating ID 
(MCV<80 fL, MCHC<32 g/dL, RDW>14%, Fe<71 µg/dL, FT<45 ng/mL, TF sat.<20%, TIBC≥360 
µg/dL, sTFR>1.76 mg/L and sTFr-LogFT index>1.5). Characterization data for iron sufficiency 
and ID individuals is presented in Table 11. From the 151 participants, 2 failed blood collection 
and therefore no data was available; from the remaining 149 participants, 44 individuals 
(29.53%) were classified as ID and 105 individuals (70.47%) as iron sufficiency. 
 
Table 11 - Characteristics of participants with and without ID 
Variables (mean; SD) Iron sufficiency ID  
Socio-demographic  
  
t(df); p; Cohen’s d 
 
Age (yrs) 66.37; 8.26 66.09; 7.11 .197(147); .844; .036 
 
Education (school yrs)  5.15; 3.87 5.18; 3.70 -.043(147); .966; .008 
Anthropometric 
  
t(df); p; Cohen’s d 
 
Weight (kg) a 73.94; 11.85 70.89; 1.73 1.426(138); .156; .267 
 
Height (m) a 1.60; .08 1.56; .08 2.218(138); .028; .415 
 
BMI (kg/m2) a 28.96; 3.75 29.13; 4.17 -.236(138); .814; .044 
 
Waist circ. (cm) a 96.58; 1.27 93.86; 11.06 1.397(138); .165; .261 
 
Hip circ. (cm) a 101.7; 7.73 101.22; 7.80 .333(138); .739; .062 
 
%BF-BIA (%) b 32.16; 7.76 34.24; 8.12 -1.394(134); .166; .266 
 
%BF-Brozek (%) a 33.70; 7.21 36.60; 6.20 -2.251(138); .026; .421 
Gender (n; %)   2(df); p;  
 Female  49; 32.89 32; 21.48 8.488(1); .004; -.239 
 Male 56; 37.58 12; 8.05  
BMI class (n; %)   2(df); p; c 
 
Normal 17; 12.14 5; 3.57 .756(2); .679; .073 
 
Overweight 47; 33.57 19; 13.57  
 Obesity 35; 25 17; 12.14  
Nutritional status (n; %)   2(df); p;  
 Risk of malnutrition 11; 7.86 8; 5.71 1.745(1); .277; -.112 
 Normal  88; 62.86 33; 23.57  
a  n=140 [Iron sufficiency =99 (70.71%). ID=41 (29.29%)]; b n=136 [Iron sufficiency =97 (71.32%). ID=39 (28.68%)]. 
 
Table 12 (Figure 11) shows neuropsychological and neurocognitive variables of 
participants by iron status classification. No significant differences were observed except for GDS, 
with a higher mean value in the ID group. Data from physical functional ability (Table 13, Figure 
12) did not show statistically significant differences between iron sufficiency and ID participants.  
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Table 12 - Neuropsychological and neurocognitive variables in iron sufficiency and ID. 
 Variables (mean; SD) Iron sufficiency ID  
Psychological   t(df); p; Cohen’s d 
 GDS  10.47; 5.89 13.20; 6.97 -2.449(147); .016; .443 
 PSS a 20.23; 8.04 20.78; 6.24 -.380(136); .704; .072 
Neurocognitive   t(df); p; Cohen’s d 
 DS – Forward  7.70; 2.24 6.7; 2.13 .714(147); .476; .129 
 DS – Backward  4.43; 2.50 3.48; 1.66 .711(147); .478; .129 
 DS – Total 12.13; 4.37 1.18; 3.34 .779(147); .437; .141 
 Stroop – W b 65.85; 21.27 63.51; 22.39 .586(141); .559; .109 
 Stroop – C  c 48.30; 15.10 47.70; 13.81 .225(144); .822; .041 
 Stroop – W&C c 3.12; 12.98 28.56; 13.10 .660(144); .511; .121 
 SRT – LTS  26.26; 13.73 22.7; 13.61 1.444(147); .151; .261 
 SRT – CLTR  16.04; 12.90 14.39; 12.91 .713(147); .477; .129 
 SRT – DR d 5.75; 2.85 5.39; 2.87 .705(139); .482; .129 
 SRT – Intrusions  2.70; 4.24 3.34; 3.49 -.879(147); .381; .159 
 CERAD – Total hits e 17.66; 4.79 17.35; 5.31 .335(138); .738; .063 
 CERAD – DR hits e 5.76; 2.47 5.70; 2.28 .133(138); .895; .025 
 MMSE 26.53; 3.45 26.52; 2.72 .018(147); .986; .003 
 MOCA f 17.95; 4.96 18.31; 5.57 -.349(115); .728; .071 
Cognitive dimensions    t(df); p; Cohen’s d 
 Executive  g .08; 1.04 -.21; .85 .852(146); .396; .291 
 Memory h .05; .99 -.14; 1.02 .754(146); .452; .183 
a n=138 [Iron sufficiency =98 (71.01%). ID=40 (28.99%)]; b n=143 [Iron sufficiency =102 (71.33%). ID=41 (28.67%)]; 
c n=146 [Iron sufficiency =103 (70.55%). ID=43 (29.45%)]; d n=141 [Iron sufficiency =97 (68.79%). ID=44 (31.21%)]; 
e n=140 [Iron sufficiency =100 (71.43%). ID=40 (28.57%)]; f n=117 [Iron sufficiency =82 (70.09%). ID=35 (29.91%)]; 
g n=141 [Iron sufficiency =100 (70.92%). ID=41 (29.08%)]; h n=132 [Iron sufficiency =92 (69.7%). ID=40 (30.3%)].  
 
Table 13 - Functional ability and functional dimensions regarding iron status classification 
Variables (mean; SD) Iron sufficiency ID  
Functional ability – QoFA a   t(df); p; Cohen’s d 
 Mobility tiredness 4.55; 1.98 4.30; 1.76 .732(146); .465; .133 
 Lower limb tiredness 4.35; 1.15 4.02; 1.05 1.608(146); .110; .291 
 Upper limb tiredness 3.76; .81 3.82; .54 -.441(146); .660; .080 
 Mobility help 11.08; 1.99 11.14; 2.00 -.166(146); .868; .030 
 PADL help 18.87; 2.49 18.14; 3.27 1.479(146); .141; .268 
Functional components a   t(df); p; Cohen’s d 
 Functional tiredness .06; 1.05 -.09; .75 .852(146); .396; .154 
 Functional help .06; .92 -.07; 1.02 .754(146); .452; .137 
a n=148 [Iron sufficiency =104 (70.27%); ID=44 (29.73%)]. 
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Figure 11 – Distribution of neurocognitive/neuropsychological dimensions by iron status 
groups. 
 
 
Figure 12 - Functional dimensions mean value by iron status groups. 
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Table 14 - Hematologic variables and dimensions in iron status groups. 
Variables (mean; SD) Iron sufficiency ID 
 
Inflammatory indices 
  
Z(U); p; r £ 
 hsCRP (mg/dL) ¥ £ 1.56; 2.42 2.90; 2.27 -2.880(1617.5); .004; .236 
Red cells indices  a   t(df); p; Cohen’s d 
 RBC (1012/L) 4.60; .43 4.45; .43 1.911(144); .058; .352 
 Hemoglobin (mg/dL) 14.17; 1.48 12.88; 1.56 4.702(144); <.001; .866 
 Hematocrit (%) 41.23; 3.83 38.23; 4.05 4.205(144); <.001; .774 
 MCV (fL) 89.61; 3.64 85.9; 4.78 5.076(144); <.001; .934 
 MCH (pg) 30.78; 1.44 28.92; 2.06 5.354(57.8); <.001; 1.144 
 MCHC (g/dL) 34.35; .92 33.65; .97 4.075(144); <.001; .750 
 RDW (%) 13.14; .64 13.95; 1.11 -4.439(52.49); <.001; 1.015 
Iron biomarkers b   t(df); p; Cohen’s d 
 Fe (µg/dL) 102.83; 24.85 70.64; 27.12 6.986(144); <.001; 1.269 
 TF (mg/dL) 232.34; 28.96 285.43; 46.29 -7.036(58.04); <.001; 1.525 
 FT (mg/mL) ¥ £ 173.00; 209.25 35.50; 41.25 -7.190(557.5); <.001; .595 
 TF sat. (%) 31.84; 8.06 18.87; 8.12 8.906(144); <.001; 1.617 
 TIBC (µg/dL) 326.30; 40,32 388.34; 61.23 -6.168(59.7); <.001; 1.314 
 sTFr (mg/L) c ¥ £ 1.02; .34 1.475; .80 -6.170(818); <.001; .507 
 sTFr-LogFT index ¥ £ .483; .19 .888; .77 -7.810(413); <.001; .646 
 Body iron (mg/kg) 17.02; 2.66 10.02; 4.70 9.249(55.2); <.001; 2.072 
Iron dimensions   t(df); p; Cohen’s d 
 Storage b .43; .49 -1.01; 1.15 7.997(49.73); <.001; 1.936 
 Transport b .37; .81 -.85; .87 8.156(144); <.001; 1.481 
 Transport S. b .36; .70 -.84; 1.10 6.666(58.55); <.001; 1.437 
 Red cells C. a .31; .72 -.77; 1.17 5.575(54.05); <.001; 1.247 
 Erythropoiesis a .19; .95 -.46; .98 3.707(144); <.001; .682 
a n=146 [Iron sufficiency =104 (71.23%). ID=42 (28.77%)]; b n=146 [Iron sufficiency =102 (69.86%). ID=44 
(30.14%)]; c n=148 [Iron sufficiency =104 (70.27%). ID=44 (29.73%)]; ¥ Variables not normally distributed. data 
presented in median and interquartile range (median. IQR); £ Mann–Whitney U test. results presented in Z(U); p; r. 
 
As expected, significant differences were observed for almost all of the hematologic 
variables between groups of iron status (Table 14, Figure 13), with the iron sufficiency group with 
higher values. Of notice, hsCRP was significantly higher in the ID group, which can impact on the 
levels of iron biomarkers. 
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Figure 13 - Hematological dimensions by iron status groups. 
 
Since several factors can contribute as confounding factors either for neurocognitive, 
neuropsychological or physical functional variables, ANCOVA was used to test differences in 
dependent variables (Executive, Memory, MMSE, MOCA, GDS, PSS, Functional-T and Functional-
H) in iron status groups (iron sufficiency versus ID). Data presented in tables -15, -16, -17 and -
18 indicate that there are no differences between groups of iron status when controlling for 
principal confounding factors, including for GDS which was significantly different before 
controlling. 
 
Table 15 – ANCOVA for neurocognitive dimensions  
 Executive Memory 
Source F(1; 134) p η2 partial F(1; 125) p η2 partial 
Age 20.674 <.001 .134 8.984 .003 .067 
Education a 16.926 <.001 .112 6.453 .012 .049 
Gender b .969 .327 .007 1.562 .214 .012 
hsCRP (Log) .261 .610 .002 .008 .931 <.001 
GDS 13.531 <.001 .092 21.386 <.001 .146 
ID c 2.971 .087 .022 .781 .378 .006 
R2; R2adjusted .398; .371 .296; .262 
a 4 years and less=0, more than 4 years=1; b female=0, male=1; c iron sufficiency=0, ID=1 
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Table 16 – ANCOVA for general cognition variables 
 MMSE MOCA 
Source F(1; 142) p η2 partial F(1; 110) p η2 partial 
Age 12.773 <.001 .083 10.028 .002 .084 
Education a 5.440 .021 .037 24.475 <.001 .182 
Gender b 3.105 .080 .021 .892 .347 .008 
hsCRP (Log) .028 .867 <.001 .020 .889 <.001 
GDS 9.868 .002 .065 9.235 .003 .077 
ID c .409 .523 .003 .014 .907 <.001 
R2; R2adjusted .271; .240 .395; .362 
a 4 years and less=0, more than 4 years=1; b female=0, male=1; c iron sufficiency=0, ID=1 
 
Table 17 - ANCOVA for neuropsychological variables 
 GDS PSS 
Source F(1; 149) p η2 partial F(1; 138) p η2 partial 
Age .003 .955 <.001 .040 .843 <.001 
Education a 3.583 .060 .024 .952 .331 .007 
Gender b 10.836 .001 .070 18.711 <.001 .124 
hsCRP (Log) .155 .695 .001 2.902 .091 .022 
ID c 3.792 .053 .026 .085 .771 .001 
R2; R2adjusted .148; .118 .138; .106 
a 4 years and less=0, more than 4 years=1; b female=0, male=1; c iron sufficiency=0, ID=1 
 
Table 18 – ANCOVA for functional dimensions 
 Functional-T Functional-H 
Source F(1; 139) p η2 partial F(1; 139) p η2 partial 
Age 4.228 .042 .030 4.718 .032 .034 
BMI 8.251 .005 .058 16.179 <.001 .107 
hsCRP (Log) .020 .887 <.001 .852 .358 .006 
ID a .697 .405 .005 .418 .519 .003 
R2; R2adjusted .116; .089 .153; .128 
a iron sufficiency=0, ID=1 
 
4.1.3 Nutritional risk factors for iron deficiency 
Dietary iron is the natural source of iron to the body; therefore, it is expected that ID is 
closely related to the individual’s nutritional status. To test if nutritional status (MNA) and/or body 
composition (BMI, %BF-Tanita and %BF-Brozek) were predictors of ID, a logistic regression was 
conducted and controlled using the enter method for the potential confounding factors (age, 
gender and hsCRP). Results from the binary logistic regression are presented in Table 19. From 
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the variables introduced in model 1 (equal to MNA, BMI and %BF-Brozek adjusted models; 
different for %BF-Tanita due to missing values), as expected, we observed that gender (Wald(1)= 
6.926; p= .008) and hsCRP (Log) (Wald(1)= 8.374; p= .004) were significant predictors of ID 
meaning that the odds of ID presence in males are 3.040 lower (OR = .329) than in females; and 
for each fold increase in hsCRP (Log) an increase of 5.278 (OR = 5.278) in the odds of the 
presence of ID is observed. After introducing nutritional status and body composition variables in 
the adjusted models 2 we observed slight differences in the previous mentioned control variables, 
but with the same tendency and significance as the previously mentioned. The Wald criterion 
demonstrated that nutritional status, measured by the MNA total score, made also a significant 
contribution to prediction of ID (Wald(1)= 5.389; p= .020). For each unit increase (1 point in the 
MNA total score) in nutritional status the odds of ID presence decreased 1.211 times (OR = 
.826). Body composition variables did not contribute significantly to the prediction of ID.  
 
Table 19 – Binary logistic regression of nutritional predictors for ID a 
Independent  
variables  
Model 1  Model 2 
B SE Wald(df); p OR (CI 95%)  B SE Wald(df); p OR (CI 95%) 
Age -.033 .026 1.643(1); .200 .967 (.919; 1.018)  -.028 .027 1.141(1); .285 .972 (.923; 1.024) 
Gender b -1.113 .423 6.926(1); .008 .329 (.143; .753)  -.920 .435 4.478(1); .034 .398 (.170; .934) 
hsCRP (Log) 1.663 .575 8.374(1); .004 5.278 (1.711; 16.284)  1.817 .598 9.236(1); .002 6.152 (1.906; 19.854) 
MNA      -.191 .082 5.389(1); .020 .826 (.704; .971) 
2(df); p; R2 Nagelkerke 17.645(3); p=.001; .169  5.533(1); p=.019; .217 
Age -.033 .026 1.643(1); .200 .967 (.919; 1.018)  -.031 .026 1.365(1); .243 .970 (.921; 1.021) 
Gender b -1.113 .423 6.926(1); .008 .329 (.143; .753)  -1.211 .435 7.746(1); .005 .298 (.127; .699) 
hsCRP (Log) 1.663 .575 8.374(1); .004 5.278 (1.711; 16.284)  1.966 .634 9.625(1); .002 7.145 (2.063; 24.749) 
BMI      -.074 .058 1.624(1); .203 .929 (.830; 1.040) 
2(df); p; R2 Nagelkerke 17.645(3); p=.001; .169  1.679(1); p=.195; .184 
Age -.028 .026 1.141(1); .285 .972 (.924; 1.024)  -.026 .026 .940(1); .332 .975 (.926; 1.027) 
Gender b -1.103 .431 6.554(1); .010 .332 (.143; .772)  -1.625 .602 7.294(1); .007 .197 (.061; .640) 
hsCRP (Log) 1.469 .577 6.478(1); .011 4.346 (1.402; 13.472)  1.742 .623 7.834(1); .005 5.711 (1.686; 19.347) 
%BF-Tanita      -.048 .036 1.775(1); .183 .953 (.887; 1.023) 
2(df); p; R2 Nagelkerke 14.942(3); p=.002; .149 1.786(1); p=.181; .166 
Age -.033 .026 1.643(1); .200 .967 (.919; 1.018)  -.024 .028 .730(1); .393 .976 (.924; 1.032) 
Gender b -1.113 .423 6.926(1); .008 .329 (.143; .753)  -1.740 .868 4.023(1); .045 .175 (.032; .961) 
hsCRP (Log) 1.663 .575 8.374(1); .004 5.278 (1.711; 16.284)  1.825 .612 8.882(1); .003 6.203 (1.868; 20.602) 
%BF-Brozek      -.053 .063 .713(1); .398 .948 (.839; 1.073) 
2(df); p; R2 Nagelkerke 17.645(3); p=.001; .169  .702(1); p=.402; .175 
a iron sufficiency=0, ID=1; b female=0, male=1;  
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4.1.4 Iron status as a possible predictor of cognition, mood and physical 
functional ability  
Hierarchical regression models were tested with the major confounding factor and known 
predictors as independent variables to predict dependent variables (block 1: model 0; tables -18, 
-19, -20 and -21). Using the enter method, hematological dimensions were tested as predictors 
(independent variable) of target variables (dependent variables) (block 2: Storage – model 1; 
Transport – model 2; Transport S. – model 3; Red cells C. – model 4; Erythropoiesis – model 5). 
Table 20 presents the results of hierarchical regression models for neurocognitive 
dimensions. Age, education (as a dummy variable), gender, hsCRP (log) and mood (GDS) were 
used in block 1, model 0 as independent variables, resulting in a significant predictor model for 
executive and memory dimensions. For the executive dimension, in block 1, model 0, age, 
education and mood were significant predictors and the model explained 37.1% (R2adjusted) of the 
variance. This pattern was verified also in Block 1 for all the remaining models, although no 
significant improvement in executive dimension variance explanation was obtained from block 2 
(models 1 to 5), with the increment of executive dimension variance explanation near to 0% 
(∆R2adjusted).  
For the memory dimension (Table 20, Figure 14), in block 1, model 0, age and mood were 
the sole significant predictors of memory dimension; however, the model with all the independent 
variables explained 26.9% (R2adjusted) of the memory dimension variance. The addition of 
hematological dimensions in block 2, resulted in a significant predictor model 1, where age, 
education, mood and the storage dimension were significant predictors and a significant 
predictor model 5, where erythropoiesis was a significant predictor and in addition to the control 
variables of model 1, gender was also seen as a significant predictor. The addition of storage 
dimension (block 2, model 1) resulted in a significant increment of 2% (∆R2adjusted) of the variance 
explanation when compared with model 0. Similar to model 1, the addition of erythropoiesis 
dimension (block 2, model 5) resulted in a significant increment of 2.6% (∆R2adjusted) of the memory 
dimension variance explanation when compared with model 0.  
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Table 20 - Hierarchical regression models to predict neurocognitive dimensions. 
  Executive Memory 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.342 (-.481; -.204) .070 -.351 -4.888; <.001 -.264 (-.418; -.109) .078 -.270 -3.376; .001 
 Education a .533 (.209; .856) .163 .238 3.261; .001 .343 (-.018; .703) .182 .155 1.880; .063 
 Gender b .219 (-.063; .502) .143 .112 1.534; .127 -.165 (-.478; .148) .158 -.085 -1.045; .298 
 hsCRP (Log) .013 (-.118; .145) .067 .014 .202; .840 -.001 (-.153; .151) .077 -.001 -.011; .991 
 GDS -.282 (-.422; -.142) .071 -.288 -3.994; <.001 -.388 (-.546; -.231) .079 -.395 -4.893; <.001 
R2adjusted; R2; ∆R2 .371; .394; .394 .269; .298; .298 
F(df1; df2) for ∆R2; p F(5; 132)=17.132; <.001 F(5; 123)=10.437; <.001 
1 Age -.329 (-.468; -.190) .070 -.338 -4.692; <.001 -.241 (-.395; -.087) .078 -.247 -3.096; .002 
 Education a .577 (.250; .903) .165 .258 3.493; .001 .407 (.046; .768) .182 .184 2.232; .027 
 Gender b .153 (-.141; .447) .149 .078 1.028; .306 -.251 (-.570; .068) .161 -.129 -1.559; .122 
 hsCRP (Log) .007 (-.124; .139) .066 .007 .109; .914 .000 (-.150; .150) .076 .000 -.001; .999 
 GDS -.265 (-.406; -.123) .071 -.270 -3.709; <.001 -.369 (-.525; -.213) .079 -.375 -4.689; <.001 
 Storage  .109 (-.033; .250) .071 .112 1.520; .131 .169 (.010; .329) .080 .167 2.105; .037 
R2adjusted; R2; ∆R2 .377; .404; .011 .289; .322; .025 
F(df1;df2) for ∆R2; p F(1; 131)=2.31; .131 F(1; 122)=4.431; .037 
2 Age -.343 (-.483; -.204) .071 -.352 -4.866; <.001 -.273 (-.427; -.118) .078 -.279 -3.497; .001 
 Education a .533 (.209; .857) .164 .238 3.252; .001 .358 (-.001; .718) .182 .162 1.972; .051 
 Gender b .213 (-.078; .504) .147 .108 1.449; .150 -.218 (-.537; .101) .161 -.112 -1.355; .178 
 hsCRP (Log) .017 (-.120; .153) .069 .017 .239; .811 .032 (-.125; .189) .079 .032 .406; .685 
 GDS -.280 (-.423; -.136) .072 -.286 -3.862; <.001 -.368 (-.527; -.210) .080 -.374 -4.595; <.001 
 Transport .013 (-.132; .158) .073 .014 .181; .857 .124 (-.039; .287) .082 .124 1.508; .134 
R2adjusted; R2; ∆R2 .366; .394; .000 .277; .311; .013 
F(df1;df2) for ∆R2; p F(1; 131)=.033; .857 F(1; 122)=2.273; .134 
3 Age -.344 (-.483; -.205) .070 -.353 -4.902; <.001 -.266 (-.420; -.111) .078 -.272 -3.395; .001 
 Education a .523 (.197; .848) .165 .234 3.178; .002 .320 (-.044; .685) .184 .145 1.740; .084 
 Gender b .208 (-.078; .494) .144 .106 1.441; .152 -.174 (-.488; .139) .158 -.089 -1.100; .273 
 hsCRP (Log) .018 (-.115; .152) .067 .019 .272; .786 .011 (-.143; .165) .078 .011 .142; .887 
 GDS -.276 (-.418; -.134) .072 -.282 -3.85; <.001 -.376 (-.536; -.216) .081 -.382 -4.661; <.001 
 Transport S. .043 (-.102; .189) .074 .042 .590; .556 .070 (-.089; .229) .080 .070 .875; .383 
R2adjusted; R2; ∆R2 .367; .395; .002 .268; .302; .004 
F(df1;df2) for ∆R2; p F(1; 131)=.348; .556 F(1; 122)=.765; .383 
4 Age -.313 (-.457; -.168) .073 -.315 -4.272; <.001 -.233 (-.394; -.071) .081 -.234 -2.856; .005 
 Education a .626 (.292; .960) .169 .273 3.704; <.001 .453 (.081; .825) .188 .200 2.413; .017 
 Gender b .149 (-.146; .443) .149 .074 .997; .320 -.236 (-.559; .088) .164 -.119 -1.440; .152 
 hsCRP (Log) .020 (-.115; .155) .068 .021 .298; .767 .006 (-.149; .161) .078 .006 .077; .938 
 GDS -.273 (-.416; -.129) .073 -.271 -3.753; <.001 -.378 (-.539; -.218) .081 -.375 -4.670; <.001 
 Red cells C. .093 (-.049; .234) .072 .094 1.299; .196 .085 (-.077; .247) .082 .084 1.040; .300 
R2adjusted; R2; ∆R2 .364; .391; .008 .266; .300; .006 
F(df1;df2) for ∆R2; p F(1; 131)=1.686; .196 F(1; 122)=1.082; .300 
5 Age -.324 (-.469; -.179) .073 -.327 -4.426; <.001 -.214 (-.373; -.056) .080 -.216 -2.677; .008 
 Education a .604 (.266; .942) .171 .264 3.535; .001 .523 (.154; .891) .186 .231 2.804; .006 
 Gender b .187 (-.143; .517) .167 .094 1.121; .264 -.416 (-.772; -.061) .180 -.210 -2.317; .022 
 hsCRP (Log) .017 (-.119; .154) .069 .018 .253; .801 -.008 (-.159; .143) .077 -.008 -.105; .917 
 GDS -.281 (-.429; -.132) .075 -.279 -3.738; <.001 -.336 (-.498; -.175) .082 -.333 -4.119; <.001 
 Erythropoiesis .008 (-.165; .180) .087 .007 .088; .930 .229 (.045; .412) .093 .227 2.470; .015 
R2adjusted; R2; ∆R2 .355; .384; .000 .295; .328; .034 
F(df1;df2) for ∆R2; p F(1; 131)=.008; .930 F(1; 122)=6.102; .015 
a Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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Figure 14 - Summary model for the correlation between memory dimension and hematological 
dimensions and associated beneficial and detrimental factors. 
 
Hierarchical regression models to predict general cognition are presented in 21. 
Independent variables were the same as used in the hierarchical regression models for 
neurocognitive dimensions. The results obtained for general cognition were similar to those 
obtained for the executive dimension; block 1, model 0 (for MMSE and MOCA) had age, 
education and mood as significant predictors and the overall model explained 25.1% (R2adjusted) and 
36.1% (R2adjusted) of MMSE and MOCA variance respectively. The pattern of significant predictors 
was maintained with the addition of hematological variables in block 2 (models 1 to 5), but 
hematological dimensions did not increment significant variance explanation for the MMSE or 
MOCA.   
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Table 21 - Hierarchical regression models to predict general cognition. 
  MMSE MOCA 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.278 (-.419; -.136) .072 -.295 -3.878; <.001 -.256 (-.415; -.098) .080 -.255 -3.206; .002 
 Education a .368 (.037; .698) .167 .169 2.199; .030 .927 (.560; 1.294) .185 .397 5.008; <.001 
 Gender b .217 (-.073; .508) .147 .115 1.478; .142 .133 (-.179; .446) .158 .067 .847; .399 
 hsCRP (Log) .036 (-.101; .173) .069 .038 .524; .601 -.004 (-.154; .145) .076 -.005 -.059; .953 
 GDS -.239 (-.383; -.095) .073 -.253 -3.284; .001 -.243 (-.397; -.089) .078 -.243 -3.127; .002 
R2adjusted; R2; ∆R2 .251; .277; .277 .365; .392; .392 
F(df1;df2) for ∆R2; p F(5; 140)=10.719; <.001 F(5; 109)=14.083; <.001 
1 Age -.273 (-.415; -.130) .072 -.290 -3.78; <.001 -.252 (-.411; -.093) .080 -.251 -3.136; .002 
 Education a .385 (.050; .720) .170 .177 2.270; .025 .952 (.576; 1.328) .190 .407 5.017; <.001 
 Gender b .191 (-.111; .493) .153 .101 1.250; .213 .113 (-.206; .433) .161 .057 .704; .483 
 hsCRP (Log) .033 (-.104; .171) .069 .035 .481; .631 -.005 (-.155; .145) .076 -.005 -.063; .950 
 GDS -.232 (-.378; -.086) .074 -.245 -3.146; .002 -.236 (-.392; -.081) .079 -.236 -3.007; .003 
 Storage  .049 (-.096; .194) .073 .051 .666; .506 .051 (-.109; .212) .081 .050 .637; .525 
R2adjusted; R2; ∆R2 .248; .279; .002 .361; .395; .002 
F(df1;df2) for ∆R2; p F(1; 139)=.444; .506 F(1; 108)=.406; .525 
2 Age -.287 (-.429; -.145) .072 -.305 -3.990; <.001 -.266 (-.426; -.105) .081 -.265 -3.286; .001 
 Education a .372 (.042; .702) .167 .171 2.227; .028 .945 (.575; 1.315) .187 .404 5.063; <.001 
 Gender b .181 (-.115; .477) .150 .095 1.208; .229 .101 (-.222; .423) .163 .050 .619; .537 
 hsCRP (Log) .057 (-.084; .197) .071 .060 .801; .425 .013 (-.143; .169) .079 .013 .164; .870 
 GDS -.223 (-.369; -.077) .074 -.236 -3.021; .003 -.230 (-.388; -.073) .079 -.230 -2.907; .004 
 Transport .091 (-.055; .238) .074 .096 1.230; .221 .067 (-.094; .228) .081 .069 .823; .413 
R2adjusted; R2; ∆R2 .254; .285; .008 .363; .396; .004 
F(df1;df2) for ∆R2; p F(1; 139)=1.514; .221 F(1; 108)=.677; .413 
3 Age -.279 (-.421; -.137) .072 -.296 -3.882; <.001 -.258 (-.416; -.100) .080 -.257 -3.238; .002 
 Education a .358 (.025; .692) .169 .165 2.124; .035 .903 (.536; 1.27) .185 .386 4.876; <.001 
 Gender b .211 (-.082; .504) .148 .111 1.425; .156 .117 (-.195; .429) .157 .059 .746; .457 
 hsCRP (Log) .040 (-.098; .178) .070 .043 .578; .564 .011 (-.140; .162) .076 .011 .142; .888 
 GDS -.232 (-.379; -.085) .074 -.245 -3.123; .002 -.226 (-.381; -.070) .078 -.226 -2.879; .005 
 Transport S. .036 (-.106; .178) .072 .038 .500; .618 .109 (-.050; .268) .080 .105 1.359; .177 
R2adjusted; R2; ∆R2 .247; .278; .001 .369; .403; .010 
F(df1;df2) for ∆R2; p F(1; 139)=.250; .618 F(1; 108)=1.847; .177 
4 Age -.269 (-.420; -.118) .076 -.275 -3.516; .001 -.255 (-.415; -.096) .080 -.252 -3.181; .002 
 Education a .429 (.081; .777) .176 .189 2.435; .016 .935 (.561; 1.308) .188 .395 4.961; <.001 
 Gender b .213 (-.096; .522) .156 .108 1.362; .175 .169 (-.151; .490) .162 .084 1.047; .297 
 hsCRP (Log) .033 (-.110; .176) .072 .034 .455; .650 -.016 (-.167; .135) .076 -.016 -.210; .834 
 GDS -.231 (-.381; -.080) .076 -.233 -3.032; .003 -.243 (-.398; -.088) .078 -.240 -3.101; .002 
 Red cells C. .050 (-.098; .199) .075 .051 .670; .504 -.026 (-.183; .130) .079 -.026 -.335; .739 
R2adjusted; R2; ∆R2 .243; .274; .002 .363; .396; .001 
F(df1;df2) for ∆R2; p F(1; 139)=.449; .504 F(1; 110)=.112; .739 
5 Age -.267 (-.418; -.116) .076 -.273 -3.492; .001 -.235 (-.392; -.077) .079 -.232 -2.957; .004 
 Education a .439 (.089; .790) .177 .193 2.480; .014 1.031 (.658; 1.404) .188 .436 5.484; <.001 
 Gender b .169 (-.173; .511) .173 .086 .976; .331 -.011 (-.362; .341) .177 -.005 -.060; .953 
 hsCRP (Log) .029 (-.114; .171) .072 .029 .399; .691 -.012 (-.160; .136) .074 -.012 -.161; .872 
 GDS -.218 (-.373; -.062) .079 -.220 -2.766; .006 -.205 (-.362; -.049) .079 -.203 -2.601; .011 
 Erythropoiesis .073 (-.102; .247) .088 .074 .822; .412 .175 (-.003; .353) .090 .174 1.951; .054 
R2adjusted; R2; ∆R2 .244; .276; .004 .383; .415; .020 
F(df1;df2) for ∆R2; p F(1; 139)=.676; .412 F(1; 110)=3.805; .054 
a Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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For neuropsychological variables the same independent variables were used as control 
variables and predictors, with exception of GDS which was, along with PSS, a dependent variable. 
Results from the hierarchical regression models for neuropsychological variables are presented in 
Table 22. Regarding GDS (Table 22, Figure 15) variance explanation for block 1 model 0, from 
all the independent variables, gender was the only significant predictor. Overall, model 0 was 
significant and explained 10.3% (R2adjusted) of GDS variance. The addition of hematological 
dimensions in block 2 resulted in the significant predictor models 2 (added transport), 3 (added 
transport S.) and 5 (added erythropoiesis). In block 2, model 2 the addition of storage 
component resulted in a significant increase in variance explanation of 2.1% (∆R2adjusted). Transport 
s. dimension addition (block 2, model 3) increased GDS variance explanation in 2.5% with 
statistical significant relevance. Block 2, model 5 was composed by the variables of model 0 and 
erythropoiesis dimension and resulted in a significant predictor model, which increased 4.1% 
(∆R2adjusted) the variance explanation when compared to Block 1 model 0. Of notice, gender is a 
significant predictor in all models with exception of model 5 where erythropoiesis is the only 
significant predictor with an impact that should be highlighted (β = -.301).  
In block 1, model 0, results obtained for PSS were similar to the ones obtained for PSS; 
gender was the only significant predictor and the overall model explained 11.5% (R2adjusted) and 
36.1% (R2adjusted) of PSS variance. Significance of gender as predictors was maintained with the 
addition of hematological variables in block 2 (models 1 to 5), but hematological dimensions did 
not increment significant variance explanation also for PSS.   
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Table 22  - Hierarchical regression models to predict neuropsychological dimensions. 
  GDS PSS 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.009 (-.173; .154) .083 -.009 -.113; .910 -.004 (-.175; .168) .087 -.004 -.044; .965 
 Education a -.289 (-.668; .090) .192 -.126 -1.505; .135 .216 (-.175; .608) .198 .094 1.092; .277 
 Gender b -.628 (-.948; -.309) .162 -.313 -3.888; <.001 -.745 (-1.079; -.41) .169 -.369 -4.404; <.001 
 hsCRP (Log) .005 (-.153; .163) .080 .005 .067; .947 -.155 (-.325; .015) .086 -.151 -1.804; .074 
R2adjusted; R2; ∆R2 .103; .127; .127 .115; .141; .141 
F(df1;df2) for ∆R2; p F(4; 141)=5.143; .001 F(4; 130)=5.346; .001 
1 Age -.024 (-.187; .140) .083 -.024 -.289; .773 -.003 (-.176; .170) .087 -.003 -.031; .976 
 Education a -.334 (-.714; .046) .192 -.145 -1.735; .085 .220 (-.177; .618) .201 .096 1.097; .275 
 Gender b -.537 (-.871; -.203) .169 -.268 -3.179; .002 -.752 (-1.102; -.401) .177 -.372 -4.244; <.001 
 hsCRP (Log) .013 (-.144; .171) .080 .014 .170; .866 -.155 (-.326; .016) .086 -.151 -1.798; .075 
 Storage  -.144 (-.309; .020) .083 -.144 -1.733; .085 .013 (-.167; .192) .091 .012 .140; .889 
R2adjusted; R2; ∆R2 .115; .146; .018 .108; .141; 0 
F(df1;df2) for ∆R2; p F(1; 140)=3.002; .085 F(1; 129)=.020; .889 
2 Age .008 (-.154; .171) .082 .008 .101; .920 -.001 (-.175; .173) .088 -.001 -.015; .988 
 Education a -.288 (-.662; .087) .189 -.125 -1.519; .131 .215 (-.179; .608) .199 .093 1.079; .283 
 Gender b -.538 (-.865; -.212) .165 -.268 -3.257; .001 -.734 (-1.084; -.385) .177 -.364 -4.161; <.001 
 hsCRP (Log) -.035 (-.196; .126) .081 -.035 -.431; .667 -.161 (-.339; .018) .090 -.156 -1.779; .078 
 Transport -.177 (-.342; -.012) .084 -.176 -2.119; .036 -.019 (-.198; .160) .091 -.019 -.209; .835 
R2adjusted; R2; ∆R2 .124; .154; .027 .108; .142; .000 
F(df1;df2) for ∆R2; p F(1; 140)=4.491; .036 F(1; 129)=.044; .835 
3 Age -.003 (-.165; .158) .082 -.003 -.039; .969 -.002 (-.174; .17) .087 -.002 -.022; .982 
 Education a -.231 (-.609; .146) .191 -.101 -1.213; .227 .245 (-.153; .643) .201 .106 1.22; .225 
 Gender b -.574 (-.893; -.255) .161 -.286 -3.561; .001 -.728 (-1.065; -.39) .170 -.360 -4.269; <.001 
 hsCRP (Log) -.016 (-.173; .141) .079 -.016 -.200; .842 -.166 (-.338; .006) .087 -.162 -1.910; .058 
 Transport S. -.182 (-.341; -.023) .080 -.181 -2.261; .025 -.075 (-.248; .098) .088 -.072 -.855; .394 
R2adjusted; R2; ∆R2 .128; .158; .031 .113; .146; .005 
F(df1;df2) for ∆R2; p F(1; 140)=5.111; .025 F(1; 129)=.731; .394 
4 Age .000 (-.167; .168) .085 .000 .001; .999 -.037 (-.213; .139) .089 -.036 -.413; .680 
 Education a -.259 (-.643; .125) .194 -.113 -1.335; .184 .130 (-.270; .529) .202 .056 .642; .522 
 Gender b -.550 (-.881; -.220) .167 -.277 -3.291; .001 -.727 (-1.073; -.380) .175 -.360 -4.151; <.001 
 hsCRP (Log) -.004 (-.162; .155) .080 -.004 -.047; .962 -.157 (-.328; .014) .087 -.153 -1.817; .072 
 Red cells C. -.077 (-.241; .087) .083 -.078 -.929; .354 -.054 (-.235; .126) .091 -.052 -.596; .552 
R2adjusted; R2; ∆R2 .085; .116; .005 .114; .147; .002 
F(df1;df2) for ∆R2; p F(1; 140)=.863; .354 F(1; 129)=.356; .552 
5 Age -.026 (-.188; .136) .082 -.026 -.318; .751 -.035 (-.212; .142) .089 -.035 -.392; .696 
 Education a -.317 (-.689; .056) .188 -.138 -1.681; .095 .131 (-.27; .533) .203 .057 .647; .519 
 Gender b -.269 (-.634; .096) .185 -.136 -1.458; .147 -.708 (-1.107; -.308) .202 -.350 -3.505; .001 
 hsCRP (Log) .008 (-.145; .161) .077 .008 .102; .919 -.152 (-.323; .019) .086 -.148 -1.755; .082 
 Erythropoiesis -.298 (-.479; -.117) .092 -.301 -3.26; .001 -.044 (-.247; .16) .103 -.042 -.424; .672 
R2adjusted; R2; ∆R2 .144; .174; .063 .113; .146; .001 
F(df1;df2) for ∆R2; p F(1; 140)=10.627; .001 F(1; 129)=.180; .672 
a Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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Figure 15 – Summary model for the correlation between depressive mood (GDS score) and 
hematological dimensions and associated beneficial and detrimental factors. 
 
For the functional dimensions (Table 23), block 1 was composed by age, BMI and hsCRP 
(Log) as independent variables (control variables). In block 1, model 0, age and BMI were 
significant predictors and the overall model explained 8.8% (R2adjusted) and 13.9% (R2adjusted) of 
functional-T and functional-H variance respectively. Regarding functional-H dimension, the 
addition of hematological variables in block 2 (models 1 to 5) did not increment significant 
variance explanation; although, age and gender remained as significant predictors.  
For the functional-T dimension (Table 23, Figure 16), after the addition of hematological 
dimensions in block 2 resulted in four models (models 1 - storage, 2 - transport, 4 – red cells c. 
and 5 – erythropoiesis) in which variance explanation was significantly increased. Transport S. 
addition in block 2 did not result in a significant increase in variance explanation. Storage, 
transport, red cells C. and erythropoiesis addition in block 2 resulted in a significant increase in 
variance explanation (∆R2adjusted) of 2.4%, 2.2%, 4.8% and 9.5% in model 1, 2 4 and 5 respectively.  
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Table 23 - Hierarchical regression models to predict functional dimensions. 
  Functional-T Functional-H 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.165 (-.319; -.011) .078 -.177 -2.116; .036 -.155 (-.298; -.012) .072 -.175 -2.148; .033 
 BMI -.220 (-.387; -.054) .084 -.231 -2.614; .010 -.315 (-.470; -.161) .078 -.346 -4.033; <.001 
 hsCRP (Log) -.031 (-.198; .136) .084 -.032 -.364; .716 .054 (-.101; .209) .078 .058 .684; .495 
R2adjusted; R2; ∆R2 .088; .108; .108 .139; .158; .158 
F(df1;df2) for ∆R2; p F(3; 133)=5.353; .002 F(3; 133)=8.344; <.001 
1 Age -.151 (-.303; .002) .077 -.162 -1.955; .053 -.151 (-.295; -.007) .073 -.170 -2.078; .040 
 BMI -.234 (-.398; -.069) .083 -.245 -2.805; .006 -.320 (-.475; -.164) .079 -.350 -4.067; <.001 
 hsCRP (Log) -.020 (-.185; .145) .083 -.021 -.241; .810 .057 (-.099; .213) .079 .062 .723; .471 
 Storage  .176 (.016; .336) .081 .177 2.174; .032 .054 (-.097; .205) .076 .057 .708; .480 
R2adjusted; R2; ∆R2 .112; .139; .031 .136; .162; .003 
F(df1;df2) for ∆R2; p F(1; 132)=4.725; .032 F(1; 132)=.502; .480 
2 Age -.179 (-.332; -.027) .077 -.193 -2.323; .022 -.156 (-.300; -.012) .073 -.175 -2.139; .034 
 BMI -.234 (-.399; -.069) .083 -.246 -2.81; .006 -.316 (-.472; -.160) .079 -.346 -4.011; <.001 
 hsCRP (Log) .026 (-.148; .199) .088 .027 .293; .770 .056 (-.108; .219) .083 .061 .673; .502 
 Transport .171 (.010; .333) .082 .179 2.102; .037 .006 (-.146; .158) .077 .007 .078; .938 
R2adjusted; R2; ∆R2 .11; .137; .029 .133; .158; .000 
F(df1;df2) for ∆R2; p F(1; 132)=4.419; .037 F(1; 132)=.006; .938 
3 Age -.165 (-.319; -.010) .078 -.177 -2.107; .037 -.155 (-.299; -.012) .073 -.175 -2.141; .034 
 BMI -.221 (-.388; -.053) .084 -.231 -2.611; .010 -.315 (-.471; -.160) .079 -.346 -4.017; <.001 
 hsCRP (Log) -.024 (-.194; .146) .086 -.025 -.277; .782 .053 (-.105; .211) .080 .058 .663; .509 
 Transport S. .038 (-.124; .200) .082 .039 .461; .646 -.004 (-.154; .147) .076 -.004 -.049; .961 
R2adjusted; R2; ∆R2 .082; .109; .001 .133; .158; .000 
F(df1;df2) for ∆R2; p F(1; 132)=.212; .646 F(1; 132)=.002; .961 
4 Age -.145 (-.298; .007) .077 -.155 -1.883; .062 -.162 (-.308; -.017) .074 -.182 -2.204; .029 
 BMI -.240 (-.402; -.078) .082 -.253 -2.937; .004 -.308 (-.463; -.154) .078 -.341 -3.943; <.001 
 hsCRP (Log) .002 (-.164; .168) .084 .002 .025; .980 .069 (-.089; .228) .080 .075 .865; .389 
 Red cells C. .218 (.057; .379) .081 .218 2.676; .008 .030 (-.124; .184) .078 .031 .385; .700 
R2adjusted; R2; ∆R2 .136; .162; .045 .131; .156; .001 
F(df1;df2) for ∆R2; p F(1; 132)=7.159; .008 F(1; 132)=.149; .700 
5 Age -.130 (-.279; .019) .075 -.139 -1.730; .086 -.156 (-.301; -.010) .074 -.174 -2.115; .036 
 BMI -.224 (-.381; -.067) .079 -.236 -2.819; .006 -.305 (-.459; -.151) .078 -.337 -3.919; <.001 
 hsCRP (Log) -.019 (-.179; .140) .081 -.020 -.240; .811 .067 (-.089; .224) .079 .073 .851; .396 
 Erythropoiesis .303 (.149; .458) .078 .305 3.886; <.001 .076 (-.075; .227) .076 .080 .997; .321 
R2adjusted; R2; ∆R2 .183; .207; .091 .136; .162; .006 
F(df1;df2) for ∆R2; p F(1; 132)=15.104; <.001 F(1; 132)=.993; .321 
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Figure 16 - Summary model for the correlation functional-T dimension and hematological 
dimensions and associated beneficial and detrimental factors. 
4.1.5 Mediation effect of nutritional status on the iron status components  
In order to assess if nutritional status (MNA) is a mediator of the hematological 
dimensions effect on the outcome of dependent variables (neurocognitive dimensions, general 
cognition, neuropsychological variables and functional dimensions) an interaction analysis on 
hierarchical multiple regression models was used. Variables carrying the information of the 
interaction between MNA and hematological dimensions were obtained by the product term of 
mean centered MNA score by the target hematological dimension (which is a z-score). Five new 
variables (MNA*Storage, MNA*Transport, MNA*Transport s., MNA*Red Cells c. and 
MNA*Erythropoiesis) were obtained and used, along with the origin variables, in the block 2 of 
similar hierarchical regression models previously presented.  
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Table 24 - Hierarchical regression models of interaction to predict neurocognitive dimensions. 
  Executive Memory 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.327 (-.467; -.187) .071 -.343 -4.631; <.001 -.263 (-.418; -.107) .078 -.269 -3.345; .001 
 Education a .484 (.156; .812) .166 .220 2.922; .004 .346 (-.017; .709) .183 .156 1.889; .061 
 Gender b .232 (-.056; .520) .146 .119 1.592; .114 -.160 (-.476; .155) .159 -.082 -1.008; .315 
 hsCRP (Log) .008 (-.129; .145) .069 .008 .119; .905 -.002 (-.155; .150) .077 -.002 -.030; .976 
 GDS -.309 (-.454; -.163) .074 -.311 -4.192; <.001 -.386 (-.545; -.228) .080 -.393 -4.834; <.001 
R2adjusted; R2; ∆R2 .366; .390; .390 .268; .297; .297 
F(df1;df2) for ∆R2; p F(5; 125)=16.005; <.001 F(5; 122)=10.313; <.001 
1 Age -.327 (-.466; -.188) .070 -.343 -4.649; <.001 -.245 (-.397; -.092) .077 -.251 -3.182; .002 
 Education a .510 (.177; .844) .168 .232 3.03; .003 .369 (.012; .727) .180 .167 2.048; .043 
 Gender b .166 (-.131; .463) .150 .085 1.106; .271 -.245 (-.560; .070) .159 -.125 -1.542; .126 
 hsCRP (Log) .004 (-.132; .140) .069 .004 .055; .956 .013 (-.135; .161) .075 .013 .176; .861 
 GDS -.221 (-.383; -.060) .081 -.223 -2.717; .008 -.331 (-.502; -.159) .087 -.336 -3.82; <.001 
 MNA .067 (.004; .131) .032 .172 2.101; .038 .030 (-.037; .097) .034 .076 .880; .381 
 Storage  .075 (-.078; .228) .077 .074 .975; .332 .182 (.023; .340) .080 .179 2.266; .025 
 MNA*Storage .018 (-.028; .065) .023 .056 .776; .439 .067 (.016; .117) .025 .199 2.626; .010 
R2adjusted; R2; ∆R2 .381; .419; .029 .317; .360; .063 
F(df1;df2) for ∆R2; p F(3; 122)=1.999; .118 F(3; 119)=3.907; .011 
2 Age -.328 (-.468; -.188) .071 -.344 -4.645; <.001 -.290 (-.445; -.135) .078 -.297 -3.702; <.001 
 Education a .492 (.166; .817) .165 .223 2.989; .003 .327 (-.033; .687) .182 .148 1.797; .075 
 Gender b .226 (-.070; .523) .150 .116 1.513; .133 -.234 (-.554; .086) .162 -.120 -1.449; .150 
 hsCRP (Log) -.018 (-.164; .127) .073 -.019 -.247; .806 .067 (-.096; .229) .082 .067 .815; .417 
 GDS -.240 (-.402; -.078) .082 -.241 -2.932; .004 -.340 (-.515; -.165) .088 -.346 -3.853; <.001 
 MNA .064 (.001; .126) .032 .163 2.016; .046 .045 (-.031; .120) .038 .113 1.175; .242 
 Transport   -.036 (-.187; .114) .076 -.037 -.480; .632 .093 (-.075; .261) .085 .093 1.096; .275 
 MNA*Transport -.018 (-.075; .038) .029 -.047 -.644; .521 .072 (-.001; .145) .037 .169 1.956; .053 
R2adjusted; R2; ∆R2 .377; .415; .025 .287; .332; .035 
F(df1;df2) for ∆R2; p F(3; 122)=1.723; .166 F(3; 119)=2.071; .108 
3 Age -.337 (-.477; -.197) .071 -.353 -4.763; <.001 -.259 (-.418; -.101) .080 -.266 -3.242; .002 
 Education a .502 (.162; .843) .172 .228 2.922; .004 .304 (-.071; .679) .189 .137 1.604; .111 
 Gender b .198 (-.092; .488) .146 .102 1.354; .178 -.183 (-.502; .136) .161 -.094 -1.136; .258 
 hsCRP (Log) .003 (-.136; .143) .070 .004 .049; .961 .012 (-.145; .168) .079 .012 .146; .884 
 GDS -.232 (-.393; -.071) .081 -.234 -2.85; .005 -.352 (-.531; -.173) .090 -.358 -3.901; <.001 
 MNA .064 (.001; .126) .032 .163 2.027; .045 .025 (-.044; .094) .035 .063 .717; .475 
 Transport A.  .019 (-.135; .172) .078 .018 .240; .811 .060 (-.103; .224) .082 .060 .731; .466 
 MNA*Transport S. -.008 (-.067; .052) .030 -.020 -.262; .794 .025 (-.041; .091) .033 .060 .743; .459 
R2adjusted; R2; ∆R2 .374; .413; .022 .26; .307; .009 
F(df1;df2) for ∆R2; p F(3; 122)=1.547; .206 F(3; 119)=.541; .655 
4 Age -.315 (-.461; -.170) .074 -.324 -4.286; <.001 -.238 (-.400; -.076) .082 -.240 -2.911; .004 
 Education a .571 (.233; .909) .171 .253 3.34; .001 .425 (.052; .797) .188 .188 2.258; .026 
 Gender b .140 (-.162; .442) .153 .071 .918; .361 -.264 (-.590; .062) .165 -.133 -1.603; .112 
 hsCRP (Log) .020 (-.123; .162) .072 .020 .276; .783 .033 (-.126; .192) .080 .033 .413; .680 
 GDS -.227 (-.391; -.064) .083 -.223 -2.751; .007 -.352 (-.530; -.175) .090 -.349 -3.932; <.001 
 MNA .074 (.010; .138) .032 .187 2.292; .024 .036 (-.034; .106) .036 .091 1.016; .312 
 Red Cells C. .046 (-.114; .206) .081 .044 .564; .574 .107 (-.063; .276) .086 .105 1.247; .215 
 MNA*Red Cells C. .019 (-.032; .070) .026 .055 .731; .466 .049 (-.005; .104) .028 .146 1.782; .077 
R2adjusted; R2; ∆R2 .37; .409; .030 .275; .321; .027 
F(df1;df2) for ∆R2; p F(3; 122)=2.058; .109 F(3; 119)=1.58; .198 
5 Age -.321 (-.467; -.175) .074 -.330 -4.342; <.001 -.212 (-.373; -.051) .081 -.214 -2.613; .010 
 Education a .566 (.224; .908) .173 .251 3.279; .001 .521 (.148; .895) .189 .230 2.763; .007 
 Gender b .164 (-.176; .504) .172 .083 .955; .341 -.435 (-.794; -.076) .181 -.219 -2.402; .018 
 hsCRP (Log) .007 (-.134; .147) .071 .007 .095; .924 -.001 (-.155; .153) .078 -.001 -.015; .988 
 GDS -.225 (-.392; -.058) .084 -.220 -2.673; .009 -.296 (-.475; -.116) .091 -.293 -3.264; .001 
 MNA .073 (.009; .136) .032 .183 2.271; .025 .034 (-.036; .104) .035 .086 .964; .337 
 Erythropoiesis   .007 (-.175; .190) .092 .007 .077; .939 .233 (.046; .420) .094 .229 2.463; .015 
 MNA*Erythropoiesis  -.002 (-.055; .052) .027 -.004 -.058; .954 .027 (-.031; .086) .029 .075 .934; .352 
R2adjusted; R2; ∆R2 .366; .405; .027 .293; .337; .044 
F(df1;df2) for ∆R2; p F(3; 122)=1.817; .148 F(3; 119)=2.618; .054 
a Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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An interaction effect was observed only in block 2, model 1 of the hierarchical regression 
model using memory dimension as focal dependent variable (Table 24, Figure 17). The overall 
model explained 31.7% (R2adjusted) of memory dimension variance. Age, education, mood, storage 
dimension and MNA*Storage were significant predictors, while gender, hsCRP (Log) and MNA 
were not. Interestingly, however, MNA score was a significant predictor of almost all dependent 
variables. MMSE and memory dimensions were the exceptions where MNA did not reveal 
predictive significance, regardless of being the only significant interaction observed in the 
memory dimension.   
 
 
 
Figure 17 - Summary model for the correlation between memory dimension and interaction of 
storage dimension with nutritional status (MNA) and associated beneficial and detrimental 
factors. 
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Table 25 - Hierarchical regression models of interaction to predict general cognition 
  MMSE MOCA 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.272 (-.416; -.128) .073 -.293 -3.748; <.001 -.245 (-.400; -.089) .078 -.247 -3.118; .002 
 Education a .370 (.033; .707) .170 .172 2.172; .032 .954 (.594; 1.314) .182 .413 5.249; <.001 
 Gender b .174 (-.124; .472) .151 .092 1.154; .250 .165 (-.142; .473) .155 .084 1.068; .288 
 hsCRP (Log) .035 (-.108; .178) .072 .036 .481; .631 -.015 (-.162; .132) .074 -.015 -.198; .843 
 GDS -.270 (-.420; -.120) .076 -.281 -3.557; .001 -.229 (-.381; -.078) .076 -.232 -3.004; .003 
R2adjusted; R2; ∆R2 .255; .282; .282 .379; .406; .406 
F(df1;df2) for ∆R2; p F(5; 131)=10.304; <.001 F(5; 108)=14.775; <.001 
1 Age -.275 (-.419; -.131) .073 -.297 -3.787; <.001 -.252 (-.404; -.099) .077 -.254 -3.274; .001 
 Education a .362 (.020; .705) .173 .168 2.091; .038 .958 (.597; 1.32) .182 .415 5.26; <.001 
 Gender b .143 (-.164; .450) .155 .075 .920; .359 .139 (-.166; .445) .154 .071 .904; .368 
 hsCRP (Log) .036 (-.107; .179) .072 .038 .499; .619 -.017 (-.161; .127) .073 -.017 -.231; .818 
 GDS -.204 (-.371; -.037) .084 -.213 -2.421; .017 -.134 (-.297; .028) .082 -.136 -1.642; .103 
 MNA .052 (-.012; .116) .032 .140 1.606; .111 .083 (.021; .146) .032 .217 2.633; .010 
 Storage  .048 (-.108; .205) .079 .048 .609; .544 .04 (-.115; .195) .078 .040 .511; .611 
 MNA*Storage .037 (-.012; .085) .025 .114 1.484; .140 .033 (-.014; .080) .024 .105 1.405; .163 
R2adjusted; R2; ∆R2 .263; .306; .024 .409; .451; .045 
F(df1;df2) for ∆R2; p F(3; 128)=1.465; .227 F(3; 105)=2.845; .041 
2 Age -.296 (-.440; -.153) .073 -.32 -4.084; <.001 -.264 (-.418; -.109) .078 -.266 -3.385; .001 
 Education a .382 (.048; .715) .169 .177 2.264; .025 .948 (.591; 1.304) .180 .410 5.269; <.001 
 Gender b .093 (-.211; .397) .154 .049 .603; .548 .126 (-.185; .437) .157 .064 .804; .423 
 hsCRP (Log) .084 (-.068; .236) .077 .088 1.097; .275 -.003 (-.156; .15) .077 -.003 -.040; .968 
 GDS -.204 (-.37; -.038) .084 -.212 -2.432; .016 -.143 (-.305; .02) .082 -.144 -1.74; .085 
 MNA .048 (-.015; .111) .032 .129 1.498; .137 .090 (.024; .156) .033 .234 2.704; .008 
 Transport   .106 (-.048; .260) .078 .111 1.365; .175 .006 (-.152; .165) .080 .006 .077; .939 
 MNA*Transport .044 (-.015; .103) .030 .112 1.463; .146 .039 (-.024; .101) .031 .097 1.227; .222 
R2adjusted; R2; ∆R2 .271; .314; .032 .406; .448; .042 
F(df1;df2) for ∆R2; p F(3; 128)=1.978; .120 F(3; 105)=2.63; .054 
3 Age -.270 (-.415; -.124) .074 -.291 -3.666; <.001 -.246 (-.400; -.091) .078 -.248 -3.147; .002 
 Education a .342 (-.007; .690) .176 .159 1.937; .055 .927 (.567; 1.288) .182 .402 5.100; <.001 
 Gender b .149 (-.152; .450) .152 .079 .982; .328 .126 (-.177; .429) .153 .064 .823; .412 
 hsCRP (Log) .036 (-.11; .182) .074 .038 .486; .628 -.010 (-.157; .136) .074 -.010 -.137; .891 
 GDS -.218 (-.386; -.049) .085 -.226 -2.558; .012 -.140 (-.303; .023) .082 -.142 -1.708; .091 
 MNA .048 (-.015; .112) .032 .130 1.51; .134 .078 (.016; .140) .031 .202 2.496; .014 
 Transport A.  .008 (-.145; .161) .077 .008 .102; .919 .061 (-.096; .218) .079 .059 .773; .441 
 MNA*Transport S. .028 (-.032; .088) .030 .074 .930; .354 .025 (-.038; .088) .032 .059 .776; .440 
R2adjusted; R2; ∆R2 .254; .298; .015 .404; .446; .040 
F(df1;df2) for ∆R2; p F(3; 128)=.938; .424 F(3; 105)=2.532; .061 
4 Age -.271 (-.424; -.118) .077 -.281 -3.509; .001 -.258 (-.409; -.106) .076 -.257 -3.377; .001 
 Education a .425 (.071; .780) .179 .189 2.373; .019 .935 (.580; 1.289) .179 .400 5.231; <.001 
 Gender b .135 (-.184; .453) .161 .068 .837; .404 .176 (-.129; .482) .154 .089 1.144; .255 
 hsCRP (Log) .051 (-.101; .204) .077 .052 .664; .508 -.015 (-.162; .131) .074 -.016 -.209; .835 
 GDS -.217 (-.389; -.044) .087 -.215 -2.485; .014 -.152 (-.311; .008) .080 -.152 -1.888; .062 
 MNA .049 (-.016; .114) .033 .127 1.482; .141 .091 (.029; .154) .032 .235 2.889; .005 
 Red Cells C. .064 (-.104; .231) .085 .062 .750; .455 -.046 (-.202; .109) .079 -.047 -.590; .557 
 MNA*Red Cells C. .041 (-.013; .094) .027 .119 1.511; .133 .042 (-.007; .090) .025 .130 1.701; .092 
R2adjusted; R2; ∆R2 .257; .301; .024 .420; .460; .051 
F(df1;df2) for ∆R2; p F(3; 128)=1.471; .226 F(3; 107)=3.376; .021 
5 Age -.263 (-.417; -.109) .078 -.272 -3.372; .001 -.232 (-.384; -.080) .077 -.232 -3.028; .003 
 Education a .464 (.104; .823) .182 .206 2.552; .012 1.089 (.731; 1.447) .181 .466 6.025; <.001 
 Gender b .069 (-.287; .425) .180 .035 .383; .702 -.021 (-.357; .316) .170 -.010 -.121; .904 
 hsCRP (Log) .028 (-.122; .178) .076 .028 .370; .712 -.032 (-.174; .110) .072 -.033 -.448; .655 
 GDS -.189 (-.367; -.012) .090 -.188 -2.113; .037 -.110 (-.271; .052) .082 -.110 -1.342; .182 
 MNA .048 (-.017; .114) .033 .126 1.468; .145 .070 (.008; .132) .031 .180 2.235; .027 
 Erythropoiesis   .106 (-.080; .292) .094 .103 1.126; .262 .204 (.031; .376) .087 .203 2.344; .021 
 MNA*Erythropoiesis  .015 (-.041; .071) .028 .041 .535; .594 -.007 (-.059; .045) .026 -.021 -.278; .782 
R2adjusted; R2; ∆R2 .252; .296; .019 .429; .468; .059 
F(df1;df2) for ∆R2; p F(3; 128)=1.155; .330 F(3; 107)=3.959; .010 
a  Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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Table 26 - Hierarchical regression models of interaction to predict neuropsychological variables. 
  GDS PSS 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.022 (-.187; .142) .083 -.023 -.268; .789 -.018 (-.184; .148) .084 -.018 -.210; .834 
 Education a -.299 (-.682; .084) .194 -.133 -1.544; .125 .187 (-.192; .566) .192 .083 .975; .331 
 Gender b -.595 (-.921; -.268) .165 -.301 -3.6; <.001 -.782 (-1.106; -.458) .164 -.397 -4.778; <.001 
 hsCRP (Log) .004 (-.160; .169) .083 .004 .050; .960 -.141 (-.305; .024) .083 -.141 -1.694; .093 
R2adjusted; R2; ∆R2 .094; .121; .121 .133; .160; .160 
F(df1;df2) for ∆R2; p F(4; 132)=4.54; .002 F(4; 129)=6.121; <.001 
1 Age .000 (-.150; .150) .076 .000 -.006; .995 .021 (-.140; .181) .081 .021 .253; .801 
 Education a -.276 (-.630; .078) .179 -.123 -1.541; .126 .271 (-.099; .641) .187 .121 1.449; .150 
 Gender b -.376 (-.689; -.063) .158 -.190 -2.375; .019 -.703 (-1.029; -.377) .165 -.357 -4.264; <.001 
 hsCRP (Log) .015 (-.134; .164) .075 .015 .200; .842 -.144 (-.302; .014) .08 -.144 -1.806; .073 
 MNA -.165 (-.225; -.105) .031 -.427 -5.409; <.001 -.126 (-.192; -.061) .033 -.313 -3.839; <.001 
 Storage  -.070 (-.233; .093) .082 -.068 -.851; .397 .057 (-.111; .226) .085 .056 .674; .502 
 MNA*Storage -.026 (-.077; .024) .026 -.079 -1.024; .308 -.025 (-.079; .029) .027 -.071 -.903; .368 
R2adjusted; R2; ∆R2 .260; .298; .177 .206; .248; .089 
F(df1;df2) for ∆R2; p F(3; 129)=10.863; <.001 F(3; 126)=4.948; .003 
2 Age .017 (-.134; .167) .076 .017 .217; .829 .012 (-.149; .173) .081 .012 .149; .882 
 Education a -.281 (-.628; .066) .175 -.125 -1.603; .111 .264 (-.100; .629) .184 .118 1.436; .153 
 Gender b -.359 (-.672; -.046) .158 -.182 -2.272; .025 -.697 (-1.022; -.372) .164 -.354 -4.247; <.001 
 hsCRP (Log) -.012 (-.172; .147) .081 -.012 -.152; .879 -.137 (-.305; .031) .085 -.137 -1.610; .110 
 MNA -.159 (-.219; -.099) .030 -.411 -5.218; <.001 -.138 (-.207; -.070) .035 -.343 -4.007; <.001 
 Transport   -.094 (-.255; .067) .081 -.095 -1.157; .250 .086 (-.084; .256) .086 .087 1.002; .319 
 MNA*Transport -.009 (-.071; .053) .031 -.022 -.283; .778 -.045 (-.115; .025) .035 -.107 -1.279; .203 
R2adjusted; R2; ∆R2 .259; .297; .176 .213; .255; .095 
F(df1;df2) for ∆R2; p F(3; 129)=10.765; <.001 F(3; 126)=5.356; .002 
3 Age .011 (-.140; .161) .076 .011 .142; .887 .014 (-.148; .175) .081 .014 .168; .867 
 Education a -.242 (-.600; .117) .181 -.108 -1.333; .185 .219 (-.158; .595) .190 .097 1.147; .254 
 Gender b -.383 (-.687; -.078) .154 -.194 -2.488; .014 -.676 (-.995; -.357) .161 -.343 -4.193; <.001 
 hsCRP (Log) -.001 (-.153; .150) .077 -.001 -.014; .989 -.134 (-.295; .028) .082 -.134 -1.641; .103 
 MNA -.156 (-.216; -.097) .030 -.405 -5.183; <.001 -.117 (-.183; -.052) .033 -.290 -3.552; .001 
 Transport A.  -.111 (-.268; .046) .079 -.109 -1.404; .163 .015 (-.151; .181) .084 .015 .182; .856 
 MNA*Transport S. .002 (-.060; .064) .031 .005 .068; .946 .007 (-.063; .078) .036 .017 .205; .838 
R2adjusted; R2; ∆R2 .262; .3; .179 .198; .241; .081 
F(df1;df2) for ∆R2; p F(3; 129)=10.995; <.001 F(3; 126)=4.48; .005 
4 Age .029 (-.125; .184) .078 .031 .378; .706 -.006 (-.171; .159) .083 -.006 -.075; .941 
 Education a -.231 (-.588; .125) .180 -.104 -1.286; .201 .166 (-.206; .538) .188 .073 .882; .380 
 Gender b -.385 (-.700; -.071) .159 -.197 -2.426; .017 -.707 (-1.031; -.383) .164 -.359 -4.314; <.001 
 hsCRP (Log) .013 (-.141; .167) .078 .013 .164; .870 -.128 (-.290; .035) .082 -.128 -1.556; .122 
 MNA -.158 (-.218; -.098) .030 -.414 -5.218; <.001 -.118 (-.184; -.051) .034 -.293 -3.515; .001 
 Red Cells C. .006 (-.163; .176) .086 .006 .073; .942 .043 (-.132; .218) .089 .042 .484; .629 
 MNA*Red Cells C. .008 (-.046; .061) .027 .023 .283; .777 .015 (-.041; .072) .029 .045 .540; .590 
R2adjusted; R2; ∆R2 .230; .269; .165 .208; .250; .085 
F(df1;df2) for ∆R2; p F(3; 129)=9.725; <.001 F(3; 126)=4.785; .003 
5 Age -.002 (-.154; .149) .077 -.002 -.029; .977 -.013 (-.179; .152) .084 -.013 -.157; .875 
 Education a -.297 (-.646; .053) .177 -.133 -1.68; .095 .148 (-.228; .524) .190 .066 .780; .437 
 Gender b -.144 (-.492; .205) .176 -.074 -.815; .417 -.663 (-1.033; -.292) .187 -.336 -3.539; .001 
 hsCRP (Log) .006 (-.142; .154) .075 .006 .081; .936 -.136 (-.296; .024) .081 -.136 -1.686; .094 
 MNA -.155 (-.213; -.097) .029 -.406 -5.264; <.001 -.115 (-.181; -.048) .034 -.285 -3.422; .001 
 Erythropoiesis   -.226 (-.404; -.047) .090 -.222 -2.503; .014 -.026 (-.219; .166) .097 -.026 -.268; .789 
 MNA*Erythropoiesis  -.019 (-.074; .036) .028 -.053 -.690; .492 .008 (-.052; .068) .030 .023 .275; .784 
R2adjusted; R2; ∆R2 .267; .305; .201 .206; .248; .084 
F(df1;df2) for ∆R2; p F(3; 129)=12.399; <.001 F(3; 126)=4.677; .004 
a  Less than 4 school years=0, More than 4 school years=1 ; b Female=0, Male=1 
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Table 27 - Hierarchical regression models of interaction to predict functional dimensions. 
  Functional-T Functional-H 
Model B (CI 95%) SE β t; p B (CI 95%) SE β t; p 
0 Age -.165 (-.319; -.011) .078 -.177 -2.116; .036 -.155 (-.298; -.012) .072 -.175 -2.148; .033 
 BMI -.220 (-.387; -.054) .084 -.231 -2.614; .010 -.315 (-.47; -.161) .078 -.346 -4.033; <.001 
 hsCRP (Log) -.031 (-.198; .136) .084 -.032 -.364; .716 .054 (-.101; .209) .078 .058 .684; .495 
R2adjusted; R2; ∆R2 .088; .108; .108 .139; .158; .158 
F(df1;df2) for ∆R2; p F(3; 133)=5.353; .002 F(3; 133)=8.344; <.001 
1 Age -.173 (-.318; -.027) .073 -.186 -2.350; .020 -.163 (-.305; -.022) .071 -.184 -2.287; .024 
 BMI -.196 (-.356; -.036) .081 -.206 -2.421; .017 -.279 (-.435; -.123) .079 -.306 -3.546; .001 
 hsCRP (Log) -.043 (-.200; .115) .080 -.044 -.535; .594 .041 (-.112; .195) .077 .045 .536; .593 
 MNA .116 (.056; .176) .030 .311 3.803; <.001 .079 (.020; .137) .030 .220 2.652; .009 
 Storage  .096 (-.062; .254) .080 .096 1.203; .231 .015 (-.139; .168) .078 .015 .187; .852 
 MNA*Storage -.010 (-.061; .041) .026 -.030 -.370; .712 .029 (-.02; .079) .025 .095 1.162; .247 
R2adjusted; R2; ∆R2 .197; .233; .125 .17; .207; .048 
F(df1;df2) for ∆R2; p F(3; 130)=7.050; <.001 F(3; 130)=2.641; .052 
2 Age -.186 (-.332; -.041) .073 -.201 -2.538; .012 -.167 (-.308; -.025) .071 -.187 -2.333; .021 
 BMI -.195 (-.354; -.036) .080 -.205 -2.43; .016 -.279 (-.434; -.125) .078 -.306 -3.576; <.001 
 hsCRP (Log) -.024 (-.193; .144) .085 -.025 -.287; .775 .044 (-.120; .207) .083 .048 .529; .598 
 MNA .116 (.056; .176) .030 .311 3.829; <.001 .082 (.024; .140) .029 .231 2.797; .006 
 Transport   .096 (-.061; .254) .080 .101 1.209; .229 -.044 (-.198; .109) .078 -.049 -.574; .567 
 MNA*Transport -.015 (-.077; .047) .032 -.038 -.476; .635 .035 (-.025; .096) .031 .094 1.148; .253 
R2adjusted; R2; ∆R2 .197; .233; .125 .172; .208; .050 
F(df1;df2) for ∆R2; p F(3; 130)=7.049; <.001 F(3; 130)=2.731; .046 
3 Age -.186 (-.334; -.038) .075 -.200 -2.488; .014 -.146 (-.288; -.003) .072 -.164 -2.025; .045 
 BMI -.184 (-.344; -.024) .081 -.193 -2.269; .025 -.272 (-.426; -.117) .078 -.298 -3.48; .001 
 hsCRP (Log) -.055 (-.216; .106) .081 -.057 -.676; .500 .031 (-.124; .185) .078 .033 .393; .695 
 MNA .127 (.068; .187) .030 .342 4.228; <.001 .084 (.026; .141) .029 .235 2.887; .005 
 Transport A.  -.025 (-.181; .130) .079 -.026 -.319; .750 -.051 (-.201; .099) .076 -.054 -.672; .503 
 MNA*Transport S. -.010 (-.072; .052) .031 -.025 -.307; .759 .047 (-.013; .106) .030 .127 1.548; .124 
R2adjusted; R2; ∆R2 .188; .224; .116 .178; .215; .056 
F(df1;df2) for ∆R2; p F(3; 130)=6.495; <.001 F(3; 130)=3.109; .029 
4 Age -.168 (-.314; -.022) .074 -.179 -2.278; .024 -.173 (-.317; -.029) .073 -.193 -2.382; .019 
 BMI -.199 (-.355; -.044) .079 -.210 -2.534; .012 -.284 (-.437; -.131) .077 -.314 -3.674; <.001 
 hsCRP (Log) -.018 (-.180; .143) .082 -.019 -.225; .822 .072 (-.087; .231) .080 .078 .895; .372 
 MNA .116 (.057; .175) .030 .310 3.919; <.001 .074 (.017; .132) .029 .209 2.553; .012 
 Red Cells C. .154 (-.008; .316) .082 .154 1.876; .063 .010 (-.150; .169) .081 .010 .119; .905 
 MNA*Red Cells C. .010 (-.043; .063) .027 .031 .383; .702 .032 (-.020; .084) .026 .102 1.232; .220 
R2adjusted; R2; ∆R2 .216; .250; .134 .165; .202; .047 
F(df1;df2) for ∆R2; p F(3; 130)=7.749; <.001 F(3; 130)=2.529; .060 
5 Age -.152 (-.296; -.009) .073 -.162 -2.100; .038 -.162 (-.307; -.017) .073 -.181 -2.211; .029 
 BMI -.189 (-.340; -.037) .077 -.199 -2.465; .015 -.281 (-.434; -.128) .077 -.310 -3.631; <.001 
 hsCRP (Log) -.036 (-.189; .118) .078 -.037 -.462; .645 .064 (-.091; .219) .078 .070 .819; .414 
 MNA .109 (.052; .167) .029 .293 3.785; <.001 .071 (.013; .129) .029 .199 2.428; .017 
 Erythropoiesis   .245 (.095; .396) .076 .247 3.224; .002 .040 (-.112; .191) .077 .042 .515; .608 
 MNA*Erythropoiesis  .003 (-.051; .057) .027 .008 .099; .922 .027 (-.028; .081) .028 .079 .973; .333 
R2adjusted; R2; ∆R2 .254; .287; .171 .163; .200; .045 
F(df1;df2) for ∆R2; p F(3; 130)=10.389; <.001 F(3; 130)=2.418; .069 
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4.2. Longitudinal analysis: iron fortification, cognition, mood and physical 
performance 
From the n=151 individuals assessed in Moment A1, n=41 were included in the quasi-
experimental intervention study after meeting inclusion (presence of ID) and exclusion criteria, as 
previously described, and accepting to continue in the study. Of these, n=1 individual was 
excluded due to initiation of intravenous iron treatment, and n=18 dropped-out (45%). From the 
dropouts two considerations should be addressed, firstly the dropouts were older than the ones 
that continued in the intervention and, secondly, dropouts had higher need of help to mobility 
(lower score on mobility help of physical functional ability) (data not shown) and these two factors 
may possibly explain the dropout of such higher number of individuals. The study sample for the 
study was, therefore, of 22 individuals, of which 10 (43%) were allocated to a non-intervention 
branch and 12 (57%) to a fortification branch. Allocation of participants had in consideration a 
similar distribution of individuals with lower levels of serum FT [FT<45 (µg/L)].  
4.2.1 Characterization of participants  
Socio-demographic and anthropometric characterization of participants is presented in 
Table 28. No significant differences were observed for all variables. Effect size (Cohen’s d) was 
very small and perhaps our sample size does not have enough statistical power to detect 
differences of this magnitude.  
Regarding neuropsychological assessment (Table 29), no statistical significant differences 
were observed between the groups for mood (measured by GDS) or perceived stress (assessed 
with the PSS). Of notice the absence of differences may be due to the small sample size as can 
be concluded by the small Cohen’s d (<.2). In neurocognitive variables and dimensions from the 
cross sectional analyses (Table 29), no differences were observed between the supplemented 
and non supplemented groups.  
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Table 28 - Characteristics comparison for participants. 
Variables (mean; SD) Non supplem. (n=10) Supplem. (n=12)   
Socio-demographic    
t(df); p; Cohen’s d 
 
Age (years) 62.30; 4.64  64.58; 6.60 -.949(19.530); .354; .399 
 
Education (school yrs)  6.50; 3.92 6.08; 3.80 .252(20); .803; .119 
Anthropometric   
t(df); p; Cohen’s d 
 
Weight (kg) 69.87; 8.08 75.58; 11.15 -1.350(20); .192; .586 
 
Height (m) 1.60; .07  1.62; .09  -.606(20); .551; .248 
 
BMI (kg/m2) 27.43; 3.44 29.06; 5.2 -.848(20); .407; .369 
 
Waist circ. (cm) 91.47; 10.51 93.07; 13.14 -.309(20); .760; .134 
 
Hip circ. (cm) 101.18; 6.90 98.44; 14.63 .542(20); .594; .239 
 
%BF-BIA (%)a 31.80; 9.31 33.75; 12.03 -.405(18); .690; .181 
 
%BF-Brozek (%)a 34.06; 8.32 36.11; 8.12 -.583(20); .567; .249 
Gender (n; %)   p(Fisher exact test; 2 tailed) 
 Females 6; 27.27 7; 31.81 >.999 
 Males 4; 18.18 5; 27.72  
BMI class (n; %)   
p(Fisher exact test; 2 tailed) 
 
Normal 2; 9.09 3; 13.63 .554 
 
Overweight 6; 27.27 4; 18.18  
 
Obesity 2; 9.09 5; 22.72  
Nutritional status (n; %)   
p(Fisher exact test; 2 tailed) 
 
Risk of malnutrition 4; 18.18 2; 9.09 .348 
 
Normal  6; 27.27 10; 45.45  
a n=20 [Non supplemented=10 (50%), Supplemented=10 (50%)].  
 
Table 30 lists data regarding physical functional ability at the baseline, values for the 
functional dimensions were the same derived from the cross-sectional analysis. No significant 
differences were observed for all the variables with exception for lower limb tiredness 
(t(14.228)=2.272; p= .039; d= .942) where the non supplemented group presented a higher mean 
score (meaning lower tiredness) than the supplemented group.  
The characterization of groups and the comparison of means for hematological variables 
are presented in Table 31. No significant differences were observed for the inflammatory status. 
As expected, the distribution of individuals with low FT levels was similar between non 
supplemented and supplemented. Regarding the red cells indices, statistical differences were 
observed in MCV and MHC.  In these two variables the mean value of the non supplemented 
group was higher than that of the supplemented group, indicating higher iron levels.  
In iron biomarkers, Fe was significantly higher in the non supplemented group, the same 
pattern was observed for TF sat. and body iron. Statistical significant higher mean (or median) 
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values were observed for the supplemented group in TF, TIBC, sTFr and sTFr-LogFT index. In iron 
dimensions (values from the cross sectional anlalysis), erythropoiesis was not significantly 
different between groups; however, differences were observed in storage, transport, transport s. 
and red cells c In all of the significantly different dimensions the non supplemented group 
presented a higher mean value. 
 
Table 29 - Neuropsychological and neurocognitive variables of participants. 
 Variables (mean, SD) Non supplem. Supplem.   
Psychological   t(df); p; Cohen’s d 
 GDS 11.40; 5.74 11.33; 6.14 .026(20); .979; .012 
 PSS  17.70; 7.66 18.58; 6.32 -.297(20); .770; .125 
Neurocognitive   t(df); p; Cohen’s d 
 DS – Forward  6.20; 1.40 7.08; 1.93 -1.206(20); .242; .523 
 DS – Backward  4.10; 1.73 4.33; 1.44 -.346(20); .733; .144 
 DS – Total 10.30; 2.50 11.42; 2.94 -9.49(20); .354; .411 
 Stroop – W  78.89; 16.34 73.33; 21.03 .656(19); .520; .295 
 Stroop – C  53.50; 16.45 55.17; 13.21 -.264(20); .795; .111 
 Stroop – W&C  37.50; 14.39 33.67; 11.90 .685(20); .502; .290 
 SRT – LTS  22.90; 11.53 29.50; 15.62 -1.107(20); .282; .480 
 SRT – CLTR  13.70; 8.87 22.58; 15.77 -1.581(20); .130; .694 
 SRT – DR  5.90; 1.52 6.42; 3.15 -.474(20); .641; .210 
 SRT – Intrusions  6.00; 7.54 2.92; 2.47 1.338(20); .196; .549 
 CERAD – Total hits  18.90; 2.85 20.50; 4.12 -1.037(20); .312; .451 
 CERAD – DR hits  5.90; 1.37  6.83; 1.80 -1.345(20); .194; .581 
 MMSE 28.10; 2.28 27.58; 1.78 .597(20); .557; .254 
 MOCA  20.20; 5.33  22.58; 3.00  -1.322(20); .201; .550 
Cognitive dimensions    t(df); p; Cohen’s d 
 Executive  .31; .58 .25; .90 .181(19); .858; .079 
 Memory  -.02; .56 .45; 1.05 -1.268(20); .219; .558 
 
Table 30 - Baseline characteristics on physical functional ability. 
Variables (mean, SD) Non supplem. Supplem.   
Functional ability – QoFA    t(df); p; Cohen’s d 
 Mobility tiredness 4.90; 1.97 3.92; 1.93 1.180(20); .252; .502 
 Lower limb tiredness 4.60; .52 3.58; 1.44 2.272(14.228); .039; .942 
 Upper limb tiredness 3.90; .32 3.92; .29 -.129(20); .899; .065 
 Mobility help 11.80; .63  11.50; .90 .883(20); .388; .386 
 PADL help 18.20; 4.37 18.50; 2.71 -.197(20); .846; .082 
Functional components    t(df); p; Cohen’s d 
 Functional tiredness .30; .49 -.29; .86 1.923(20); .069; .014 
 Functional help .13; .89 .11; .77 .067(20); .947; .024 
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Table 31 – Hematological characterization and comparison at baseline 
Variables (mean, SD) Non supplem. Supplem.   
Inflammatory indices   Z(U); p; r 
 hsCRP (mg/dL) ¥ † 1.53; 2.85 2.90; .60 -1.541(37); .134; .329 
Red cells indices   t(df); p; Cohen’s d 
 RBC (1012/L) 4.49; .50 4.63; .44  -.678(20); .506; .297 
 Hemoglobin (mg/dL) 13.55; 1.74 12.73; 1.65 1.139(20); .268; .483 
 Hematocrit (%) 39.51; 4.51  37.85; 3.77  .941(20); .358; .399 
 MCV (fL) 87.96; 3.32  81.79; 3.52 4.198(20); <.001; 1.803 
 MCH (pg) 30.12; 1.48  27.43; 1.6  4.071(20); .001; 1.745 
 MCHC (g/dL) 34.25; .83 33.53; 1.29 1.508(20); .147; .663 
 RDW (%) 13.51; .60 14.1; 1.14 -1.548(17.252); .140; .647 
Iron biomarkers   t(df); p; Cohen’s d 
 Fe (µg/dL) 90.80; 27.18  60.17; 21.67  2.944(20); .008; 1.246 
 TF (mg/dL)  249.10; 28.68 295.08; 53.71 -2.428(20); .025; 1.068 
 FT (ng/mL)  ¥ † 67.50; 148.75 19.50; 109.25 -1.814(32.5); .072; .387 
 TF Sat (%) 28.18; 9.66  16.19; 7.49  3.283(20);.004; 1.388 
 TIBC (µg/dL) 327.60; 31.48 390.42; 74.34 -2.485(20); .022; 1.100 
 sTFr (mg/L) ¥ † 1.11; .38  1.62; .86  -3.166(12); <.001; .675 
 sTFr-LogFT index ¥ † .69; .33  1.21; .99  -2.506(22); .011; .534 
 Body iron (mg/kg) 13.84; 3.64  8.97; 5.54  2.380(20); .027; 1.041 
FT class (n; %)   p(Fisher exact test; 2 tailed) 
 FT<45 (ng/mL) 5; 22.72 8; 36.36 .666 
 FT≥45 (ng/mL) 5; 22.72 4; 18.18  
Iron dimensions   t(df); p; Cohen’s d 
 Storage  -.06; .66   -1.32; 1.40 2.031(20); .016; 1.261 
 Transport  -.03; .96  -1.17; .74  3.170(20); .005; 1.330 
 Transport S. .15; .62 -.97; 1.31 2.463(20); 0.023; 1.093 
 Red cells C.   -.08; .72  -1.43; .98  3.722(19.711); .001; 1.570 
 Erythropoiesis -.18; 1.13  -.40; .99  .476(20); .639; .207 
¥ Variables not normally distributed, data presented in median and interquartile range (median, IQR); † Mann–
Whitney U test, results presented in Z(U); p; r. 
 
4.2.2 Variation of hematological dimensions during intervention 
New component scores for hematological dimensions were calculated for moment A and 
moment B using the hematological variables and the same methodology as previously described 
(storage moment A, Cronbach’s alpha: .969; storage moment B, Cronbach’s alpha: .959; 
transport moment A, Cronbach’s alpha: .976; transport moment B, Cronbach’s alpha:.975; 
transport s. moment A, Cronbach’s alpha: .996; transport s. moment B, Cronbach’s alpha: .991; 
red cells c. moment A, Cronbach’s alpha: .810; red cells c. moment B, Cronbach’s alpha: .916; 
erythropoiesis moment A , Cronbach’s alpha: .964; erythropoiesis moment B, Cronbach’s alpha: 
.935).  The new component scores for hematological dimensions obtained for moment A and B 
were compared using repeated measures ANOVA (Table 32). No significant effects for time or 
time by group were observed in any of the hematological components. A group effect was 
observed for storage, transport, transport s., and red cells c.; however, it was not significant for 
erythropoiesis. 
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Table 32 - Repeated measures ANOVA for hematological dimensions 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
Storage .57; .63 -.47; 1,02  .47; .61 -.39; 1,11  F(1; 20)=.021; .887; .001 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=6.268; .021; .239  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=2.523; .128; .112  
Transport .62; .95 -.52; .73  .82; .64 -.68; .67  F(1; 20)=.010; .923; .000 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=23.213; <.001; .537  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=1.165; .293; .055  
Transport S. .52; .53 -.43; 1,11  .59; .55 -.49; 1,04  F(1; 20)=.005; .946; .000 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=7.870; .011; .282  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.559; .463; .027  
Red cells C. .68; .66 -.64; .89  .52; .39 -.47; 1,16  F(1; 19)=.000; .991; .000 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=12.100; .003; .389  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=1.190; .289; .059  
Erythropoiesis .12; 1.09 -.13; .10  .22; 1,03 -.2; .97  F(1; 19)=.013; .909; .001 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=.602; .447; .031  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=.398; .536; .021  
 
Regarding the analysis of repeated measures for hematological variables (Table 33) and in 
consonance with the results of the hematological dimensions, no significant effects (for time, 
group or time by group interaction) were observed for the variables that composed the 
erythropoiesis dimension (RBC, hemoglobin and hematocrit). The variables that composed the 
red cells C. dimension (MCV, MCH, MCHC and RDW) did not reveal a significant effect of time by 
group interaction, the group effect was significant only for MCH and RDW and MCH and MCHC 
displayed a significant time effect, not present in MCV and RDW. The variables that composed 
transport s. (TF and TIBC) and transport (Fe and TF sat.) dimensions did not reveal significant 
time or time by group interaction effects, although a significant group effect was observed. 
Regarding the variables that composed the storage dimension, no significant effects were 
observed for FT (logarithmic transformed), significant time and group effects were observed for 
sTFR (logarithmic transformed), a significant effect group was observed for sTFr-LogFT index 
(logarithmic transformed) and a significant interaction of time by group was observed for body 
iron.  
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Table 33 - Repeated measures ANOVA for hematological variables. 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
RBC (1012/L) 4.49; .50 4.62; .46  4.61; .47 4.61; .39  F(1; 19)=.583; .454; .030 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=.118; .735; .006  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=.840; .371; .042  
Hemoglobin (mg/dL) 13.55; 1.74 12.65; 1.71  13.82; 1.53 12.69; 1.87  F(1; 19)=.510; .484; .026 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=1.976; .176; .094  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=.296; .592; .015  
Hematocrit (%) 39.51; 4.51 37.71; 3.93  40.74; 4.07 38.71; 4.02  F(1; 19)=4.063; .058; .176 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=1.247; .278; .062  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=.043; .838; .002  
MCV (fL) 87.96; 3.32 81.61; 3.63  88.38; 3.28 84.05; 6.66  F(1; 19)=4.215; .054; .182 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=8.424; .009; .307  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=2.100; .164; .100  
MCH (pg) 30.12; 1.48 27.31; 1.62  29.96; 1.39 27.51; 3.10  F(1; 19)=.003; .956; .000 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=10.293; 0.005; 0.351  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=0.252; 0.621; 0.013  
MCHC (g/dL) 34.25; .83 33.46; 1.33  33.89; .72 32.65; 1.68  F(1; 19)=7.741; .012; .289 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=4.241; .053; .182  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=1.142; .299; .057  
RDW (%) 13.51; .61 14.17; 1.17  13.25; .32 14.14; 1.01  F(1; 19)=.620; .441; .032 
F(df1;df2); p; η2 partial  (Group) F(1; 19)=5.674; .028; .230  
F(df1;df2); p; η2partial  (Time*group) F(1; 19)=.353; .560; .018  
Fe (µg/dL) 90.80; 27.18 60.17; 21.67  102.8; 18.44 62.50; 21.61  F(1; 20)=1.917; .181; .087 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=19.374; <.001; .492  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.872; .362; .042  
TF (mg/dL) 249.10; 28.68 295.08; 53.71  237.40; 21.50 286.67; 41.59  F(1; 20)=3.995; .059; .166 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=8.712; .008; .303  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.106; .748; .005  
FT (Log) (ng/dL) # 77.59 (42.13; 142.90) 31.46 (13.91; 71.16)  78.22 (40.15; 152.39) 43.68 (21.25; 89.77)  F(1; 20)=1.078; .312; .051 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.924; .348; .044  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.034; .856; .002  
TF Sat. (%) 28.18; 9.66 16.19; 7.49  31.85; 6.41 16.72; 5.83  F(1; 20)=1.696; .208; .078 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=24.583; <.001; .551  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.939; .344; .045  
TIBC (µg/dL) 327.60; 31.48 390.42; 74.34  325.50; 31.16 377.25; 56.16  F(1; 20)=1.583; .223; .073 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=6.810; .017; .254  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.832; .373; .040  
sTFr (Log) (mg/L) # 1.10 (.95; 1.27) 1.73 (1.37; 2.18)  1.25 (1.16; 1.35) 1.85 (1.41; 2.42)  F(1; 20)=5.174; .034; .206 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=7.047; .015; .261  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=.064; .803; .003  
sTFr-LogFT index (Log) # .59 (.46; .77) 1.23 (.80; 1.90)  .67 (.55; .83) 1.17 (.76; 1.81)  F(1; 20)=.012; .915; .001 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=3.985; .060; .166  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=1.601; .220; .074  
Body iron (mg/kg) 13.84; 3.64 8.97; 5.54  13.42; 3.59 9.92; 5.22  F(1; 20)=.925; .348; .044 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=4.464; .047; .182  
F(df1;df2); p; η2partial  (Time*group) F(1; 20)=6.467; .019; .244  
# Data presented as geometric mean and back-transformed 95% confidence intervals. 
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4.2.3 Comparison of pre- and post-intervention differences in cognitive variables  
Due to the impossibility to repeat some of the neurocognitive test in a short interval of 
time, no repeated measures were available from moment A to moment B; however, different 
measures for the same construct were used in moments A and B. PCA was used to reduce 
MMSE and MOCA total scores to a dimension termed general cog. (general cognition dimension 
from MMSE and MOCA, Cronbach’s alpha: .782) which measured the same construct as the 
ACER total score (transformed to a z-score to express the variable in the same scale as the 
general cog.). MMSE, MOCA and ACER can be divided into sub-scores measuring different areas 
of cognitive function such as attention, memory, verbal fluency, language and visuospatial 
orientation. Similar to general cog., PCA was used to reduce the sub-scores of MMSE and MOCA, 
resulting in 4 dimensions measuring cognitive ability in moment A similar to the sub-scores (as z-
scores) of the ACER measured in moment B. Briefly, attention dimension (attention and 
orientation, Cronbach’s alpha: .776) was obtained from the sum of the scores of questions 1 
(orientation), 2 (registration) and 3 (attention and calculation) of MMSE and the sum of attention 
and orientation of MOCA; memory dimension (memory and recall, Cronbach’s alpha: .112) as 
result of PCA of the question 4 (recall) of MMSE and delayed recall question of MOCA; language 
dimension (language skills, Cronbach’s alpha: .610) composed by question 5 (language) of 
MMSE and language question (first question of language) of MOCA; and a visuospatial dimension 
(flexibility, planning and conceptualization ability, Cronbach’s alpha: .730) composed by question 
6 (constructive ability) of MMSE and visuospatial/executive questions of MOCA. Since verbal 
fluency is not assessed in the MMSE, a verbal fluency domain (phonetic and semantic fluency, 
Cronbach’s alpha: .650) was obtained from PCA of the COWAT-FAS admissible (FAS – Ad.) score 
and the verbal fluency question (second question of language) of MOCA, which was used also for 
comparison with verbal fluency sub-scale (z-score) of ACER. 
The low reliability (measured by Cronbach’s alpha: .112) of the memory dimension 
prevented us from using this dimension in the analysis. For the remaining dimensions (general 
cog., attention, verbal fluency, language and visuospatial), no significant differences were 
observed between non supplemented and supplemented group in moments A or B (Table 34). 
Due to the use of different tests in each moment (although measuring the same construct), the 
test of differences between the same group in the different moments or the use of repeated 
measures ANOVA was not possible.  
 
 89 
 
Table 34 - Neurocognitive pre- and post-intervention comparison of differences. 
Variables  Pre-treatment (moment A)  Post-treatment (moment B) 
(mean; SD) Non supplem. Supplem. t(df); p; Cohen’s d  Non supplem. Supplem. t(df); p; Cohen’s d 
General Cog.        
 General cog . (MMSE&MOCA) -.09; 1,25 .07; .79 -.375(20); .712; .168  
   
 Z – ACER total     -.23; 1,15 .19; .86 -.994(20); .330; .449 
Attention        
 Attention (MMSE&MOCA) -.28; 1,20 .23; .77 -1,163(14,774); .263; .544     
 Z – Attention ACER     -.08; 1,13 .06; .92 -.317(20); .755; .142 
Verbal fluency        
 Fluency (FAS-Ad.&MOCA) .08; 1,01 -.07; 1,03 .330(20); .745; .148     
 Z – Fluency ACER     -.12; 1,01 .1; 1,03 -.493(20); .627; .221 
Language        
 Language (MMSE&MOCA) -.09; 1,14 .08; .91 -.378(20); .709; .170     
 Z – Language ACER     -.35; 1,06 .29; .89 -1,541(20); .139; .692 
Visio-spatial        
 Visio-spatial (MMSE&MOCA) -.06; 1,14 .05; .91 -.239(20); .814; .107     
 Z – Visio-spatial ACER     -.18; .97 .15; 1,04 -.787(19,675); .441; .351 
 
Repeated measures from moment A to moment B were available for BNT-15 and SRT 
(CLTR, LTS, DR and intrusions) and, therefore, repeated measures ANOVA was used to assess 
the test time, group and time by group effects on the scores for these tests. In order to reduce 
multiple comparisons PCA was used to obtain a memory (SRT-PCA) dimension (memory moment 
A, Cronbach’s alpha: .935; memory moment B, Cronbach’s alpha: .931) was composed by LTS, 
CLTR and DR scores (intrusions score was excluded due to low communalities). The 
standardized value of the BNT-15 was used since different sets of images were used in moments 
A and B. Statistical analysis was performed using repeated measures ANOVA and is presented in 
Table 35. 
A significant effect of time by group was observed for the BNT-15, meaning that the 
tendency of non supplemented and supplemented groups was significantly different over 
intervention. The effects over time and between groups were not statistical significant. In moment 
A, non supplemented group scored higher than supplemented group, after intervention, in 
moment B, supplemented group scored higher than non supplemented group. Of notice, since 
these results are presented in z-scores, an improvement in the values of supplemented group will 
lead to a decrease in the values of non supplemented group; furthermore, the change in the 
signal (from positive to negative z-scores in non supplemented group and the other way around in 
the supplemented group) indicates that the improvement was in a magnitude sufficient to change 
the position of these groups in relation to the mean value of the variable. Regarding the memory 
(SRT-PCA) dimension no significant effects for group, time or time by group were observed. Since 
the use of standardized residuals of the PCA can hide the real difference, the original values that 
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composed the memory (SRT-PCA) dimension, were used. No significant effects were observed for 
SRT – LTS, SRT – CLTS AND SRT – DR, which is consistent with the results of the repeated 
measures ANOVA for the memory (SRT-PCA) dimension. 
 
Table 35 - Repeated measures ANOVA of neurocognitive assessment. 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
BNT-15 (z-score) .70; .89 -.59; .66  -.05; 1.08 .04; .98  F(1; 20)=.094; .762; .005 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=3.277; .085; .141  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=11.419; .003; .363  
Memory (SRT-PCA) -.26; .66 .22; 1.20  -.31; .72 .26; 1.15  F(1; 20)=.001; .980; .000 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=1.888; .185; .086  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=.076; .785; .004  
SRT – LTS  22.90; 11.53 29.50; 15.62  26.50; 10.99 36.42; 13.06  F(1; 20)=3.868; .063; .162 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.385; .542; .019  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=2.816; .109; .123  
SRT - CLTR 13.70; 8.87 22.58; 15.77  19.10; 10.27 27.83; 14.90  F(1; 20)=3.107; .093; .134 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=3.494; .076; .149  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=.001; .980; .000  
SRT - DR 5.90:1.52 6.42; 3.15  5.30; 1.77 5.83; 3.43  F(1; 20)=1.926; .180; .088 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.243; .628; .012  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=.000; .985; .000  
 
4.2.4 Longitudinal analysis of psychological morbidity difference between groups 
Similar to the neurocognitive assessment, no repeated measures were available for 
neuropsychological evaluation and therefore different measures were used to assess the same 
construct. For the same reason and as explained for the neurocognitive analysis, the use of 
repeated measures ANOVA or the test of difference for the same group between the different 
moments was not possible.  Data regarding neuropsychological assessment and test of 
differences between groups for each moment are presented in Table 36. Values are presented 
both in original scores and in z-scores allowing for an easier comparison. No significant 
differences were observed between groups at moments A or B in any of the scales used to 
assess psychological morbidity.  
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Table 36 - Pre- and post-intervention comparison of differences for neuropsychological 
assessment 
Variables  Pre-treatment (moment A)  Post-treatment (moment B) 
(mean; SD) Non supplem. Supplem. t(df); p; Cohen’s d  Non supplem. Supplem. t(df); p; Cohen’s d 
Depression         
 BDI  7.00; 5.27 5.75; 5.85 .522(20); .608; .234     
 Z – BDI  .12; .96 -.10; 1.06   
    EADS – D      3.00;2.40 1.33;1.44 2.015(20); .058; .905 
 Z – EADS  – D      .44; 1.16 -.37; .69  
Anxiety         
 BAI  13.30; 7.42 1.92; 7.27 .759(20); .457; .341  
    Z – BAI  .18; 1.02 -.15; 1.00   
 EADS – A      2.30; 1.57 3.42; 2.75 -1.195(17.932); .248; .511 
 Z – EADS – A      -.26; .68 .22; 1.19  
Stress        
 PSS  17.70; 7.66 18.58; 6.32 -.297(20); .770; .133  
    Z – PSS  -.07; 1.13 .06; .93   
 EADS – S      2.70; 2.91 3.25; 2.90 -.443(20); .663; .199 
 Z – EADS – S      -.11; 1.02 .09; 1.02  
 
4.2.5 Time-treatment interaction on physical performance and functional ability 
The assessment of physical performance consisted in the evaluation of balance evaluation 
(static balance, gait balance and total; POMA); walking ability (time, steps, gait and cadence; 
6MTW), strength (hand and forearm muscular strength; hand grip strength) and functional ability 
(mobility tiredness, lower limb tiredness, upper limb tiredness, mobility help and physical 
activities of daily living help; QoFA). 
Data and results from repeated measures ANOVA of balance are presented in Table 37. 
Briefly, significant effects of time were observed only on gait balance. No significant effects of 
group were observed in any of the assessments performed. The effects of the time by group 
interaction were significant in all dimensions assessed for balance. In moment A the non 
supplemented group scored higher than the supplemented group in POMA – static balance, - gait 
balance and  -total; after intervention the mean score of the supplemented group increased in a 
sufficient magnitude to equal the non supplemented group both in moments A and B.  Regarding 
walking ability (Table 38) no significant effects were observed for group or time by group 
interaction. For steps and cadence, a significant effect of time was observed. On hand grip 
strength (Table 39) a significant effect of time by group interaction was observed even though no 
significant effect was observed for time or group. In moment A the non supplemented group 
scored higher than the supplemented group; after intervention the score of non supplemented 
 92 
 
group decreased when compared to baseline, and that of the supplemented group improved 
when compared to baseline.   
 
Table 37 - Repeated measures ANOVA for balance 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
POMA – Static balance  14.60; 1.17 13.83; 2.17  14.00; 1.25 14.50; 1.83  F(1; 20)=.018; .895; .001 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.038; .847; .002  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=6.467; .019; .244  
POMA – Gait balance 11.60; .97 10.50; 1.57  11.60; .70 11.58; .79  F(1; 20)=3.667; .070; .155 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=2.325; .143; .104  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=3.667; .070; .155  
POMA – Total 26.20; 1.61 24.33; 3.37  25.60; 1.83 26.08; 2.54  F(1; 20)=1.627; .217; .075 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.509; .484; .025  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=6.796; .017; .254  
 
 
Table 38 - Repeated measures ANOVA for walking ability 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
6MTW – Time  3.99; .57 4.58; 1.12  3.70; .37 4.62; 1.42  F(1; 20)=.523; .478; .025 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=3.719; .068; .157  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=.888; .357; .043  
6MTW – Steps  8.03; 1.02 9.19; 1.78  8.73; 1.05 9.45; 1.32  F(1; 20)=7.587; .012; .275 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=2.852; .107; .125  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=1.699; .207; .078  
6MTW – Gait  91.86; 13.03 82.71; 18.55  98.22; 9.18 84.58; 25.48  F(1; 20)=2.433; .134; .108 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=2.422; .135; .108  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=.722; .406; .035  
6MTW – Cadence  121.40; 9.29 122.10; 11.68  141.88; 11.75 128.45; 21.23  F(1; 20)=9.118; .007; .313 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=2.114; .161; .096  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=2.529; .127; .112  
 
 
Table 39 - Repeated measures ANOVA for hand grip strength 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
Hand grip strength  29.5; 8.39 30.58; 7.15  27.90; 8.17 31.42; 8.46  F(1; 20)=.433; .518; .021 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.460; .506; .022  
F(df1;df2); p; η2 partial (Time*group) F(1; 20)=4.362; .050; .179  
 
Similarly to the cross sectional analysis, PCA was used to obtain dimensions of functional 
ability (functional tiredness and functional help) for each moment (moment A and B). The 
obtained dimensions were functional-T (functional tiredness moment A, Cronbach’s alpha: .341; 
functional tiredness moment B, Cronbach’s alpha: .549) and functional-H (functional help 
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moment A, Cronbach’s alpha: .569; functional help moment B, Cronbach’s alpha: .434). The low 
reliability of the components (Cronbach’s alpha <.6) prevented us from using them and therefore 
each sub-scale of the QoFA was analyzed independently (Table 40).  A significant effect of time 
by group interaction was observed for lower limb tiredness; however, no significant effects of time 
or group were observed. Once again, the non supplemented group scored higher than 
supplemented group in moment A; after treatment the mean value of supplemented group was 
very similar to the mean value of the non supplemented group. In the remaining sub-scales 
(mobility tiredness, upper limb tiredness, mobility help and PADL help) no significant effects of 
time, group or time by group interaction were observed.  
 
Table 40 - Repeated measures ANOVA for functional ability 
Variables  Pre-treatment (moment A)  Post-treatment (moment B)  
F(df1;df2); p; η2 partial (Time) 
(mean; SD) Non supplem. Supplem.  Non supplem. Supplem.  
Mobility tiredness 4.90; 1.97 3.92; 1.93  5.30; .82 5.08; 1.24  F(1; 20)=3.821; .065; .160 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=1.231; .280; .058  
F(df1;df2); p; η2 partial  (Time*group) F(1; 20)=.915; .350; .044  
Lower limb tiredness 4.60; .52 3.58; 1.44  4.30; .95 4.58; .90  F(1; 20)=2.048; .168; .093 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=1.002; .329; .048  
F(df1;df2); p; η2 partial  (Time*group) F(1; 20)=7.064; .015; .261  
Upper limb tiredness 3.90; .32 3.92; .29  3.90; .32 3.83; .39  F(1; 20)=.826; .374; .040 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.035; .854; .002  
F(df1;df2); p; η2 partial  (Time*group) F(1; 20)=.826; .374; .040  
Mobility help 11.80; .63 11.50; .91  12.00; .00 11.67; .78  F(1; 20)=.961; .339; .046 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=1.881; .185; .086  
F(df1;df2); p; η2 partial  (Time*group) F(1; 20)=.008; .930; .000  
PADL help 18.20; 4.37 18.50; 2.71  18.40; 3.75 18.67; 2.31  F(1; 20)=.630; .437; .031 
F(df1;df2); p; η2 partial  (Group) F(1; 20)=.041; .841; .002  
F(df1;df2); p; η2 partial  (Time*group) F(1; 20)=.005; .943; .000  
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For a long time it has been known that iron homeostasis is important for health and that 
imbalances of this tightly regulated metabolism leads to adverse effects on several mechanisms 
(Nancy C. Andrews, 1999). Specifically, low iron status or iron deficiency, which is the focus of 
this work, has been associated with negative outcomes in cognitive performance, depression, 
behavior and physical capacity (J. L. Beard & Connor, 2003; Haas & Brownlie, 2001; Laura E. 
Murray-Kolb, 2011). Despite of this well-known effect on these domains of human health, the 
main body of research regarding iron deficiency has been conducted in infants, children and 
women of child bearing age. However, older individuals are particularly susceptible of being at 
risk of iron deficiency. Furthermore, due to the aging process, they are more likely to develop 
cognitive deficits (Deary et al., 2009), depressive mood (Jamison et al., 2006) and physical 
disabilities (Janssen et al., 2002). Still, little is known about correlates of low iron status in the 
aging process.  
In this work, we examined the associations of normal and lower iron status with cognitive 
performance, neuropsychological morbidity, functional ability and physical performances in older 
individuals. In order to explore and understand these associations, we used two distinct 
approaches: (i) an observational approach, with a cross-sectional design, and (ii) an exploratory 
approach, using a quasi-experimental study design with iron-based fortification intervention 
component. Three main objectives served as the guiding thread to the work here addressed. 
First, using a cross-sectional methodology we investigated the associations of iron deficiency and 
low iron status with cognition, mood and physical functional ability. Second, we investigated 
whether iron supplementation ameliorated the iron status. And, third, whether fortification 
improved neurocognitive and physical performance.  
5.1. Strengths and limitations 
The novelty of this work deserves to be highlighted. The population-based observational 
study is the first work that examines the associations of iron deficiency with cognitive function, 
neuropsychological morbidity and physical functional ability in older community dwellers. 
Furthermore, both hematological and neurocognitive assessments were very comprehensive 
which allowed us to detect association(s) between specific dimensions of iron status (such as 
storage) and specific dimensions of cognition (such as memory). Since this work was supported 
by a larger study addressing predictors of healthy cognitive aging, several measures were 
available to correlate with iron status and the extensive characterization of participants allowed 
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controlling the main confounding factors that could confound and/or act as effectors in the 
associations under analysis. The richness of available data and the statistical approach should be 
highlighted as strengths of this work. 
Some limitations of this work should also be addressed. The cross-sectional nature of 
observational study limits conclusions on the nature of the association between low iron status 
and the dependent variables addressed. The sample size can also be a limitation. Although it was 
sufficient to allow the observation of significant associations, it could be not enough to detect 
more subtle associations in other variables, especially in case of small effect sizes. As such, 
effect sizes were reported throughout the work. Furthermore, the low prevalence of anemic 
individuals in our sample did not allow to explore the differential association of iron deficiency, 
iron deficiency anemia, anemia and normal iron nutriture. In order to overcome these limitations 
(sample size and conditions prevalence) a larger population-based study should be used. As for 
all the observational studies, here also, no causality relationship can be established for each 
association found. This limitation, inherent to the nature of the design, could be overcome using 
a randomized controlled trial, preferentially double (or even) triple blind. However, due to several 
practical limitations (including, chiefly ethical constrains), a double blind randomized controlled 
trial was not performed. Instead a quasi-experimental study design, here designated as 
intervention study, was used, which complemented the observational study.  
In the intervention study the sample size is, in fact, the major limitation although, the 
nature of the design, which include repeated measures, allows the use of small samples to 
detect significant differences. Furthermore, the distribution of subjects by branch can also 
represent a bias. The two branches had similar number of individuals classified as low FT and if, 
in theory, only the low FT [which are undoubtedly iron deficient (G. H. Guyatt et al., 1992) benefit 
from iron fortification, the improvements may be diluted by the ones that did not improve for 
being false iron deficient. Perhaps other approaches should be considered in which all individuals 
are fortified and results will be compared between the ones that benefit from the intervention, 
measured by hemoglobin and/or FT response (Mei et al., 2005), and the ones that do not 
benefit.   
Finally, novelty was also one of the features of the intervention study. To our knowledge, 
the present work was the first one to test the effects of iron fortification on iron status of older 
individuals, and further address if this strategy correlates with (positive) effects in cognition, 
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neuropsychological morbidity, functional ability and physical performance. Furthermore, it was 
also the first that used iron food fortification as a vehicle for iron delivery.  
5.2. Iron deficiency or low iron status – What matters? 
The participants enrolled in this study were cognitively “healthy” community dwellers  (no 
diagnosed cognitive impairment, dementia and/or neuropsychiatric disorder), whom were 
clinically considered as “normal/healthy” agers, particularly considering absence of 
neuropathology, and/or central nervous system disease and/or overt thyroid pathology. 
Nevertheless, despite of this, subjects with conditions that could affect iron status (chronic kidney 
disease, malnutrition, inflammatory states and suspects of iron overload) were also further 
excluded from the analysis. Although iron status is a continuum from iron overload to iron 
deficiency, our aim was only to address the associations of iron deficiency or low iron status and 
for that reason, subjects with suspects of iron overload were excluded.  
Individuals were classified as iron deficient using a very complete panel of iron biomarkers 
and according the values proposed in the scientific literature (see Table 1). Since inflammation 
influences the levels of several of the iron-status biomarkers, all the cases of inflammatory states 
were excluded (hsCRP>10mg/dL). Even having excluding inflammatory states, a significant 
difference in the value of hsCRP between iron sufficiency cases and ID cases was observed and, 
not surprisingly, higher values of hsCRP were observed in the ID group. As expected, the ID 
group presented significantly different values in the red cells indices, in the iron biomarkers and 
in the hematological dimensions, without exceptions. Coherently, all the differences indicate a 
significantly lower iron status of the ID group. The occurrence of hypoferremia following infection 
(which leads to inflammation) has been recognized for more than a half of century (Thurnham & 
McCabe, 2012). Furthermore, it is known that inflammatory hallmarks are present in the etiology 
of ACD and that this relation is mediated by hepcidin, which is over expressed in inflammatory 
states and negatively regulates iron availability (T. Ganz & Nemeth, 2006; Hentze et al., 2010). 
Here we classify as iron deficient a group of individuals with a higher inflammatory profile and for 
that reason we cannot conclude if we are in the presence of an absolute or functional iron 
deficiency (Thomas et al., 2013).  
In order to exclude the inflammation effects on iron status and its associations with the 
target variables (cognitive, psychological and physical functional ability), all the analyses were 
controlled for hsCRP levels. Additionally to the hsCRP, all the analyses were controlled for other 
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main confounding factors. The analysis of neurocognitive and neuropsychological variables was 
controlled for age, gender and education; GDS score was also used in the analysis of 
neurocognitive variables, following previous observation in similar cohorts (Nadine Correia Santos 
et al., 2014). Physical ability variables were also controlled for age and BMI. This strategy gives 
us a stronger confidence in the results obtained. We used ANCOVA to test whether the iron 
deficiency classification could be a predictor of the dependent variables and no significant results 
were observed in any of them, which was unexpected since in other types of population (namely 
children, adolescents and childbearing age women) iron deficiency was associated with 
impairments on cognition, mood and physical performance (J. L. Beard et al., 2005; Bodnar, 
Cogswell, & McDonald, 2005; Grantham-McGregor & Ani, 2001; Halterman, Kaczorowski, Aligne, 
Auinger, & Szilagyi, 2001). The minimum value of hemoglobin found in our sample was 9.3 
mg/dL, where it is known that severe ID will lead to deficient erythropoiesis and therefore to 
anemia, which will be severe in the same proportion as the ID. The inefficiency of the 
classification of ID to predict the target variables may be explained by the fact that, in our 
sample, ID was not sufficiently severe.  
Iron status is a continuum and no clear cutoff exists between normal iron status and iron 
deficiency. In order to test the association of iron status/dimensions with neurocognition, 
neuropsychological morbidity and physical functional ability hierarchical regression models were 
constructed. Our data indicate that, even after controlling for the main confounding factors, iron 
status is associated with memory dimension, GDS and the functional tiredness dimension.  
In the same line as previously proposed (J. L. Beard, 2001), and taken together our 
results, these findings suggest that, from the point of view of cognitive function, mood and 
physical ability, classifying individuals as iron deficient or non deficient is not a biological reality, 
since none of the variables taken as dependent was different between iron-deficient and iron-
sufficient individuals. Instead considering iron status/nutriture as a continuum seems more 
accurate and reliable to assess the consequences of different levels of severity.   
 
5.3. Nutritional status and iron nutriture – obviously! 
It was previously proposed that an iron deficient state could be a surrogate marker for 
malnutrition (Fairweather-Tait et al., 2013; Hsu et al., 2013). Although the MNA test was 
designed to detect protein-energy malnutrition (Guigoz, 2006), some authors (Murphy, Brooks, 
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New, & Lumbers, 2000) found significantly lower intakes of iron in malnourished orthopedic 
patients when compared with well-nourished patients.  These differences were not corroborated 
by a study in institutionalized older individuals (Ruiz-López et al., 2003). Using the MNA score as 
a continuum, a significant correlation was found with iron intake in hospitalized patients. Even 
though, in theory, MNA scores can be associated with iron status, only a small study so far, to 
our knowledge, has investigated this (Langkamp-Henken, Hudgens, Stechmiller, & Herrlinger-
Garcia, 2005). This study reported a positive association of MNA with hematocrit and hemoglobin 
in pressure ulcers patients, but they included individuals that ranged from undernourished to 
normal nutritional status. In our population, excluding undernourished individuals, we observed 
that ID states can be significantly predicted by MNA. Nutritional status is a predictor of ID and for 
a long time is a known factor associated to cognition (Goodwin, Goodwin, & Garry, 1983), mood 
(Boult, Krinke, Urdangarin, & Skarin, 1999) and physical performance (Olin, Koochek, Ljungqvist, 
& Cederholm, 2004). Taken together, these associations led us to hypothesize that nutritional 
status could be a mediator of the association of iron status with the target variables. In this study, 
our hypothesis revealed to be true regarding a mediation effect in the association of storage 
dimension with memory dimension and will be further discussed. 
 
5.4. Memory - the neurocognitive facet of lower iron status  
From the literature it is clear that the focus of low iron status research and cognition has 
been based on the categorical classification of iron deficiency, particularly in children and/or in 
animal models (Fretham et al., 2011) or in anemic individuals (Deal, Carlson, Xue, Fried, & 
Chaves, 2009; Denny et al., 2006; Lucca et al., 2008; Terekeci et al., 2010). In this work, as 
previously discussed, classification as iron deficient was not sensitive to discriminate cognitive 
performance of subjects. From the 151 enrolled subjects only 23 were anemic and from these 
only 8 were also iron deficient (data not shown). The discrepancy between the number of anemic 
subjects in each possible condition (unknown=2; iron deficient=36; iron deficiency anemia=8; 
anemic=15; normal=90) prevented us to conduct an analysis regarding anemia or iron deficiency 
anemia.  
Classification of anemia is made with base in the hemoglobin levels and since it was not 
possible to perform an analysis with respect to that classification we used hemoglobin levels to 
construct the erythropoiesys dimension along with hematocrit and RBC. Theoretically, the 
 102 
 
associations found with this dimension should be similar, and in the same direction, to the 
differences found between anemic and non anemic individuals when analyzing similar constructs. 
The results of hierarchical regression models indicate that the erythropoiesys dimension 
predicted the memory dimension but did not predict the executive dimension, MMSE or MOCA. It 
is puzzling that no significant predictive value was observed for the above mentioned variables 
since several studies reported differences in the performance of these tests (or other tests 
measuring the same cognitive functions) among anemic and non-anemic older individuals (Deal 
et al., 2009; Lucca et al., 2008; Terekeci et al., 2010). The absence of statistical significant 
results can probably be explained by the different methodological approaches and/or it is 
possible that we do not have sufficient sample size to observe subtle associations. Still, the 
sample size was sufficient to detect the association of erythropoiesys dimension and memory, 
indicating perhaps that the magnitude of the possible undetected association is smaller for the 
executive dimension, MMSE or MOCA than for memory dimension. With respect to the predictive 
value of the erythropoiesys for memory, our observation is consistent with that by Shah et al. (R. 
C. Shah et al., 2009) who reported lower memory ability in individuals with lower levels of 
hemoglobin. Similar to our methodological approach the authors considered that the use of 
hemoglobin as a continuous variable may be a better way to characterize its relationship with 
cognitive function. 
The neurocognitive dimensions/variables were not predicted by any of the remaining 
hematological variables with exception for the storage dimension which was a predictor of the 
memory dimension. Once again, our results do not fit with previous reports in which an 
association between ID and MMSE was observed (Yavuz et al., 2012). In other population 
groups, namely young women, iron status has been associated with executive function and 
cognition but in some case this associations are found between the time to complete a task and 
not the result of the task (Blanton, Green, & Kretsch, 2013; L. E. Murray-Kolb & Beard, 2007). 
The neurocognitive tests that we used have a defined duration to be completed and are 
considered finished after a defined number of mistakes, or do not take time into consideration. 
Several hypotheses can be put forward to explain the discrepancy of results between our study 
and some previous reports but sample size and especially methodological approach are again 
the most probable.  
Despite of the conflicting results of low iron status and cognitive performance, the 
observations for memory and storage are consistent with previous observations in children, 
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adolescents and pregnant women (Fretham et al., 2011; Gordon, 2003; Groner, Holtzman, 
Charney, & Mellits, 1986). Insights from experiments on animal models of iron deficiency provide 
clues that possibly explain this interesting finding. The hippocampus is the central processing 
area for memory (Squire, 2004) and alterations of hippocampus neurochemical profile of rats 
were observed during perinatal ID which causes neurochemical alterations and possibly 
persistent changes in the resting energy status, neurotransmission and myelination (Rao, Tkac, 
Townsend, Gruetter, & Georgieff, 2003). Tran et al. (Tran, Fretham, Carlson, & Georgieff, 2009) 
showed that fetal-neonatal ID lowers hippocampal brain-derived neurotrophic factor expression 
and function even in adult age. These findings are relevant to the understanding of the molecular 
basis of the reported association; however, they concern to a period of the brain development in 
which iron is paramount (Roskams & Connor, 1994). During aging process a certain degree of 
brain iron accumulation is expected, but its effects are deleterious (Tracey A. Rouault & 
Cooperman, 2006). Since no studies were published regarding these mechanisms, both in 
humans and animal models, here we can only suggest the existence of similar mechanisms 
during iron deficiency in aging.  
Since, in the absence of parenteral iron administration dietary iron is the only source of 
iron (Miret et al., 2003), and nutritional status is associated with cognitive function, depressive 
mood and physical ability of older individuals (Goodwin et al., 1983; Stuck et al., 1999), we 
hypothesized that the association of iron status and the dependent variables under analysis could 
be mediated by nutritional status. Here the only interaction with significant predictive value was 
storage on memory and it was positive, which means that for individuals with higher stores of 
iron, if in a good nutritional status, memory function will be at a potential maximum. This finding 
is particularly interesting and to our knowledge is reported for the first time. It is possible that 
higher levels of insufficiency are necessary to impact on several of the dimensions studied, and 
therefore our sample may lack power to detect them.  
Interestingly, from the hematological dimensions constructed with iron biomarkers 
(storage, transport and transport s.) only the storage dimension, alone or in interaction with the 
nutritional status, was a significant predictor of memory. Stored iron, assessed using storage 
dimension as a proxy, is readily available when and where it is needed (Linder, 2013), which may 
justify its impact on memory function.  
 104 
 
5.5. Depressive mood in depressed iron status  
The analysis of the predictive value of iron related hematological dimensions on 
neuropsychological variables revealed that only depressive mood could be predicted. Specifically, 
erythropoiesis, transport s. and transport dimensions were significant predictors of GDS score. 
Regarding the erythropoiesis dimension, hemoglobin is one of the principal components and 
therefore is expected that our results follow the same direction of the reports exploring the 
associations of anemia and depression. Despite of the differences in the methodological 
approach our results are in accordance with the results of three previous studies examining the 
association of anemia and depressive mood. In the InChianti study (Onder et al., 2005) a higher 
prevalence of anemia was observed among the individuals displaying depressive symptoms. In 
the same line, the results of the English longitudinal study of ageing (Hamer & Molloy, 2009) 
showed that, at baseline, anemia was associated with depressive mood, although it was not a 
predictor of its incidence at a two years follow-up. More recently, Stewart et al. (R. Stewart & 
Hirani, 2012), in a study examining the associations between anemia and iron status with 
depressive symptoms, found anemia to be associated with depressive mood, although it was 
reflecting primarily the anemia of chronic disease. This result should be interpreted with caution, 
since inflammation is a component of anemia of chronic disease and it is associated with 
depression per se (Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008). Altogether, these 
studies suggest that altered brain oxygenation and dopaminergic function can underlie the 
observed mood outcome, given the well described involvement of monoamines imbalance in the 
etiology of depression (Meyer et al., 2006). Other neurotransmitter systems are likely also 
involved, namely serotoninergic and noradrenergic (Burhans et al., 2005).  
5.6. If we are not made of iron, we get tired 
The amount of literature reporting lower physical functioning in anemic older individuals is 
convincing (Chaves, 2008; Penninx et al., 2003; Penninx et al., 2004; M. Thein et al., 2009). In 
the present work we observed that both erythropoiesis and red cells c. dimensions were 
associated with the tiredness dimension of physical functional ability. The logical explanation for 
the higher fatigability observed in individuals with lower scores in these hematological dimension 
is the lower oxygenation of the muscles (J. L. Beard, 2001; Penninx et al., 2003). 
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Literature in the study of iron deficiency and physical ability in older subjects is surprisingly 
scarce, contrary to the large amount of literature examining the same in anemia. We report a 
significant predictive value of storage and transport dimensions on the functional-T dimension. 
Ours is the first report on these aspects in the older population, and seems to be in accordance 
with reports on other populations, such as hospitalized anemic patients and several physical 
workers from both sexes (Haas & Brownlie, 2001). Of notice, in iron-depleted, nonanemic women 
iron supplementation was associated with a significant improvement in muscle fatigability, which 
can be interpreted as an indication of higher fatigability due to low iron status (Brutsaert et al., 
2003).  
5.7. Can we reverse it and its liabilities? 
Using a quasi-experimental design we tested the hypothesis of cognitive function, mood 
and physical performance amelioration or normalization with daily iron food fortification with low 
iron dosage.  
From the hematological dimensions/variables, with exception of body iron, no significant 
effects of the intervention were observed. Rimon et al. (Rimon et al., 2005) reported an increase 
in hemoglobin and ferritin concentrations in iron deficient anemic elderly treated with a daily 
dosage of 15 mg of iron during 60 days. Although the dosages in our study and theirs were 
similar and the duration of our intervention was greater we did not observed the same findings. 
Several differences should be considered. In their work the subjects were iron deficient anemic 
and therefore more prompt to absorb iron and to have a greater amelioration of hematological 
parameters. Also, different formulations of iron were used; however, Na(Fe3+)EDTA should be 
better absorbed than the liquid ferrous gluconate they used (Dary & Hurrell, 2006). Despite of no 
significant effects observed in almost all the hematological variables, body iron significantly 
increased (significant effect of time by group interaction) from pre-treatment to post treatment in 
the supplemented group which could have implications for the results that will be discussed 
further ahead.  
Here neurocognitive and neuropsychological variables were not different between the two 
time points and/or as a result of the intervention. Results from randomized controlled trials 
indicate that iron supplementation is capable of ameliorating or normalizing neurocognition 
(Falkingham et al., 2010) and neuropsychological morbidity (Laura E. Murray-Kolb, 2011) in 
children and adults. The iron dosage used in these studies was higher than the one that we used 
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and it is possible that our iron dosage is insufficient to promote a visible amelioration. The BNT-
15 score was significantly improved by the intervention, although it is possible that this result is 
more dependent on the engagement of the individuals on the fortification branch than as a result 
of the iron fortification.  
The main findings on the longitudinal study are the improvement on the balance (POMA – 
static balance, POMA – gait balance and POMA – total), on the hand grip strength and the 
reduction in lower limb tiredness. These observations are consistent with the hypothesis that iron 
contributes to physical performance. Anemia has been associated with an increased risk of falls 
(Dharmarajan, Avula, & Norkus, 2007; Mei Sheng et al., 2008) and if the type of association is 
causal, the treatment of anemia will result in a reduced risk of falls. Here we observed an 
improvement in the scores of POMA, which is used to assess the risk of falls in older individuals 
(Tinetti, 1986).  
Hand grip strength and lower limb tiredness improved with supplementation, which may 
reflect endurance and aerobic capacity. Iron deficiency, particularly iron deficiency anemia was 
associated with a compromised aerobic and endurance capacity in a large number of studies 
from animal to humans and it was hypothesized that, further to deficient oxygen delivery, tissue 
iron deficiency may also play a role through reduced cellular oxidative capacity (Haas & Brownlie, 
2001).  
5.8. Concluding remarks and future directions 
Iron deficiency is the most common nutritional deficiency in the world and older individuals 
are particular susceptible to developed negative imbalances in iron homeostasis, particularly if a 
pathological condition is present. In an aging society, efforts to understand and identify issues 
that can be used to improve or maintain health and wellbeing of agers are paramount. Cognition 
and physical functioning are particularly relevant to maintain independence in late life. Thus, the 
study and investigation of strategies for a healthy aging is particularly relevant, not only given the 
health and social benefits, but also by the reduction of the expenditure of the health and welfare 
systems of nations.  
Here, using complementary study designs, we demonstrated an association of the lower 
half of the iron status range and memory, depressive mood and physical functional tiredness in 
older community dwellers. These finding are particularly relevant if we take into account the 
dimension of the public health problem that is ID and that it impacts essential capabilities of 
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aging individuals. The traditional viewpoint that iron deficiency does not have consequences until 
the development of anemia is challenged here, since our sample had a very low number of 
anemic individuals.  
The observations from the longitudinal study indicate that physical performance and ability 
probably can be ameliorated with nutritional interventions of iron fortified foods.  
In conclusion, low iron status of older individuals is associated with more depressive 
mood, higher tiredness from physical activities of daily living and lower memory, which seem to 
be modulated by nutritional status. Further research is needed to replicate and confirm our 
results, as well as, insights from animal models of low iron status and aging, which can be an 
advantage to understand the mechanistic aspects that underlie these observations.  
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